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1 Summary 
1.1 Critique of the decision problem in the company submission 
The company narrowed the population from adults with acute myeloid leukaemia (AML) and 
bone marrow blasts more than 30% (as per the NICE Scope) to adults aged ≥65 years who 
are not eligible for haematopoietic stem cell transplantation with AML and bone marrow 
blasts more than 30% to adults. This change was to coincide with the European Medicines 
Agency marketing authorisation for azacitidine and was deemed a reasonable change by the 
ERG. 
The intervention in the decision problem was azacitidine, as in the NICE Scope. 
The comparator(s) in the decision problem were different from the NICE Scope. The 
company replaced three individual comparators (intensive chemotherapy [IC], non-intensive 
chemotherapy with low dose cytarabine [LDAC] and best supportive care [BSC]) with one 
composite comparator (conventional care regimen; CCR) on the basis that there are no 
established criteria for selecting one CCR. As a result, the company has not assessed 
whether azacitidine demonstrated clinical and/or cost-effectiveness versus each of the CCR 
comparators. The ERG considered this to be a weakness of the submission. 
The company reported the same outcomes to that of the NICE Scope. 
The NICE Scope asked for evidence, if available, on the following subgroups: people with 
AML secondary to myelodysplastic syndrome (MDS) and people with adverse-risk 
cytogenetics. The company reported that these subgroups were assessed. Although the 
submission looked at the subgroup of AML with MDS-related changes (which is a broader 
subgroup than AML secondary to MDS), these other considerations were deemed 
acceptable by the ERG. 
1.2 Summary of clinical effectiveness evidence submitted by the 
company 
The primary focus of the company’s submission was the RCT AZA-AML-001. Patients were 
randomised to azacitidine (N=241) or to a conventional care regimen (N=247; BSC=45, 
LDAC=158, IC=44). Baseline characteristics were reported as being balanced between 
arms. Outcome results were as follows: 
Overall survival 
Azacitidine was numerically superior to CCR in prolonging survival of adults ≥65 years with 
AML with >30% bone marrow blasts but statistical significance was not reached. Median 
duration of follow up was 24.5 months. By the study end, there were 193 deaths (80.7%) 
following treatment with azacitidine and 201 deaths (81.4%) following CCR treatment.  
Secondary endpoints 
1-year survival rates were 46.5% for azacitidine compared to 34.3% in the CCR arm 
(difference 12.3 %; 95% CI: 3.5, 21.0). 
Measures of haematologic response, duration of remission and remission free survival were 
similar between treatment arms when CCR was combined. When CCR was not combined, it 
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appeared that IC was numerically superior to azacitidine for these outcomes, although the 
study was not powered to detect any such differences. 
No statistical analyses were presented for the health-related quality of life (HRQoL) data. 
Appearances from the figures suggest that CCR was favourable to azacitidine. 
Adverse events 
Treatment related AEs were common for both azacitidine, LDAC and IC. Unsurprisingly, AEs 
were less common for BSC. 
1.3 Summary of the ERG’s critique of the clinical effectiveness 
evidence submitted 
The company presented a poorly constructed systematic review of the literature. Their 
searches were weak and their inclusion criteria were both over- and under-exclusive. 
Ultimately however, the ERG concluded that the company did not miss any evidence. 
The primary focus of the company’s submission was the RCT AZA-AML-001. This was 
generally an appropriately-designed RCT, although it was underpowered for comparisons of 
azacitidine to each of the CCR arms. It is not clear whether the proportion of patients pre-
selected to each CCR therapy in the RCT (18% IC, 64% LDAC and 18% BSC) are 
representative of NHS clinical practice; data from a registry in Yorkshire suggests more 
patients may receive BSC xxxxx and fewer LDAC xxxxx, while clinical expert advice is that 
more patients would be expected to receive IC. The use of subsequent therapies following 
treatment assignment was permitted, and this was a limitation to the study design as it 
resulted in confounded estimates for the primary efficacy endpoint and other endpoints. 
The open-label design of the trial, although unavoidable as the treatments generally require 
different levels of medical intervention, increases the risk of bias. 
Statistical analyses of time-to-event outcomes relied on the proportional hazards 
assumption, which transpired not to be justified. 
1.4 Summary of cost-effectiveness evidence submitted by the 
company 
1.4.1 Company’s systematic review of economic evaluations 
The company conducted a systematic review of economic evaluations, which did not find 
any pre-existing studies adequately addressing the decision problem. 
1.4.2 Company’s submitted economic evaluation 
1.4.2.1 Methods 
The company presented a model-based economic evaluation to address the decision 
problem. 
A semi-Markov (survival partition) model was used with four health states: Remission, Stable 
disease, Relapse/Post-progression and Death. Patients achieving remission started the 
model in the Remission state, while patients not achieving remission started in the Stable 
disease state. A model cycle length of four weeks was used, and a time horizon of ten years 
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was used. Outputs of the model (costs, life years and quality-adjusted life years [QALYs]) 
were discounted at 3.5% per annum. 
Two treatment arms were modelled. The azacitidine (AZA) arm modelled treatment with 
azacitidine until discontinued, followed by BSC. The CCR arm modelled a mixture of 
conventional treatments (IC, LDAC and BSC), with IC and LDAC followed by BSC after 
discontinuation. 
Overall survival, relapse-free survival and progression-free survival curves were constructed 
by fitting parametric survival models to data from the AZA-AML-001 trial. The treatment 
effect was modelled using proportional hazards for all survival curves. A model selection 
process was followed, which resulted in the selection of an exponential survival model for 
overall survival, a Weibull model for relapse-free survival and a Gompertz model for 
progression-free survival. Hazard ratios of 0.84 and 0.85 were used for relapse-free and 
progression-free survival respectively, while a hazard ratio of xxxx was used for overall 
survival based on an analysis adjusting for subsequent treatment with azacitidine in patients 
randomised to CCR. 
Health state utility values were estimated by mapping EORTC QLQ-30 data collected in the 
AZA-AML-001 trial to EQ-5D utility values, and were not modelled as varying according to 
treatment given. The impact of adverse events on health-related quality of life was also 
directly modelled by treatment. 
Costs were modelled from the NHS and personal social services perspective. Drug 
acquisition costs were estimated using the average daily dose in AZA-AML-001 and list 
prices (British National Formulary; BNF), with a confidential patient access scheme (PAS) 
discount of xxx applied to the cost of azacitidine. In the base case full wastage was assumed 
(i.e., no vial sharing across days or across patients). Patients were assumed to receive the 
relevant first-line treatment until relapse or progression. Drug administration, medical 
management, diagnostic test and transfusion resource use were estimated through a survey 
of clinicians conducted by the company. The PSSRU Unit cost of health and social care and 
the NHS reference costs were used to estimate unit costs. Costs of adverse events were 
also modelled. 
Univariate and probabilistic sensitivity analyses were conducted to explore uncertainty in the 
incremental cost-effectiveness ratio (ICER) and to identify parameters to which the model 
was sensitive. Scenario analyses were also conducted. 
1.4.2.2 Results 
In the company’s base case analysis, treatment with CCR resulted in 0.6365 QALYs and 
£40,608 cost, while treatment with azacitidine resulted in xxxxxx QALYs xxxxxxxxx and 
xxxxxxx cost xxxxxxxxx, with a corresponding ICER of £20,648 per QALY. 
Azacitidine was predicted to provide QALY gains across all health states, and was predicted 
to result in increased costs in the Remission and in Relapse/Progressive disease health 
states, partially compensated for by savings in the Stable disease health state. 
Drug acquisition costs were the largest cost component in the AZA arm xxxxxxxx more 
costly than in the CCR arm), while drug administration costs were the largest cost 
component in the CCR arm xxxxxxxx more costly than in the AZA arm). Other costs were 
largely similar between the two arms. 
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In their probabilistic sensitivity analysis, incremental QALYs were similar to the deterministic 
analysis, while incremental costs were marginally lower. The resulting ICER for azacitidine 
was £17,423 per QALY. At cost-effectiveness thresholds of £20,000, £30,000 and £50,000 
per QALY, azacitidine was cost-effective versus CCR in 69.9%, 90.8% and 99.6% of 
iterations respectively. 
Univariate sensitivity analyses identified that the results were sensitive to a number of 
parameters, with administration costs in the CCR arm, the hazard ratio for overall survival, 
the remission rates in the CCR arm and the acquisition and administration costs in the AZA 
arm as the five parameters to which the model was most sensitive. 
One notable scenario analysis showed that when overall survival in the CCR arm was not 
adjusted for subsequent treatment, this resulted in improved cost-effectiveness of azacitidine 
(£11,537 per QALY). 
1.5 Summary of the ERG’s critique of the cost-effectiveness evidence 
submitted 
The ERG identified several issues with the company’s submitted economic evaluation. 
The model assumed that no patients would receive active treatment following 
discontinuation of first-line treatment. However, in the AZA-AML-001 trial underpinning the 
analysis, 29% of participants received active second-line treatment. Advice from clinical 
experts suggests that active second-line treatment is considered for some patients in the 
NHS. 
The model assumed proportional hazards for all time-to-event outcomes, even though this 
was not supported for overall survival and relapse-free survival by results from the AZA-
AML-001 trial. 
Overall survival in the AZA arm was not adjusted for subsequent active treatment, resulting 
in an inconsistency between the modelled health outcomes and costs, since only the costs 
of best supportive care were modelled following azacitidine. 
Implementation issues were identified in the model. The most significant of these was an 
error in the calculation of the duration of first-line treatment which resulted in an 
underestimate of the drug acquisition and administration costs in both arms. 
The ERG also identified that there were significant differences in the cost associated with the 
Relapse/progressive disease state between the AZA and CCR arm, even though all patients 
(in both arms) are expected to be receiving BSC at this point.  
1.6 ERG commentary on the robustness of evidence submitted by the 
company 
1.6.1 Strengths 
The company’s submission was based on a recent and relevant RCT (AZA-AML-001) with 
the following strengths: 
 Multicentre RCT conducted across multiple countries, including countries in Western 
Europe; 
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 Sufficient follow-up for mature estimates of survival outcomes, including overall 
survival; 
 Appropriate dosing in the intervention and comparator arms; 
 Appropriate randomisation, including concealment of allocation prior to randomisation 
and stratified blocking on key prognostic variables; 
 Appropriate and relevant outcomes measured. 
The company’s submitted economic evaluation had the following strengths: 
 Simple and transparent overall model structure; 
 Inclusion of relevant costs from an NHS and personal social services perspective; 
 Suitable cycle length and time horizon; 
 Transparent process for fitting survival models; 
 Utility values suitably mapped from health-related quality of life measurements from 
AZA-AML-001; 
 Probabilistic sensitivity analysis to estimate the importance of parameter uncertainty 
in the decision problem. 
1.6.2 Weaknesses and areas of uncertainty 
The decision problem addressed by the company’s submission had a key weakness that 
instead of individual conventional care regimens as comparators (as in the NICE Scope), a 
combined comparator was used. 
The company’s systematic review of clinical effectiveness evidence was hampered by poorly 
designed and reported searches. 
The pivotal trial (AZA-AML-001) had the following weaknesses: 
 Underpowered for comparisons between azacitidine and individual conventional care 
regimens; 
 Significant proportion of patients used subsequent active treatments, including 
treatments not currently used in the NHS, and these were not balanced between 
treatment arms; 
 Limited proportion of patients allocated intensive chemotherapy as their conventional 
care regimen compared to expectation of routine clinical practice according to clinical 
experts; 
 Open-label design increases the risk of bias; 
 Statistical analyses relying on proportional hazards assumption which is not justified. 
The company’s submitted economic evaluation had the following weaknesses: 
 Inconsistency between the treatments costed post-discontinuation (BSC only) and 
the subsequent treatments reflected in overall survival estimates (AZA: active 
treatments; CCR, active treatments except azacitidine); 
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 Inappropriate proportional hazards assumption for overall survival and relapse-free 
survival outcomes; 
 Implementation errors, including a significant underestimate of treatment duration in 
both arms; 
 Inadequate exploration of structural uncertainty; 
 Significantly greater costs after relapse/progression in the CCR arm despite patients 
in both arms receiving BSC only in this state. 
The following areas of uncertainty remain: 
 The overall survival benefit demonstrated in AZA-AML-001 did not reach statistical 
significance in pre-planned analyses, yet it is interpreted nevertheless as a positive 
result; 
 It is not clear to what extent azacitidine is a clinically effective and cost-effective 
alternative to IC, LDAC and BSC as individual comparators. 
1.7 Summary of exploratory and sensitivity analyses undertaken by the 
ERG 
The ERG preferred base case ICER is £169,606 per QALY, compared to the company’s 
base case ICER of £20,648 per QALY. The reasons for the increased ICER are: 
 Corrections to errors in model formulae (increases ICER from £20,648 to £62,518 
per QALY); 
 Increased costs in the AZA and CCR arms due to correcting the implementation of 
treatment duration in the model (increases ICER from £62,518 to £131,698 per 
QALY); 
 Equalised costs in the Relapse/progressive disease health state across the model 
(increases ICER from £131,698 to £238,674 per QALY); 
 Overall survival in both arms adjusted for subsequent active treatment (reduces 
ICER from £238,674 to £171,511 per QALY); 
 Relapse-free survival Kaplan-Meier curves used for AZA and CCR arms (increases 
ICER from £171,511 to £174,205 per QALY); 
 Progression-free survival Kaplan-Meier curves used for AZA and CCR arms 
(increases ICER from £174,205 to £246,488 per QALY); 
 Adjusting overall survival for baseline covariates (reduces ICER from £246,488 to 
£169,606 per QALY). 
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2 Background 
2.1 Critique of company’s description of underlying health problem 
Celgene describe acute myeloid leukaemia (AML) as ‘an aggressive, clonal myeloid 
neoplasm with maturation arrest of myelopoiesis, leading to an accumulation of myeloblasts 
in the [bone marrow (BM)] and/or blood.’ (Source: Celgene submission, Section 3.1, p. 31). 
AML is a haematological cancer affecting the myeloid line of blood cells. In AML, myeloid 
stem cells in the bone marrow produce immature blood cells (usually myeloblasts) which do 
not develop fully and build up in the bone marrow. These immature blood cells are not able 
to function properly and they reduce the ability of the bone marrow to produce other cells the 
body needs. 
AML can develop following myelodysplastic syndrome (MDS), or can develop as a result of 
therapy (e.g., cytotoxic therapy), or can arise without previous associated disease or 
treatment (primary AML). 
The World Health Organisation (WHO) system requires involvement of at least 20% of blood 
and/or bone marrow by myeloblasts for AML diagnosis, and is also used to classify AML into 
subtypes to aid clinical decision making and prognosis. 
Celgene describe the following signs and symptoms of AML (Source: Celgene submission, 
Section 3.1, p. 31): 
The clinical signs and symptoms of AML are diverse and non-specific, but they are 
usually directly attributable to the leukaemic infiltration of the [bone marrow], with 
resultant cytopenias (reduction in blood cell counts). Typically, patients present with 
signs and symptoms of fatigue, haemorrhage, and/or infections and fever due to 
reductions in [red blood cells], platelets, and [white blood cells].1 The corresponding 
impact on physical and psychological aspects of quality of life is significant and 
increases over the course of the condition.2 
 
The ERG believes the description given is appropriate. 
2.1.1 Epidemiology 
Celgene give the following estimates of the incidence of AML (Source: Celgene submission, 
Section 3.1, p. 31): 
AML is the most frequent form of leukaemia, accounting for approximately 25% of all 
leukaemia cases in adults in the Western world.3 […] In the UK between 2009 and 
2011, an average of 40% of cases were diagnosed in men and women aged 75 
years and over, and almost three quarters of cases (73%) were diagnosed in those 
aged 60 and over.4 The median age of diagnosis is between 65 and 72 years for the 
entire population, and 78 years when evaluating the population who are aged over 65 
years.5-10 
The annual incidence rate of AML in England has been estimated to be 4.1 per 
100,000.11 The incidence increases dramatically with older age, rising to 18.35 per 
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100,000 in people aged 65 years and over,11 equating to approximately 1,777 new 
cases of AML in this patient group in England annually.11-13 
 
The incidence statistics provided by Celgene appear to be well-sourced, but we estimate a 
marginally lower number of new cases in adults aged over 65 per year in England (1,610 
versus 1,777) using the same datasets but a different method (applying the different age-
specific rates to the relevant population estimates and aggregating afterwards rather than 
applying an aggregated rate to an aggregate population estimate). This also corresponds to 
a marginally lower incidence rate for the over-65s of 16.88 per 100,000 (rather than 18.35). 
2.1.2 Diagnosis 
Diagnostic criteria are given by Celgene (Source: Celgene submission, Section 3.1, p. 31): 
Diagnosis of AML requires the examination of peripheral blood and BM specimens, 
using morphology, cytochemistry, immunophenotyping, cytogenetics, and molecular 
genetics. According to the WHO classification of myeloid neoplasms, a myeloid 
neoplasm with ≥20% blasts in the peripheral blood or BM is considered to be AML 
when occurring de novo, evolution to AML when it occurs with previous diagnosis of 
MDS or myelodysplastic/myeloproliferative neoplasm.14 
 
An abnormal result on a complete blood count is a typical finding prior to a diagnosis of AML. 
An excess of white blood cells is commonly seen, and counts for platelets and/or red blood 
cells may be reduced. 
2.1.3 Prognostic markers and risk factors 
Celgene have provided general information on survival in AML (Source: Celgene 
submission, Section 3.4, p. 34): 
AML is a heterogeneous disease in terms of response to treatment and OS. 
Prognostic factors that contribute to this heterogeneity can be patient-related (such 
as increased age, reduced performance status, comorbidities, vulnerability, or frailty) 
or disease-related (such as genetic factors, adverse cytogenetics, somatic mutations, 
or whether the patient has MDS-related changes).15-17 
Survival is highly age dependent with survival rates being significantly lower in older 
patients.5 The median [overall survival (OS)] of elderly patients with AML in 
population-based studies has remained unchanged since 1995 at 1.5 to 3 months.18, 
19 Furthermore, a recent analysis of the [Haematological Malignancy Research 
Network] HMRN registry highlights the current poor outcomes in UK routine practice, 
with a median OS of xxx months for non-transplant-eligible AML patients 65 years or 
older treated with [conventional care regimens (CCR)].20 There is also a clear 
disparity in 5-year survival rates between AML patients of different ages. Between 
2003 and 2009, 5-year survival rates for patients <65 years of age was 41.6%, but 
just 5.4% in patients ≥65 years of age.21 In contrast, the life expectancy of people in 
the general population once they have reached 75 years of age is a further 10.6 
years (males) and 12.9 years (females).22 Therefore, AML represents a challenging 
disease to treat, and results in a significant reduction in patient’s life expectancy. 
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Age and cytogenetics appear to be the most important prognostic factors. The NICE Scope 
identified two subgroups to be considered if evidence allowed, these were: people with AML 
secondary to myelodysplastic syndrome, and people with adverse-risk cytogenetics. 
AML secondary to myelodysplastic syndrome is associated with reduced likelihood of 
treatment response and therefore with worse prognosis.9 
Cytogenetics are generally classified as being favourable, intermediate or poor, with survival 
differing markedly between these groups. In a recent analysis of patients enrolled in the 
Cancer and Leukaemia Group B first-line trials, median (overall) survival for patients aged 
over 60 was 1.6 years for individuals in the favourable group (based on cytogenetics and 
molecular genetics), 0.9 years for individuals in the intermediate groups, and 0.5 years for 
individuals in the adverse groups.23 
2.1.4 Burden and impact on quality of life 
Celgene note the following in relation to the impact on the quality of life of the patient 
(Source: Celgene submission, Section 3.2, p. 32): 
When compared with the general population, patients with AML experience a 
significant reduction in physical functioning (as determined via the physical 
component domain of quality of life assessments), and experience a higher incidence 
of depression.2 Furthermore, quality of life deteriorates over time, with a significant 
reduction observed as early as 2 weeks after AML diagnosis.2 Patients with AML can 
also experience appetite loss and fatigue; both having a negative impact on overall 
measures of quality of life.24 The burden of the disease continues until death, with 
patients frequently suffering from open bleeding, infection, and pain during the final 
stages of the disease.25 
 
The ERG note that the study by Sekeres et al.2 found similar SF-12 mental component 
scores for AML patients as population norms, which should be considered alongside the 
finding of a higher incidence of depression. Other than this the description is appropriate and 
relevant.  
Celgene also note the potential impact on caregivers (Source: Celgene submission, Section 
3.2, p. 32): 
The impact is far reaching with caregivers, including family or friends, often having to 
deal with numerous and concurrent stressful events, and often suffering negative 
psychological, behavioural and physiological effects on their daily lives and their 
health.26 
 
The ERG note that the publication by Bevans and Sternberg26 cited by the company is a 
case study of a single individual with AML secondary to MDS, who also received HSCT. The 
ERG considers that this does not constitute high-quality evidence of an impact on 
caregivers, although the ERG does not dispute that such impacts may exist. 
 Page 21 of 145 
 
2.2 Critique of company’s overview of current service provision 
The company gives the following overview of the clinical pathway of care for elderly patients 
with AML – the company’s decision problem focuses on elderly patients as opposed to all 
adults, see Section 3 (p. 23) – (Source: Celgene submission, Section 3.3, p. 33): 
Due to the heterogeneity of disease, there is no standard of care for elderly patients 
with AML, resulting in complex treatment guidelines.27-30 Despite differences between 
published treatment guidelines, there is a general consensus that treatment 
decisions should be based on a number of patient- and disease-related prognostic 
factors. Patients with favourable prognostic factors are more likely to be assessed as 
“fit” to receive treatment with IC while patients with unfavourable prognostic factors, 
such as increased age, poor performance and/or cytogenetic risk status, and 
increased comorbidities are typically deemed unfit for treatment with IC. As such, 
these patients are usually offered less intensive chemotherapy options, such as 
LDAC and those unable to tolerate chemotherapy or who chose not to receive LDAC 
should receive BSC only.  
Despite this general guidance there is no widely accepted risk algorithm which 
clinicians use in the UK when deciding which patients are most likely to benefit from 
intensive or non-intensive treatment options. A recent review further demonstrated 
the lack of structure when making treatment decisions, concluding that decisions 
remain complex and selection is subjective based on the clinician’s judgement.31 
Patient choice was also found to be a confounding factor, accounting for 
approximately 8% of treatment decisions, irrespective of the clinicians’ 
recommendation.32 
 
The company also provide the following information in relation to current service provision 
(Source: Celgene submission, Section 3.7, p. 37): 
Treatment options for elderly patients with >30% BM blasts AML include HSCT, IC, 
low-dose chemotherapy (LDAC), or BSC alone.28 However, HSCT is rarely used in 
patients older than 65 years.33 Decitabine is also licenced in the EU for the treatment 
of elderly WHO-defined AML but it is not reimbursed (NICE TA27034) and so is not 
used in UK routine clinical practice. Treatment with IC is typically contraindicated for 
patients aged ≥65 years with an adverse performance status, organ damage, and 
comorbidities.28 Treatment with IC can however be successfully used in older 
patients, if restricted to patients with a favourable performance status, minimal organ 
dysfunction and/or comorbidity, and favourable cytogenetics, but is associated with 
an increased risk of treatment-related mortality.5, 28 In this patient population, 
treatment options usually consist of LDAC or BSC and patients suffer from low 
survival rates, with a 26% 30-day mortality reported in patients receiving low-intensity 
treatment.21, 28 
 
The ERG note that a Swedish registry study covering 98% of Swedish patients diagnosed 
with AML by the French-American-British criteria (requiring at least 30% bone marrow 
blasts) found that 55% of patients aged at least 65 years with ECOG PS 0–2 were reported 
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fit for intensive chemotherapy, and 45% of patients aged at least 65 years of any ECOG 
PS.22 
Our clinical expert (CR) advised that IC is administered in an inpatient setting, while LDAC 
may be self-administered at home. Azacitidine would most likely be administered as a 
regular day case in the NHS, which presents the problem of administering azacitidine on 
seven consecutive days since many day case units do not currently operate over the 
weekend. Patients treated with azacitidine would normally attend for five consecutive days 
(Monday to Friday) and then two consecutive days after a weekend break (Monday and 
Tuesday). Prevailing clinical opinion is that this schedule is non-inferior to administration 
over seven consecutive days. Patients treated with best supportive care may be admitted at 
times to treat certain complications (e.g., infection). A UK study recently found that of 
patients with one of three haematological malignancies (AML, diffuse large B-cell lymphoma 
and myeloma), 74% died in hospital, 15% at home, and the remainder in a hospice or 
nursing home.35 
The ERG believes that these descriptions are appropriate and relevant to the company’s 
chosen decision problem (see Section 3, p. 23). 
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3 Critique of company’s definition of the decision problem 
The company presented their decision problem within the Executive Summary chapter, 
under the subheading ‘statement of the decision problem’ (Celgene submission, Section 1.1, 
p. 12–16). A summary table of the NICE Scope,36 the company’s decision problem and the 
ERG’s critique is presented below (Table 1). Further comments to the decision problem 
follow the table. 
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Table 1: Summary table of decision problem critique 
Decision 
problem 
NICE Scope Company’s decision problem ERG notes 
Population Adults with acute myeloid leukaemia with bone 
marrow blasts more than 30% 
Adults aged ≥65 years who are not eligible for 
HSCT with AML with >30% marrow blasts 
The changes in population by the company 
brought the population in line with the EMA 
marketing authorisation for azacitidine. The ERG 
is satisfied this is a reasonable change. 
Intervention Azacitidine As per Scope No comments. 
Comparator  Intensive chemotherapy with an anthracycline 
in combination with cytarabine 
 Non-intensive chemotherapy with low dose 
cytarabine 
 Best supportive care which may include blood 
product replacement, antibiotics, antifungals 
and intermittent low dose chemotherapy with 
hydroxycarbamide 
 Conventional care regimen (CCR; consisting 
of IC, LDAC and BSC)  
The company have replaced three individual 
comparators with one composite comparator on 
the basis that there are no established criteria for 
selecting one CCR. As a result the company have 
not assessed whether azacitidine demonstrates 
clinical and cost effectiveness compared to each 
CCR (in patients for whom that CCR would be 
appropriate). The ERG considers this to be a 
weakness of the submission. 
Outcome The outcome measures to be considered include: 
 Overall survival 
 PFS 
 Time to disease progression 
 Response rates, including haematologic 
response and improvement 
 Blood-transfusion independence 
 Infections 
 Adverse effects of treatment 
 Health-related quality of life 
 Cost per quality-adjusted life year. 
The outcomes measured include: 
 Overall Survival 
 PFS – estimated from EFS and RFS for the 
purpose of economic modelling 
 Time to disease progression 
 Response rates, including CR, CRc, and PR 
 Blood-transfusion independence 
 Infections 
 Adverse effects of treatment 
 Health-related quality of life 
 Cost per quality-adjusted life year. 
Two outcomes (PFS and response rate) reported 
by the company do not match exactly to the 
Scope. Differences are either terminology or 
added detail for clarification. These differences 
are deemed acceptable. 
Other 
considerations 
If the evidence allows the following subgroups will 
be considered. These include:  
 People with AML secondary to 
myelodysplastic syndrome  
 People with adverse-risk cytogenetics  
 
A number of pre-defined patient- and disease-
related subgroups were assessed during the 
pivotal trial, AZA-AML-001 and included those 
with MDS-related changes, and poor cytogenetic 
risk status, as per Scope 
AML secondary to MDS is a subgroup of AML 
with MDS-related changes (constituting just over 
half), but outcomes are expected to be similar. 
Key: AML, acute myeloid leukaemia; BM, bone marrow; BSC, best supportive care; CCR, conventional care regimens; CR, complete remissions; CRc, cytogenetic complete remission; EFS, 
event-free survival; EMA; European Medicines Agency;  HSCT; haematopoietic stem cell transplantation; IC, intensive chemotherapy; IV, intravenous; LDAC, low-dose cytarabine; 
MDS, myelodysplastic syndromes; OS, overall survival; PFS, progression-free survival; PR, partial remission; RFS, relapse-free survival; SC, subcutaneous.   
Source: NICE Scope 
36
 and Celgene submission, Table 1, p. 12–16 
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3.1 Population 
The population in the company’s submission did not match for age and eligibility (adults 
aged ≥65 years who are not eligible for haematopoietic stem cell transplantation), to the 
population specified in the NICE Scope (adults).36 Celgene justify this inconsistency by 
stating that: 
This submission specifically evaluates the efficacy and tolerability of azacitidine in 
patients aged ≥65 years and who are not eligible for HSCT in line with the new 
indication approved by the EMA. 
 
The European Medicines Agency (EMA) indication for azacitidine has been expanded, and 
now includes: “Treatment of adult patients aged 65 years or older who are not eligible for 
HSCT with AML with >30% marrow blasts according to the WHO classification.” Therefore, 
the population reported by the company matches the EMA marketing authorisation for 
azacitidine but does not match the NICE Scope. Overall we agree that the population 
considered by the company’s submission is appropriate based on it matching the EMA 
indication. 
3.1.1 Subgroups to be considered 
The NICE Scope states that if evidence allows, the following subgroups should be 
considered: 
 People with AML secondary to myelodysplastic syndrome; 
 People with adverse-risk cytogenetics. 
The company’s decision problem suggests that pre-defined subgroups were assessed in the 
pivotal trial, including those with MDS-related changes and those with poor cytogenetic risk 
status. The ERG note that AML with MDS-related changes is a broader category including 
AML secondary to MDS, and that in the pivotal trial there were 158 patients with MDS-
related changes but only 87 patients with prior MDS.37 Nevertheless, the prognosis of AML 
with MDS-related changes is likely to be similar to the prognosis of AML secondary to MDS. 
3.2 Intervention 
The company’s decision problem specified the intervention as ‘azacitidine’, which matches 
the NICE Scope.36 
The NICE Scope describes azacitidine as follows; ‘Azacitidine (Vidaza, Celgene) is an 
analogue of nucleotide cytidine that reduces DNA methylation by inhibition of DNA 
methyltransferase. Azacitidine is administered subcutaneously.’ 
The EMA recommend the following for administering azacitidine: 
The recommended starting dose of Vidaza is 75 mg per square metre body surface 
area (calculated using the patient’s height and weight). It is given as an injection 
under the skin… …every day for one week, followed by three weeks with no 
treatment. This four-week period is one ‘cycle’. Treatment continues for at least six 
cycles and then for as long as it benefits the patient. The liver, kidneys and blood 
should be checked before each cycle. If the blood counts fall too low or if the patient 
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develops kidney problems, the next treatment cycle should be delayed or a lower 
dose should be used. Patients who have severe liver problems should be carefully 
monitored for side effects, but Vidaza must not be used in patients with advanced 
liver cancer. 
 
Our clinical advisor (CR) commented that they would typically administer azacitidine for five 
days (Monday to Friday), and then administer the remaining two days on Monday and 
Tuesday of the following week, as this is more convenient for the patients and the day case 
setup at the hospital. 
3.3 Comparators 
The comparators in the submission do not match those in the Scope.36 There is more detail 
given by the Scope, regarding component treatments, than by the company who just report 
the overarching term for the comparator. The company also refer to decitabine, a treatment 
that was included in the NICE Draft Scope as a form of non-intensive chemotherapy. 
Decitabine has marketing authorisation in the UK but has not received a positive NICE 
recommendation following termination of NICE technology appraisal 270.34 The company 
note that decitabine was removed for the Final Scope and do not include it in their decision 
problem.  
The comparator in the company submission is a composite comparator, containing the 
comparators as identified in the Scope. This comparator is referred to as Conventional Care 
Regimen (CCR). Further details on dosing schedules for the CCR are as follows: 
 Intensive Chemotherapy (IC): generally consists of cytarabine 100-200 mg/m2 per 
day by continuous intravenous infusion for 7 days, plus three days of either 
daunorubicin 45-60 mg/m2 per day or idarubicin 9-12 mg/m2 per day for one cycle, 
followed by up to two consolidation cycles.28 Our clinical expert commented that 
there are various different schedules for the administration of the IC treatment; 
however these differing combinations are unlikely to alter the clinical effectiveness of 
the drugs. 
 LDAC: subcutaneously, 20 mg twice per day for 10 days.28 This dosing practice was 
considered routine by our clinical expert. 
 BSC: typically BSC will consist of prophylactic anti-infectious treatment (including 
fungal and antibiotic prophylaxis) and transfusion support (platelet, red blood cell and 
granulocyte transfusion).28 This dosing practice was considered routine by our clinical 
expert. 
Our clinical advisor (CR) commented that most patients are offered IC even if they ultimately 
receive an alternative treatment. 
The ERG considers it a weakness to use a combined comparator in the decision problem, 
since it is possible that azacitidine could be effective and cost-effective (at a chosen cost-
effectiveness threshold) versus some individual comparators but not others, but this would 
be obscured. This could result in either: azacitidine being used in patients when it would 
have been better for them and/or a better use of limited NHS resources for an alternative 
treatment to be used; or, azacitidine not being used in patients when it would have been 
better for the patient and/or a better use of limited NHS resources. 
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3.4 Outcomes 
The outcomes in the company submission match those in the Scope. However, they have 
made the following amendments to progression free survival and response rate: 
Progression free survival (PFS) - estimated from event-free survival (EFS) and 
relapse-free survival (RFS) for the purpose of economic modelling.  
Response rate – including complete remission, cytogenetic complete remission and 
partial remission. 
 
The company justify the alterations to PFS, by suggesting that PFS is not a standard 
endpoint for AML. Our clinical advisor (CR) believes that estimating PFS from EFS and RFS 
would be an appropriate alternative measure. 
For the measure of response rate, the Scope specified response rate, including 
haematologic response and improvement, whereas the company reports that the outcome 
response rate included complete remission, cytogenetic complete remission and partial 
remission. These are only terminological differences. 
3.5 Other relevant factors 
In response to special considerations relating to equity and equality, the company make the 
following statement within their decision problem. The ERG has no comments on their 
statement. 
AML presents primarily in the elderly population, with 64% of newly diagnosed cases 
in the UK in patients aged ≥65 years.4 Equity of treatment of the elderly is a concern, 
as evident from a report published by the National Audit Office in January 2015.38 
AML is also an orphan disease.39 The Cancer Patient Experience Survey in 2010 
found that people with rarer forms of cancer reported a poorer experience of their 
treatment and care than people with more common forms of cancer.40 Therefore, 
access where appropriate to a treatment such as azacitidine should help to promote 
equality for both elderly patients and those with rarer forms of cancer. 
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4 Clinical effectiveness 
4.1 Critique of the methods of review(s) 
4.1.1 Searches 
Celgene presented a literature search protocol to support its review of clinical effectiveness. 
This protocol included systematic searches of key biomedical databases using a literature 
search strategy, hand-searching of conference abstracts, and a search of ClinicalTrials.gov. 
The literature search was last updated in November 2015. 
The bibliographic database searching used a search strategy that took the following form: 
1. (controlled index terms for acute granulocytic, acute myeloblastic, acute 
myelomonocytic, acute monocytic or acute megakaryocytic leukemia or 
erythroleukemia or promyelocytic) and 
2. (controlled index terms for Azacitidine, cytarabine, gemcitabine, deoxycytidine, 
etoposide, etopofos, fludarabine, anthracycline, mitoxantrone, daunorubicin or 
tioguanine or best supported care) and 
3. (a range of search terms for study design (RCTs and observational), limits to remove 
studies conducted on animals and studies published in languages other than English. 
Systematic reviews and meta-analysis were also excluded from identification. The 
searches were date limited 2000 to current). 
The search strategy was applied in the following bibliographic databases: MEDLINE (OVID), 
EMBASE (OVID) and Cochrane CENTRAL (OVID).  
The following conference proceedings were hand-searched: European Haematology 
Association (EHA) Annual Congress, American Society of Haematology (ASH) Annual 
Conference, and the British Society for Haematology (BSH) Annual Scientific Meeting 
between January 2013 and April 2015. Finally, ClinicalTrials.gov was searched for relevant, 
unpublished studies. 
The ERG believes the literature searching for clinical effectiveness studies was poorly 
conducted and reported. 
The literature search strategies provided rely entirely on controlled indexing search terms. 
Free-text search terms for acute myeloid leuk(a)emia or AML (as used in the submission of 
cost-effectiveness literature searching) have been omitted. This is inappropriate for two 
reasons: 
1. The searches (as presented) will only return studies that have been indexed. Newly 
published studies (or additional trial outcome data), or relevant studies published 
ahead of print, will likely be excluded from these searches as, whilst studies are 
uploaded to bibliographic databases on receipt, there is a delay between a study 
being published and then indexed. This point affects the currency of the literature 
searches and introduces bias into the identification of studies.  
2. Any studies that have been incorrectly indexed but are of relevance to the decision 
problem would be missed by these searches. The inclusion of free-text terms for 
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AML, for example, would address this risk. This point affects the sensitivity of the 
literature search, which is poor.  
The search strategy excludes the identification of systematic reviews and meta-analyses. In 
clarification, the manufacturer stated that the bibliographies of systematic literature reviews, 
meta-analyses and other included studies were used as a search strategy to identify further 
studies. As systematic reviews and meta-analyses were excluded from bibliographic 
searching it is not clear how they were identified and therefore how this particular search 
was actually conducted. This affects the replicability of the literature searching. 
The literature searching is difficult to validate and it has been poorly reported.  
The literature search strategies for MEDLINE and EMBASE have been combined and 
reported as if one search. This makes it difficult to validate and repeat the literature search 
used in MEDLINE as the EMBASE search strategy has been used and presented as the 
base search. Furthermore, the combination, and practicable use of study design literature 
search filters, is poorly considered when balanced against the decision problem of the 
review. This affects the transparency of the literature searching. 
In view of these points, the ERG has undertaken its own scoping searches to ensure that no 
phase III RCTs have been missed by this review. Whilst basic scoping searches have not 
identified any additional studies, the ERG has been unable to validate aspects of this search, 
and the overall quality of the approach to literature searching is sufficiently poor, that it raises 
questions if it is truly fit for purpose. 
4.1.1.1 Adverse events 
Celgene did not undertake separate literature searches to identify studies reporting adverse 
events. In their submission, Celgene stated that (Source: Celgene submission, Section 4.12, 
p. 85):  
No further studies that report additional adverse events …that are of relevance to the 
decision problem are available 
 
In clarification, Celgene confirmed that no separate literature searches to identify studies 
reporting adverse events were undertaken, stating that their literature searches were not 
limited by adverse event outcomes. Whilst it is true that Celgene’s literature searches were 
not limited by outcomes, Celgene’s literature searches were limited by study design. It is 
therefore possible that studies reporting adverse events may have been missed. 
4.1.2 Inclusion criteria 
Celgene’s inclusion criteria are given below (Table 2) with an additional column added to the 
right of the table, taken from the Scope36 for reference and comparison. Comments about 
the differences in inclusion criteria are outlined below the table. 
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Table 2: Scope of the literature review: PICOS criteria for study inclusion 
Criteria From Celgene From Scope 
Definition 
Population Older adult AML patients
a
 with peripheral 
blood or BM leukaemic myeloblasts 
>20%, who either: 
 Are newly diagnosed with AML  
 Have developed AML secondary to 
“preleukaemic” blood disorders such 
as MDS or myeloproliferative disease 
 Have developed AML secondary to 
exposure to leukaemogenic therapy 
or agents with primary malignancy in 
remission for at least 2 years  
Adults with acute myeloid leukaemia 




 Azacitidine 75 mg/m
2
  
 LDAC (20 mg SC once or twice a day 
for 10-14 days) 
 Decitabine 20 mg/m
2
 
 Other high dose chemotherapy: 
o Combination of etoposide or 
fludarabine (plus granulocyte-
colony stimulating factor aka “G-
CSF”) with cytarabine (preferred 
for patients with cardiac disease) 
o 7+3: continuous IV infusion of 
cytarabine for 7 days followed by 
3 days of IV anthracycline push 
o Combination of IV mitoxantrone, 
etoposide IV, and cytarabine 
o Combination of IV daunorubicin, 
cytarabine, and etoposide 
o Combination of IV cytarabine, 
daunorubicin, and oral 
thioguanine 
o Combination of IV cytarabine and 
daunorubicin: 3+10 for cycle 1 
followed by DA 3+8 for cycle 2 
(standard for UK) 
 Best supportive care
b
 
Intervention: Azacitidine  
 
Comparators:  
 Intensive chemotherapy with an 
anthracycline in combination with 
cytarabine  
 Non-intensive chemotherapy with 
low dose cytarabine  
 Best supportive care which may 
include blood product replacement, 
antibiotics, antifungals and 
intermittent low dose chemotherapy 
with hydroxycarbamide  
 
Outcomes Studies are eligible if at least one of the 
following outcomes are included:
c
 
 Efficacy outcomes 
o Overall survival 
o Event-free survival 
o Progression-free survival 
o Relapse-free survival 
o Complete response 
 Safety outcomes 
o Treatment-related mortality 
o Hospitalisation due to AE 
o Grade 3 or 4 haematologic AEs 
o Discontinuations due to AEs 
o Discontinuations due to reasons 
other than disease progression 
The outcome measures to be 
considered include:  
 Overall survival  
 Progression free survival  
 Time to disease progression  
 Response rates, including 
haematologic response and 
improvement  
 Blood-transfusion independence  
 Infections  
 Adverse effects of treatment  
 Health-related quality of life  
 
 Page 31 of 145 
 
Criteria From Celgene From Scope 
Definition 
Study Design  Randomised controlled trials and 
comparative non-randomised studies 
(prospective and retrospective 
observational studies) 
 Studies must compare two unique 
treatment classes (e.g. IC vs. IC or 
dose-ranging studies not eligible) 
 
Other  English language only 
 Published in or after the year 2000 
(Selected on the advice of a panel of 
haematologists who advised that 
there would be limited evidence of 
relevance pre the year 2000). 
 
Key: AE, adverse event; AML, acute myeloid leukaemia; BM, bone marrow; CR, complete response; EFS, 
event-free survival; IC, intensive chemotherapy; IV, intravenous; LDAC, low-dose cytarabine; MDS, 
myelodysplastic syndrome; OS, overall survival; PFS, progression-free survival; RFS, relapse-free 
survival; SC, subcutaneous. 
Notes: a, Note that although the primary population of interest is those 65 years of age and older, this criteria 
was relaxed (e.g. 55 years of age and older) to ensure sufficient evidence was available; b, It was 
expected that definitions in best supportive care would vary; c, Note that additional outcomes were of 
interest, but only those identified in the table above were used to guide the selection of studies; safety 
outcomes were extracted only for those studies providing efficacy data.  




Celgene’s population was broader (bone marrow blasts more than 20%) than the Scope 
(bone marrow blasts more than 30%).36 The company explained that this was to capture 
studies on bone marrow blasts over 20% that had included sub-analysis on the 30% bone 
marrow blast population.  
Conversely, Celgene’s population was narrower (older adult AML patients) than the Scope 
(adults with AML).36  Older adults were defined by Celgene for their systematic review as a 
population over 55 years. In order to check if any studies were excluded based on 
population; the ERG checked the reasons given in table of excluded studies (Celgene 
appendices to submission, Appendix 2, Table 1, pp. 10–11) and found none. However, we 
cannot exclude the possibility studies may have been excluded from title/abstract screening. 
4.1.2.2 Interventions/comparators 
The intervention/comparators for inclusion broadly match the Scope.36  However, there are 
some key differences. For the intervention azacitidine and two of the comparators (LDAC 
and decitabine) drug doses were included. It is not clear whether studies were excluded 
based on the drug administration dose, nevertheless drug administration doses are not 
specified within the Scope.  
The comparators for inclusion reported by the company include all of those reported in the 
Scope and also decitabine.36  The company also include specific drug combinations to be 
given alongside intensive chemotherapy rather than, ‘with an anthracycline in combination 
with cytarabine’ as per the Scope. This may have resulted in relevant studies being 
excluded. 
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4.1.2.3 Outcomes 
The outcomes overall survival, progression-free survival match the Scope.36 However, 
event-free survival, relapse-free survival and complete response are not within the Scope. 
Other outcomes within the Scope, but not in the inclusion table submitted by the company 
include: time to disease progression; response rates, including haematologic response and 
improvement; blood transfusion independence; infections; adverse effects of treatment and 
health related quality of life. In order to check if any studies were excluded based on 
outcomes; the ERG checked the reasons given in table of excluded studies (Celgene 
appendices to submission, Appendix 2, Table 1, p. 10–11) and found none. However, we 
cannot exclude the possibility studies may have been excluded from title/abstract screening. 
4.1.2.4 Study Design 
The Scope did not restrict study design. However, the NICE reference case guide to the 
methods of technology appraisal 2013 (Chapter 5.2.3)41 recommends studies should be 
restricted to RCTs and when they are not available, non RCTs. Studies included in the 
company submission were RCTs, observational studies and information from registries. We 
are satisfied the study designs meet the reference case. 
4.1.2.5 Other 
Celgene applied an English language restriction to their systematic review. Language was 
not given as a reason for exclusion from full-text screening (Celgene appendices to 
submission, Appendix 2, Table 1, p. 10–11). However, we cannot exclude the possibility 
studies may have been excluded from title/abstract screening. 
Another restriction was to exclude studies published before 2000. The decision to restrict the 
studies to only include studies post-2000 was (Source: Celgene submission, Section 4.1.2, 
p. 40):  
Selected on the advice of a panel of haematologists who advised that there would be 
limited evidence of relevance pre the year 2000 
 
The ERG notes that azacitidine was used for primarily haematologic malignancies in the 
1960s-1980s.42-44 Consequently, studies excluded based on date limitation could add 
relevant information for the use of azacitidine in treating AML. Reference citations for the 15 
RCT studies reported as excluded based on publication date (Celgene appendices to 
submission, Appendix 2, Table 1, p. 10–11) were requested and subsequently examined. 
None of the 15 studies would have been eligible for inclusion in this submission.  
4.1.2.6 Study selection 
Celgene’s submission explains the process used in study selection (i.e., that two 
researchers independently reviewed the abstracts and the full-texts of studies, that 
discrepancies between investigators were resolved by involving a third investigator and 
coming to a consensus). These are standard procedures for systematic reviews.41 
From the 8,450 citations the company identified from their searches, 8,363 citations were 
excluded and 87 were taken to full-text screening at the abstract screening stage. From the 
full-text screening, 80 citations were excluded with reasons for exclusion provided (Celgene 
appendices to submission, Appendix 2, Table 1, pp. 10–11). The company go on to explain 
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that three further materials were added from manual searches of literature databases and 
conference proceedings. One of the three additional materials identified from the manual 
searches was the pivotal trial AZA-AML-001. The company included ten citations from seven 
trials. The PRISMA diagram reported in Celgene’s submission is copied below (Figure 1). 
Figure 1: PRISMA study flow diagram 
 
Notes: * 3 materials added; ** 4 RCTs and 3 observational studies. 
Source: Celgene submission, Figure 4, p. 42 
From the seven included studies, the company go on to exclude a further five studies. The 
exclusion of these five studies is justified by the company on the basis that their inclusion 
criteria were over-inclusive. Four studies were excluded as the population was those with 
bone marrow blasts over 20% and not 30% as per the Scope. The fifth study was excluded 
as the comparator treatment was decitabine, a comparator not included in the decision 
problem. 
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The remaining two studies were an RCT by Dombret et al. 2015.45 and an observational 
study by Lao et al. 2015.46 The main focus of the submission was the RCT study by Dombret 
et al. (AZA-AML-001). The company also refer to registry data from three countries (Austria, 
Spain and France) within their submission. 
4.1.3 Data extraction 
The submission explains the process of data extraction used, which is in line with the 
standard review process (Source: Celgene submission, Section 4.1.2, p. 40) 
Two investigators independently extracted data on study characteristics, 
interventions, patient characteristics at baseline, and outcomes for the study 
populations of interest for the final list of selected eligible studies. Any discrepancies 
found between the data extracted by the two data extractors were resolved by 
involving a third reviewer and coming to a consensus.  
 
The ERG notes that in relation to the pivotal RCT by Dombret et al.,45 all the typical data 
(including but not limited to: participant inclusion criteria, baseline characteristics, methods, 
primary and secondary study outcomes and adverse events) has been extracted from the 
paper, but that there were several typographic errors in the extracted data reported in their 
submission. The ERG has referred to the original publication and the clinical study report for 
AZA-AML-00137 to resolve discrepancies where they have been identified. 
4.1.4 Quality assessment 
Details of the company’s critical appraisal of the RCT AZA-AML-001,45  alongside our 
critique, can be seen below in Table 3. The critical appraisal appears (since no reference is 
given to the tool used) to have been performed by the company using the CRD assessment 
criteria for risk of bias in RCTs. However, they have slightly adjusted the wording of the 
questions, as they do not match exactly. The meanings behind the questions remain the 
same. 
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Patients were randomised in a 1:1 ratio. 
Randomisation was performed using an 
IVRS.  
Patients were stratified at randomisation 
by: 
 CCR selection (IC, LDAC or BSC),  
 ECOG performance status at 
baseline (0–1 versus 2) 
 Cytogenetics (intermediate-risk 
versus poor-risk) 
 
Further information on the 
randomisation process from the paper 
reports that: a central, stratified, and 
permuted block randomisation method 
and IVRS were used to randomly assign 
1:1 to received azacitidine or CCR. This 
is an acceptable system for 






Open-label study. Blinding of study 
treatment was not feasible due to 
multiple comparators and routes of 
administration. However, all central 
reviewers were blinded to subject 
treatment assignment. 
Celgene have not answered this 
question. Allocation sequence 
concealment obtains strict 
implementation of an allocation 
sequence without prior knowledge of the 
intervention assignments. Methods for 
allocation concealment refer to 
techniques used to implement the 
sequence, not to generate it. For this 
trial, central randomisation ensured 





at the outset 




Yes. Patient demographics in the 
azacitidine and combined CCR groups 
were well balanced in terms of age, age 
distribution, sex, geographic location, 
race, weight and BSA. The azacitidine 
and combined CCR groups were also 
comparable for all baseline disease 
characteristics (including AML 
classification, prior history of MDS, time 
since AML diagnosis, ECOG 
performance status and cytogenetic 
status), with the exception of prior 
anticancer systemic therapies. 
 
As Celgene have written, demographics 
between azacitidine and combine CCR 
are well balanced and we are satisfied 
with this assessment. More meaningfully 
perhaps, baseline characteristics for the 
three individual CCR arms could have 
been compared to the azacitidine arm 
split by the CCR assignment prior to 
randomisation. However, this data was 
not available. Confusingly, Celgene 
contradict themselves by reporting (p. 
26) that they provided evidence to the 
CHMP that outcome failures were due to 
an imbalance of patients’ baseline 
characteristics/prognostic factors. 
 








Although the trial was open-label, all 
central reviewers were blinded to 
subject treatment assignment. 
Evaluations by central review were used 
for the statistical efficacy analyses.  
The independent review committee 
which reviewed and confirmed the 
haematologic responses and durations 
was blinded to treatment, investigative 
site, and subject identifier. 
 
Since the study was open labelled, the 
care providers and participants could not 
be blinded to treatment allocation. 
Awareness of treatment allocation will 
have introduced the potential for bias 
within the study, particularly with 
reporting of adverse events. All central 
reviewers were however, blinded to 
treatment assignment. 













No. The most common reasons for 
discontinuation from the treatment 
phase in both the azacitidine and CCR 
groups were occurrence of an AE 
(36.9% and 26.7%, respectively) or 
death (22.0% and 23.5%, respectively).  
Discontinuations due to occurrence of 
an AE or study closure were more 
common in the azacitidine group 
whereas discontinuations due to 
withdrawal of consent were more 
common in the CCR group, with the 
highest percentage in the BSC group.  
The percentages of subjects who were 
discontinued from treatment because of 
death or disease progression were 
comparable between the azacitidine and 
the CCR treatment groups. No subject 
discontinued due to loss of follow-up or 
protocol violation in the azacitidine 
group. One subject discontinued due to 
loss of follow-up in the IC group and one 
subject discontinued due to protocol 
violation in the LDAC treatment group. 
 
The drop-outs provided by Celgene 
represent the figures reported in the 
RCT. However, neither Celgene nor the 
RCT report the drop outs for the three 
CCR treatments separately, therefore it 
is unknown whether the actual 
treatments that make up the CCR are 
comparatively different to azacitidine. 
The dropout rates due to an AE look 
imbalanced for azacitidine (36.9%) 
compared to the CCR group (26.7%). 










No. All treatment outcomes were 
reported other than those that are not 
currently available for analysis 
(exploratory molecular markers). 
The ERG agrees with Celgene’s 











to account for 
missing data? 
The ITT population was used for the 
analysis of the primary and secondary 
efficacy endpoints. The ITT population 
was the most appropriate population as 
it included all randomised patients.  
Yes – the main analysis adopts 
‘intention to treat’ principles. 
Key: AE, adverse event; AML, acute myeloid leukaemia; BSA, body surface area; BSC, best supportive care; 
CHMP, Committee for Medicinal Products for Human Use; CCR, conventional care regimens; ERG; 
evidence review group; IC, intensive chemotherapy; ITT, intent-to-treat; IVRS, interactive voice 
response system; LDAC, low-dose cytarabine; MDS, myelodysplastic syndromes. Clinical effectiveness 
results of the relevant randomised controlled trials.  
Source: Celgene submission, Table 17, p. 64 
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4.1.5 Evidence synthesis 
From the searches, one RCT was identified. Therefore synthesis of the evidence was not 
required. 
4.2 Critique of the trials of the technology of interest, their analysis and 
interpretation 
4.2.1 Methods 
The single RCT (study name AZA-AML-001; main publication by Dombret et al. 201545) 
identified was presented in detail within the submission. 
4.2.1.1 Study objectives 
The company submission reports the study objectives as follows (Source: Celgene 
submission, Section 4.3.1, p. 43): 
The primary objective of the study was to demonstrate superiority in OS of 
azacitidine compared with combined CCRs in subjects aged 65 years or over who 
had newly diagnosed AML with more than 30% BM blasts according to the WHO 
criteria,14, 47 and who were not eligible for haematopoietic stem cell transplantation. 
Overall survival was defined as time from randomisation to death from any cause. 
 
Secondary objectives included 1-year OS rate, EFS, RFS, overall remission rate, 
cytogenetic complete remission (CRc) rate, safety and toxicity assessments, HRQoL and 
health resource utilisation. 
The primary objective concurs with the primary outcome; an outcome specified within the 
NICE Scope.36 The secondary objectives correspond in parts to the outcomes from the 
Scope. The differences are the same as those already discussed in Section 4.1.2.3 (page 
32). 
4.2.1.2 Study design and treatment 
The study AZA-AML-001 was a multicentre (over 18 countries), randomised, open-label, 
parallel-group study.  
Before randomisation, the most appropriate CCR (IC, LDAC or BSC) was determined by 
investigators on the basis of age, Eastern Cooperative Oncology Group Performance Status 
(ECOG PS), comorbidities and regional guidelines and/or institutional practice. Once the 
CCR had been chosen, a central, stratified, and permuted block randomisation method and 
interactive voice response system was used to randomly assign 1:1 to receive azacitidine 
with BSC or the pre-selected CCR. The random treatment assignment was concealed so 
that investigators and subjects did not know in advance the next treatment assignment. 
Following randomisation and drug administration, follow-up appointments were scheduled 
once per week during the first two treatment cycles, then every other week thereafter. The 
frequency of safety and efficacy measures ranged from weekly to every 12 weeks, 
depending on the procedure. Drug administration and data collection protocols are outlined 
in Table 4.  
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By design, there is awareness of the treatment allocated for both the patient and primary 
care givers from an open-labelled study. Awareness of treatment allocation will have 
introduced the potential for bias within the study, particularly with reporting of adverse 
events. Based on the treatments administered within the study, an open-label study design 
was the most appropriate study design to be utilised. Treatment protocols for administration 
were confirmed as appropriate by our clinical advisor (CR) and follow-ups were similar and 
appropriate in time. 
Table 4: Treatment protocol 








/day, subcutaneously for 7 consecutive 
days per 28-day treatment cycle for at least 6 cycles.  
Dosing could be reduced or delayed as needed until 
the blood count recovered.  
BSC: as for BSC and including transient use of 
hydroxyurea (hydroxyurea was not allowed within 72 
hours before or after azacitidine administration). 
Within 7 days before 
initiation of every second 
cycle beginning at cycle 3 
Best supportive 
care 
Included, but was not limited to, treatment with red 
blood cell or whole blood transfusions, fresh frozen 
plasma transfusions, platelet transfusions, antibiotic 
and/or antifungal therapy, and nutritional support. 
Hydroxyurea use was permitted under certain 
conditions 
On day 1 of every third 
cycle (a BSC cycle was 
defined as 28 days), 
beginning at cycle 4. 
LDAC and BSC 20 mg of cytarabine twice per day, subcutaneously 
for 10 days per 28-day treatment cycle for at least 4 
cycles).  
Dosing could be reduced or delayed as needed until 
the blood count recovered. BSC: as for BSC and 
including transient use of hydroxyurea 
Within 7 days before 
initiation of every second 
cycle beginning at cycle 3 
IC and BSC Cytarabine 100-200 mg/m
2
/day by continuous 
intravenous infusion for 7 days, plus on days 1-3 if 
cytarabine an anthracycline (either daunorubicin 45-
60 mg/m
2
/day or idarubicin 9-12 mg/m
2
/day) for 1 
cycle. Followed by up to 2 consolidation cycles (i.e., 
the same anthracycline regimen as used at induction 
and the same cytarabine dose used for induction but 
administered for 3 to 7 days) for those achieving 
complete response or partial response. Re-induction 
was not allowed. BSC: as for BSC and including 
transient use of hydroxyurea 
At screening and within 7 
days before each 
treatment cycle 
Key: BSC, best supportive care; IC, intensive chemotherapy; LDAC, low-dose cytarabine 
Notes: a, consisting of cytogenetic testing and pathological samples (BM aspirates, BM biopsies, and 
peripheral blood smears) to confirm diagnosis.  
Concomitant medications were kept to a minimum, but where necessary and where unlikely 
to interfere with trial drugs, were given at the discretion of the investigator. Concomitant 
medications included and excluded were as described in Table 5. 
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Table 5: Concomitant medications in/excluded 
Included Excluded 
 Hydroxyurea  
 Serotonin  
 Blood product support (red blood cells and platelets)  
 Myeloid growth factors (only for the treatment of 
neutropenic infections, prophylactically during IC 
treatment, or in subjects with two or more previous 
episodes of neutropenic infection who were at risk of 
subsequent neutropenic infection. For subjects who 
developed an absolute neutrophil count (ANC) <0.5 x 
10
9
/L, administration of prophylactic fluoroquinolone was 
permitted.)  
 Erythropoietic agent. 
 Clofarabine 
 Decitabine 
 Targeted agents (e.g. FLT-3 
antagonists) 
 Systemic anticancer therapy 
(excluded hydroxyurea) 
 Oral retinoids (topical retinoids 
were permitted) 
 Use of any other investigation 
drug or therapy 
Key: ANC, absolute neutrophil count; FLT-3, FMS-like tyrosine kinase 3 
Subjects had follow-up visit for the collection of AEs up to 28 days after the last dose of trial 
drug or up to the end-of-study visit, whichever period was longer. After this visit, subjects 
were followed for survival on a monthly basis until death, lost to follow-up, withdrawal of 
consent, or end of the study. Considering the short survival duration for people with AML, 
perhaps assessing AEs on a monthly basis was not frequent enough to capture all the 
changes over time for AEs. 
4.2.1.3 Study duration 
Celgene report the following for the planned study duration (Source: Celgene submission, 
Section 4.3.2.1, p. 46): 
The expected duration of the study was 31 months. This time frame consisted of a 
19-month subject enrolment period, followed by 12 months of subject treatment and 
observation. The study was planned to conclude 12 months after the last subject was 
randomised. 
 
Study duration was suitable, enabling adequate assessment of the outcomes following 
treatment for AML. 
4.2.1.4 Blinding 
The treatment of AML within AZA-AML-001 necessitated an open-labelled design due 
differing routes of administration (subcutaneous injection / intravenous infusion) and time 
periods of treatment. Open-label design creates an opportunity for bias, particularly for 
reporting of AEs. Central review of peripheral blood, BM samples and cytogenetics was 
conducted by a pathologist and cytogeneticist blinded to treatment. AML classification for 
each person was determined by local investigators at study entry. The Independent Review 
Committee which reviewed and confirmed the International Working Group responses and 
durations was blinded to treatment, investigative site, and subject identifier. Blinding of the 
central reviewers was appropriate. 
 Page 40 of 145 
 
4.2.1.5 Inclusion/exclusion 
Table 6 gives the inclusion/exclusion criteria from the trial.45 Critique of these follows the 
table.  
Table 6: Eligibility Criteria 
Key inclusion criteria Key exclusion criteria 
 Newly diagnosed, histologically 
confirmed de novo or 
secondary AML 
 BM blasts >30% 
 Adults aged ≥65 years 
 Not considered eligible for 
hematopoietic stem cell 
transplantation,  
 Intermediate- or poor-risk 
cytogenetics (NCCN 2009 
criteria) 
 ECOG performance status of 
2 




 Acute promyelocytic leukaemia with t(15;17)(q22;q12)  
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), 
t(8;21)(q22;q22), or t(9;22)(q34;q11.2) 
 AML arising from previous hematologic disorders other than 
myelodysplastic syndrome (e.g., myeloproliferative 
neoplasms) 
 Other malignancies 
 Uncontrolled systemic infection 
 Prior recipient of decitabine, azacitidine, or cytarabine 
treatment 
 Prior AML therapy (except hydroxyurea, which was allowed 
up to 2 weeks before the screening haematology sample 
was taken) 
 Any experimental drug within 4 weeks of starting study 
treatment 
Key: AML, acute myeloid leukaemia; BM, bone marrow; ECOG, Eastern Cooperative Oncology Group 
Source: Dombret et al. 2015
45
 
Additional exclusion criteria provided in the company submission but not specified in the 
RCT paper include: Prior BM or stem cell transplantation, proven central nervous system 
leukaemia, inaspirable BM, unstable angina, significant cardiac arrhythmia, or New York 
Heart Association class 3 or 4 chronic heart failure, pregnant or lactating women, active viral 
infection with known HIV or viral hepatitis B or C, known or suspected hypersensitivity to 
azacitidine or mannitol, use of any experimental drug or therapy within 28 days prior to day 1 
of cycle 1, unwilling or unable to complete PRO assessments without assistance or minimal 
assistance, any condition, including laboratory abnormalities, which would place the subject 
at an unacceptable risk, any significant medical condition, including the presence of 
laboratory abnormalities, or psychiatric illness which would interfere with subject 
participation, any condition that confounded the ability to interpret data from the study. 
Of note, the exclusion criteria related to cytogenetics are all primarily favourable 
characteristics (in line with the inclusion criteria of intermediate- or poor-risk cytogenetics), 
except for t(9;22) which is classed as poor-risk and is managed as the blast crisis phase in 
chronic myeloid leukaemia with the addition of tyrosine kinase inhibitors. 
4.2.1.6 Location 
The location of investigation sites were reported to be as follows (Source: Celgene 
submission, Section 4.3.4, p. 48): 
Screening was conducted in 107 investigational sites, of which, 98 sites randomised 
at least one patient across 18 countries in different geographic regions. Locations 
included: Asia (12 sites); Australia (6 sites); the US/Canada (12 sites); Eastern 
Europe (12 sites); and Western Europe and Israel (56 sites). These included 5 sites 
in the UK which in total randomised 26 patients: Oxford (n=4), Bournemouth (n=1), St 
Bartholomew’s (n=13), King’s College (n=4) and Wolverhampton (n=4). 
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In terms of the 26 people recruited from the UK, these people made up 5.3% of the total 
patient population from the trial. Fifteen UK people we randomised to receive azacitidine and 
11 people received CCR (three to BSC and eight to LDAC). People recruited from Western 
Europe/Israel made up 48.8% of the total patient population. 
4.2.1.7 Study endpoints 
The study endpoints and definitions are presented in Table 7. 





Primary end point 
Overall survival (OS) Defined as the time from randomisation to death as a result of any 
cause 
Secondary end points 
1-year OS rate No definition provided in either submission or Dombret et al 2015. 
Presumed to mean the number (or percentage) of people still alive 1 
year post randomisation. 
Event free survival (EFS; 
not in Scope) 
 
Defined as the interval from the date of randomisation to the date of 
treatment failure,
a
 progressive disease, relapse after complete 
response (CR) or complete response with incomplete blood count 
recovery (CRi), death from any cause, or loss to follow-up, whichever 
occurred first 
Relapse free survival 
(RFS; not in Scope) 
 
Defined only for subjects who achieved CR or CRi and was measured 
as the interval from the date of first documented CR or CRi to the date 
of relapse, death from any cause, or loss to follow-up, whichever 
occurred first. Relapse defined as either the recurrence of >5% blasts in 
the peripheral blood following Cr or CRi, (the percentage of peripheral 
blood blasts must have been ≤5% at the time of CR or CRi or a single 
finding of >15% blasts in the BM following a CR or CRi 
Overall remission rate 
(CR+CRi) 
 
Conditions for CR include: the BM should contain fewer than 5% blast 
cells; ANC ≥1,000/μL and Platelet count ≥100,000/μL. No RBC, platelet, 
or whole blood transfusions for 1-week prior to the haematology 
assessment used for the response evaluation. 
CRi was defined as a morphologic complete remission but the ANC 
count may be <1,000/μL and/or the platelet count may be <100,000/μL. 
Duration of remission (CR 
+ CRi) 
 
Defined as the time from the date of CR or CRi until the date of relapse 
from Cr or CRi 
Cytogenetic complete 
remission rate (CRc) 
 
Defined as morphologic CR with a return to a normal karyotype at the 
time of CR (based on ≥10 metaphases) 






Progressive disease (PD) Defined as either: 
1) a >50% increase in BM blast count from baseline that persists for at 
least 2 BM assessments separated by at least 1 month, or if the 
baseline BM blast count is >70% and persists for 2 post-baseline BM 
assessments separated by at least 1 month, or  
2) a doubling of the baseline absolute peripheral blood blast count that 
persists for at least 7 days and the final absolute peripheral blood blast 
count is >10 x 10
9
/L. The date of PD is defined as the first date that 
there was either a >50% increase in BM blast count from baseline, a 
persistence of BM blasts >70% in subjects with a baseline BM blast 
count of >70%, or a doubling of the peripheral blood blast count. 
Partial remission (PR) 
 
Defined as an ANC ≥1,000/μL and platelet count ≥100,000/μL with a 
>50% decrease in the percentage of BM blasts to 5–25% 
Stable disease (not in 
Scope) 
 
Defined as any evaluable time point where criteria for all other response 
categories (i.e., CR, CRi, PR, progressive disease, treatment failure, 
not assessable) are not met 
Safety/tolerability  
 
Covering type, frequency, severity, and relationship of AEs to study 
treatments; physical examinations, vital signs; clinical laboratory 
evaluations; and concomitant medication/therapy  
Patient-reported quality of 
life 
 
Using the European organisation for research and treatment on cancer, 
quality of life questionnaire C-30 (EORTC QLQ-C30) Completed on day 
1 of cycle 1 (baseline), every other cycle thereafter, and at the end-of-
study visit 
 
Measures of healthcare 
resource utilisation (HCRU) 
 
Any consumption of healthcare resources directly or indirectly related to 
the treatment of the subject. Five items of HCRU were collected: 
inpatient hospitalisations, transfusions, procedures or surgeries, and 
concomitant medications 
Additional endpoints 
Transfusion status (RBC 
and platelet transfusion 
status [dependence or 
independence]) 
 
On-treatment RBC/platelet transfusion independence was defined as 
the absence of any RBC/platelet transfusions for 28 or 56 consecutive 
days during the treatment period 
Peripheral blood counts  To include platelets, absolute neutrophil count, haemoglobin, white 
blood cell, and blasts 
Key: AE, adverse event; AML, acute myeloid leukaemia; ANC, absolute neutrophil count; BM, bone marrow; 
CR, complete response; CRi, complete response with incomplete blood count recovery; DNA, 
deoxyribonucleic acid; EFS, event-free survival; EORTC, European Organization for Research and 
Treatment on Cancer; Hgb, haemoglobin; IWG, international Working Group; MDS, myelodysplastic 
syndrome; PR, partial remission; QLQ, quality of life questionnaire; RBC, red blood cell; RFS, relapse-
free survival; WBC, white blood cell. 
Notes: a, Treatment failure defined as death during cycle 1 or within 28 days of the last dose and prior to day 1 
of cycle 2 
These endpoints are common and reasonable for a study investigating AML. A similar AML 
study48 investigating a different drug to that of AZA-AML-001, report fewer endpoints than 
AZA-AML-001. However, the endpoints that they do report, match those of AZA-AML-001. 
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4.2.1.8 Statistical methods 
4.2.1.8.1 Analysis population 
The different populations reported within Celgene’s submission for their analyses, along with 
their definitions are presented in Table 8. Celgene also included analysis of a modified ITT 
population and an evaluable population. These analyses were deemed not relevant to the 
question asked from this STA by the ERG. 






All subjects who were randomised, independent of whether or not they 
received study treatment. The ITT population was used for the analysis of the 
primary and secondary efficacy endpoints. Subjects in the ITT population 
were analysed as randomised. 
HRQoL evaluable 
population 
All randomised subjects who completed the baseline HRQoL assessment 
(day 1) and had at least one follow-up assessment. 
Safety population All randomised subjects who had received at least one dose of trial drug and 
had at least one post-dose safety assessment. Subjects who were 
randomised to BSC within the CCR group were considered to be included in 
the safety population is that had at least one post-randomised safety 
assessment. Drug exposure and all safety analyses were based on the safety 
population. All subjects were analysed according to the initial treatment they 
received. 
Key: BSC, best supportive care; CCR, conventional care regimen; ITT, intention-to-treat; HRQoL, health-
related quality of life 
The ITT population is the most appropriate population to use for analysis and the definition 
of the ITT population is correct. There is a risk of bias for the HRQoL population, as this 
population represents those who were well enough to complete the questionnaire and 
provide data. The safety population is defined appropriately. 
4.2.1.8.2 Determination of sample size 
Celgene report in their submission the determination of sample size to have been as follows 
(Source: Celgene submission, Section 4.4.3., p. 54): 
The equality of OS curves was to be compared between the azacitidine and 
combined CCR groups using a stratified log-rank test. The planned sample size was 
approximately 480 subjects (240 per treatment arm), calculated on the assumption of 
a median OS of 10.5 months in the azacitidine arm and 7.5 months in the combined 
CCR arm (40% improvement), with a dropout rate of 1% from both treatment groups. 
The investigator selection of CCR was anticipated to be 50%, 30%, and 20% of 
subjects to the IC, LDAC, and BSC groups, respectively. This design required 374 
deaths to allow the demonstration of a statistically significant difference in OS at a 
one-sided significance level of 0.025 with at least 90% power to detect a constant HR 
of 0.71. 
 
The study was powered for azacitidine compared to combined CCR. The results would have 
been more meaningful if the study had been powered to each of the CCR treatments 
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individually. Celgene anticipated the selection of CCR to be 50:30:20 for IC:LDAC:BSC. The 
actual study recruitment to CCR has the ratio 18:64:18. Celgene were asked to comment on 
the difference in anticipated selection of CCR and actual selection on CCR. Their anticipated 
selection for CCR was based on an educated guess since there was little real-world data to 
inform the prospective split. 
4.2.1.8.3 Primary and secondary efficacy analysis 
The company report the following for their primary efficacy analysis (Source: Celgene 
submission, Section 4.4.4, p. 54): 
The primary efficacy analysis was performed using the ITT population. The analysis 
of the primary efficacy endpoint was conducted using an unstratified log-rank [test] 
and a stratified log-rank test (stratified by CCR selection, ECOG performance status, 
and cytogenetic risk status). The Kaplan Meier (KM) method was used to estimate 
the survival distribution functions for each treatment group. KM estimates for median 
OS, 25th and 75th percentiles, and associated two-sided 95% CIs were summarised 
for each treatment group (both unadjusted for the stratification variables and within 
strata). Additionally, the numerical difference and associated 95% CI in the median, 
and the 25th and 75th percentiles between the two treatment groups (azacitidine vs. 
CCR) were presented for the unstratified KM estimates. 
Cox proportional hazards models (unstratified and stratified) were used to estimate 
the hazard rate ratio and the corresponding 95% CI for azacitidine vs CCR. 
Surviving subjects were censored upon study discontinuation (loss to follow-up, 
withdrawal of consent) or at the end of the post-study follow-up. 
 
The company report the following for their secondary efficacy analysis (Source: Celgene 
submission, Section 4.4.5, p. 55): 
All secondary endpoints were analysed using the ITT population, except for HRQoL 
and healthcare resource utilisation (HCRU). Analyses for both HRQoL and HCRU 
were conducted using a HRQoL evaluable population, defined as all randomised 
subjects who completed the baseline HRQoL assessment (day 1) and had at least 
one follow-up assessment.  
Kaplan-Meier methods were used to estimate the 1-year survival probabilities for 
time to death from any cause and death probabilities at 30 and 60 days.  
Time-to-event endpoints (EFS and RFS) were analysed using the same methods as 
the primary efficacy analysis, but without stratification. For EFS, subjects who were 
alive and event-free were censored at the date of their last response assessment, 
and for RFS, subjects who were in continuous CR or CRi were censored at the date 
of their last response assessment. 
Haematologic status was explored by examining the percentage of responders, 
defined as CR and CRi, and the duration of remission, CRc, peripheral blood counts, 
and transfusion requirements. All responses were based on the modified 
International Working Group (IWG) response criteria for AML. 
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For duration of remission, subjects who were lost to follow-up or were alive at follow-
up without documented relapse were censored at the date of their last response 
assessment. Summary statistics included KM estimates of median duration of 
remission, and 1-year cumulative incidence of relapse for each treatment group. 
For transfusion status, subjects who maintained red blood cell/platelet transfusion 
independence to the end of the treatment period were censored at the date of 
treatment discontinuation or death, whichever was sooner. Duration of transfusion 
independence was estimated and summarised using KM methods.  
For HRQoL analyses, the mean change from baseline for each domain at each time 
point was compared with the minimal important difference to determine whether the 
change was clinically meaningful. A mean change of at least 10 points on the 
standardised domain scores was required to be considered meaningful.49 
All reported log-rank or Fisher’s exact test p values for secondary endpoints are 
nominal. 
 
The majority of the statistical methods used in the trial to analyse time-to-event data (and in 
particular, the primary efficacy outcome, overall survival) assume proportional hazards or 
have reduced efficiency in the presence of non-proportional hazards. There is no justification 
given for expecting this assumption to hold, and considering the results (e.g., Figure 2, page 
47) this assumption was not reasonable. 
In the presence of non-proportional hazards, appropriate alternatives to the log-rank test 
employed in the trial would be the Wilcoxon–Breslow–Gehan and Peto–Peto–Prentice tests 
(the choice between these based on the assessment of there being any differences in 
censoring patterns). In the presence of non-proportional hazards, there is no simple 
alternative to using a hazard ratio, but statistics such as the difference in restricted mean 
survival could be meaningful. 
Using both stratified and unstratified tests is not directly justified. Overstratification can lead 
to loss of information, but unstratified tests are not appropriate when there is heterogeneity 
between strata.50 Given the variables used for stratification are considered prognostic 
indicators, this suggests that the stratified analyses are more appropriate. Furthermore, the 
set of variables used for stratification was reduced in the event that stratification with the full 
set of variables would lead to individual strata with fewer than 16 patients, which should 
have reduced the risk of overstratification. 
The ERG considers the censoring events loss to follow-up and withdrawal of consent may 
be informative for overall survival (which would violate the necessary assumptions for 
Kaplan–Meier analyses) but the most common reason for censoring was the patient being 
alive at the time of study closure,37 so this is unlikely to have significantly impacted on 
results. 
4.2.2 Results 
4.2.2.1 Population distribution 
In total, 488 people were randomised. Of these, 241 subjects were randomised to receive 
azacitidine, and 247 people were randomised to receive conventional care treatment. The 
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number of participants evaluable for each of the different population (ITT, safety, evaluable, 
HRQoL evaluable), are presented in Table 9. Table 9 also presents the distribution of pre-
selected CCR within the 247 people randomised to the azacitidine arm. 
























ITT 44 154 43 241 45 158 44 247 
Safety 42 151 43 236 40 153 42 235 
Evaluable 35 114 30 179 25 132 34 191 
HRQoL 
evaluable 
— — — 157 — — — 134 
Key: AZA, azacitidine; BSC, best supportive care; CCR, conventional care regimens; HRQoL, health related 
quality of life; IC, intensive chemotherapy; ITT, intent-to-treat; LDAC, low-dose cytarabine. 
Notes: a, Number of patients randomised to azacitidine for each prespecified CCR 
Source: Celgene submission, Table 14, p. 59 
4.2.2.2 Baseline characteristics and demographics 
Baseline characteristics of the ITT population are summarised in Table A1 (Appendix 1) and 
baseline disease characteristics are presented in Table A2 (Appendix 1). The demographic 
characteristics are well balanced between those randomised to azacitidine and the 
combined CCR. Those in the IC group were slightly younger than any of the other treatment 
groups. Conversely, those in the BSC group were slightly older than other treatment groups. 
These age differences are to be expected based on the participant demographic typically 
assigned to these types of CCR treatments. The azacitidine and combined CCR treatment 
groups were comparable for baseline disease characteristics. 
4.2.2.3 Treatment exposure 
Median treatment cycles were as follows: 
 Azacitidine treatment cycles received 6 (range, 1-28 cycles); 
 IC treatment cycles received 2 (range, 1-3 cycles); 
 LDAC treatment cycles received 4 (range, 1-25 cycles); 
 BSC treatment cycles received 65 days (range, 6-535 days). 
From the azacitidine group, 52.5% received 6 or more treatment cycles and 32.2% received 
12 or more treatment cycles. From the LDAC group, 35.9% received 6 or more treatment 
cycles and 17.6% received 12 or more treatment cycles. Cumulative patient-years of study 
drug exposure were 174.9 for azacitidine, 82.9 for LDAC, 14.1 for IC, and 9.6 (i.e., time on 
study) for BSC.45 
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4.2.2.4 Clinical effectiveness results 
4.2.2.4.1 Primary efficacy analysis – overall survival 
The median duration of follow up was 24.4 months. By study end, 394 deaths (80.7%) had 
occurred; 193 (80.1%) in the azacitidine group and 201 (81.4%) in the CCR group. The 
Kaplan-Meier plot of time to death from any cause is presented in Figure 2 and a summary 
of OS is presented in Table 10 (both taken from the submission). The primary OS analysis 
was performed with and without stratification. Stratification minimises the potential for bias 
by restricting comparisons to more homogeneous groups. Pre-specified stratification factors 
were: preselected CCR (IC versus LDAC or BSC); ECOG performance status (0–1 versus 
2); and cytogenetic risk (intermediate versus poor). 
Reporting mean OS may have offered superior understanding for the efficacy of treatments 
in comparison to what the median offers. It would have been better if Celgene had presented 
both the mean and median for OS. 
Figure 2: Kaplan-Meier plot of overall survival 
 
Key: CCR, conventional care regimens; CI, confidence interval; HR, hazard ratio. 
Source: Celgene submission, Figure 8, p. 66 
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Table 10: Summary of overall survival in the ITT population 
Outcome Azacitidine (N=241)  CCR (N=247)  
Event, n (%)  193 (80.1)  201 (81.4)  
Censored, n (%)  48 (19.9)  46 (18.6)  
Median OS (95% CI), months
a
  10.4 (8.0, 12.7)  6.5 (5.0, 8.6)  
Difference (95% CI), months
a
 3.8 (1.0, 6.5)  
HR [AZA:CCR] (95% CI)
b
 0.85 (0.69, 1.03)  
Stratified log-rank test: p-value
c
  0.1009  
HR [AZA:CCR] (95% CI)
d
  0.84 (0.69, 1.02)  
Unstratified log-rank test: p-value
e
 0.0829  
1-year survival, % (95% CI) 46.5 (40.1, 52.7) 34.3 (28.3, 40.3) 
Difference, % (95% CI)
f
 12.3 (3.5, 21.0) 
Key: AZA, azacitidine; CCR, conventional care regimens; CI, confidence interval; ECOG, Eastern 
Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; KM, Kaplan Meier; OS, overall 
survival; PH, proportional hazards. 
Notes: a, Median, 25th, and 75th percentile estimates of OS are from an unstratified KM analysis. Differences 
were calculated as AZA:CCR. The CIs for the differences were derived using Kosorok's method; b, The 
HR is from a Cox PH model stratified by ECOG performance status and cytogenetic risk status; c, p-
value is two-sided from a log-rank test stratified by ECOG performance status, and cytogenetic risk 
status; d, the HR is from an unstratified Cox PH model; e, p-value is two-sided from an unstratified log-
rank test; f, CI for the difference in the 1-year survival probabilities was derived using Greenwood's 
variance estimate. 
Source: Celgene submission, Table 18, p. 66 
4.2.2.4.2 Secondary efficacy endpoints 
A summary of secondary endpoints for azacitidine versus CCR is presented in Table 11. The 
ERG used the data reported by Celgene to produce Kaplan-Meier figures for event-free 
survival (Figure 3), relapse-free survival (Figure 4) and progression-free survival (Figure 5). 
Table 12 and Table 13 present outcomes based on pre-selection prior to randomisation. 
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Table 11: Secondary endpoints: azacitidine versus CCR 
 Azacitidine (N=241) CCR (N=247) HR 95% CI p value 
N % N % 
Death estimates 
30-day 16 6.6 25 10.1 – – – 




CR + CRi 67 27.8 62 25.1 – – 0.5384 
CR 47 19.5 54 21.9 – – 0.5766 
CRc-20 5 2.1 14 5.7 – – 0.0589 
PR 3 1.2 3 1.2 – – 1.0 
Progressive 
disease 
20 8.3 20 8.1 – – 1.0 
Stable 
disease 
71 29.5 59 23.9 – – 0.1833 
















CR or CRi 
43 63.2 35 56.5 – – 0.4712 
Duration of remission 
Median, 
months 




RBC 65 38.5 45 27.6 – – – 
Platelets 41 40.6 24 29.3 – – – 
Key: CCR, conventional care regimens; CI, confidence interval; CR, complete response; CRc-20, complete 
cytogenetic remission in at least 20 metaphases; CRi, complete remission with incomplete blood count 
recovery; EFS, event-free survival; PR, partial remission; RBC, red blood cell; RFS, relapse-free 
survival. 
Notes: a, Defined by International Working Group criteria and was adjusted by an independent review 
committee; b, Events included treatment failure, progressive disease, relapse after CR or CRi, or death; 
c, Defined as no transfusions for 56 consecutive days on study for patients who were transfusion 
dependent at baseline. 
Source:  Celgene submission, Table 22, p. 72 
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Figure 3: Kaplan-Meier plot of event-free survival 
 
Key: CCR, conventional care regimens; CR, complete remission; CRi, complete remission with incomplete 
blood count recovery 
Notes: Event-free survival, defined for all patients as the time from randomisation to treatment failure, disease 
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Figure 4: Kaplan-Meier plot of relapse-free survival 
 
Key: CCR, conventional care regimens; CR, complete remission; CRi, complete remission with incomplete 
blood count recovery 
Notes: Relapse-free survival, defined for patients achieving CR or CRi as the time from first documented CR or 
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Figure 5: Kaplan-Meier plot of progression-free survival 
 
Key: CCR, conventional care regimens; CR, complete remission; CRi, complete remission with incomplete 
blood count recovery 
Notes: Progression-free survival, defined as for event-free survival but for patients achieving neither CR nor 
CRi 

















Haematologic response, n (%)
a
 
CR + CRi 7 (15.9) 0 (0.0) 42 (27.3) 41(25.9) 18 (41.9) 21 (47.7) 
CR 6 (13.6) 0 (0.0) 28 (18.2) 38 (24.1) 13 (30.2) 16 (36.4) 
CRc-20 1 (2.3) 0 (0.0) 3 (1.9) 8 (5.1) 1 (2.3) 6 (13.6) 
PR 0 (0.0) 0 (0.0) 3 (1.9) 1 (0.6) 0 (0.0) 2 (4.5) 
Progressive 
disease 
4 (9.1) 5 (11.1) 10 (6.5) 14 (8.9) 6 (14.0) 1 (2.3) 
Stable disease 14 (31.8) 6 (13.3) 47 (30.5) 46 (29.1) 10 (23.3) 7 (15.9) 
Key: AZA, azacitidine; CCR, conventional care regimens; CR, complete response; CRc-20, complete 
cytogenetic remission in at least 20 metaphases; CRi, complete remission with incomplete blood count 
recovery; PR, partial remission. 
Notes: a, Defined by International Working Group criteria and was adjusted by an independent review 
committee. 
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BSC LDAC IC 











4.5 3.1 7.3 4.8 8.1 9.7 
Hazard ratio 
(95% CI) 
0.67 (0.43, 1.04) 0.89 (0.70, 1.13) 1.02 (0.64, 1.63) 




  8.6 9.9 10.8 12.1 
Hazard ratio 
(95% CI) 
 1.11 (0.68, 1.81) 1.21 (0.58, 2.51) 
p-value  0.6638 0.6135 
Relapse after 
CR or CRi, n 
(%) 
2 (28.6) NA 31 (73.8) 25 (61.0) 10 (55.6) 10 (47.6) 
Duration of remission 
Median, 
months 
  9.2 11.2 17.3 19.8 
Key: AZA, azacitidine; CCR, conventional care regimens; CI, confidence interval; CR, complete response; 
CRi, complete remission with incomplete blood count recovery. 
Sources: Celgene submission, Table 23, p. 73-74; AZA-AML-001 Clinical Study Report
37
 
Similarly to the primary outcome, OS, reporting the mean for the secondary outcomes may 
have offered superior understanding for the efficacy of treatments in comparison to what the 
median offers. There is also limited reporting of time-to-event reporting for the secondary 
outcomes. 
One-year survival 
Comments on one year survival from Celgene were as follows (Source: Celgene 
submission, Section 4.7.5.1, p. 75): 
Azacitidine improved 1-year survival compared with CCR (46.5% vs. 34.3%, 
respectively), resulting in a clinically meaningful difference of 12.3% in favour of 
azacitidine (95% CI: 3.5, 21.0). 
1-year survival was also improved for azacitidine when compared with each of the 
CCR therapies (within investigator pre-selection) (BSC only: 30.3% vs. 18.6%, 
LDAC: 48.5% vs. 34.0%, and IC: 55.8% vs. 50.9%, respectively), and in a post-hoc 
analysis, when compared with BSC plus LDAC (within investigator pre-selection) 
(44.5% vs. 30.6%, respectively). 
 
None of these improvements reported by Celgene were significantly different. 
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Event-free survival 
Additional information about event-free survival from Celgene was given (Source: Celgene 
submission, Section 4.7.5.3, p. 75): 
Overall, 212 (88.0%) events (defined as treatment failure, progressive disease, 
relapse after CR or CRi, death from any cause, or loss to follow-up) were reported in 
subjects treated with azacitidine and 216 (87.4%) events in subjects treated with 
CCR. 
 
4.2.2.4.3 Health-related quality of life 
The European organisation for research treatment of cancer (EORTC) QLQ-C-30 was used 
to assess HRQoL. The questionnaire was completed at baseline, on day 1 of every other 
cycle and at the end-of-study visit. To be evaluable as the HRQoL population, baseline 
assessment and at least one other post-baseline assessment was required. The HRQoL 
population comprised of initially of a total of n=291 (n=157 azacitidine and n=134 CCR). The 
size of the HRQoL population decreased in size over time in both groups. Table 14 presents 
the evaluable HRQoL population throughout treatment up to cycle 9. 
Primary HRQoL endpoints reported include fatigue score, dyspnoea, physical functioning 
and global health status. Changes over time for these four endpoints are depicted in Figure 
6. 
Table 14: HRQoL assessment rates 
HRQoL 
assessment  















237 210 (89) 157 (66) 236 210 (89) 134 (57) 
Cycle 3 174 152 (87) 137 (79) 131 113 (86) 102 (78) 
Cycle 5 146 127 (87) 112 (77) 86 72 (84) 67 (78) 
Cycle 7 118 105 (89) 94 (80) 67 58 (87) 54 (81) 
Cycle 9 98 89 (91) 81 (83) 49 38 (78) 36 (73) 
Key: AZA, azacitidine; CCR, conventional care regimens; CI, confidence interval; HR, hazard ratio. 
Notes: HRQOL assessment rates = number of patients with an EORTC QLQ-C30 assessment ÷ the total 
number of patients receiving treatment at the scheduled cycle visit. Numbers reported in this table 
represent all HRQOL assessments at each cycle; some patients may not be included in HRQL analyses 
due to missing baseline HRQOL assessments. Evaluable patients completed an HRQL assessment at 
baseline and had ≥ 1 post-baseline assessment. 
Source: Celgene submission, Table 24, p. 77 
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Figure 6: Mean absolute score change from baseline for primary and secondary 
HRQoL endpoints (HRQoL evaluable population) 
 
Key: AZA, azacitidine; CCR, conventional care regimens.  
Notes: Decreasing scores indicate improvement in the Fatigue and Dyspnoea domains of the QLQ-C30, and 
increasing scores indicate improvement in the Physical Function and Global Health Status/QoL 
domains. 
The minimally important difference, defined as a mean change of at least 10 points from baseline and 
representing a clinically meaningful effect is denoted by bold black lines at 10 and -10 on the y-axis.  
*Met the threshold for minimally important difference. 
Source: Celgene Submission, Figure 10, p. 78 
Statistical tests were not reported between treatment arms for HRQoL. From Figure 6, the 
CCR arm appears to be favourable in comparison to azacitidine for cycle three, five and 
seven the four HRQoL measures reported (fatigue, dyspnoea, global health status and 
physical functioning). For the final cycle reported (cycle nine), CCR is favourable for fatigue 
and global health status, whilst azacitidine is favourable for physical functioning and 
dyspnoea. 
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There are two significant critiques of the HRQoL analyses by Celgene: 
 Assessments are made at the start of each cycle, after a significant recovery period 
for patients after treatment; 
 A significant number of patients (197 patients, 40%) are not represented in the 
HRQoL assessment at any time point as they did not have a baseline assessment 
(14%) and/or lacked a post-baseline assessment; these patients are likely to have 
been more ill (lower HRQoL) than the patients who were assessed and evaluable. 
4.2.2.4.4 Adverse events 
AML-AZA-001 included 471 subjects in the safety population who had newly diagnosed AML 
with >30% blasts and were randomised to receive azacitidine or CCR. The median age of 
the safety population was 75.0 years with 53.3% of subjects ≥75 years of age, 32.7% of 
subjects had AML with MDS-related changes, 18.0% had a prior history of MDS, 35.7% had 
a poor or very poor cytogenetic risk status, and 22.9% had ECOG performance status of 2. 
Median baseline BM blast count was 71.5%. 
A summary for adverse events (AEs) is presented in Table 15. Table 16 reports the 
incidences of AEs for > 10 % of people in any treatment arm. Tables A3, A4 and A5 
(Appendix 1) presents AEs for both treatment arms, based on the number of events 
occurring in ≥10% of people in the azacitidine group.  
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Table 15: Summary of adverse events 
Adverse events AZA, n (%) 
(N=236) 
CCR 
BSC, n (%) 
(N=40) 
LDAC, n (%) 
(N=153) 
IC, n (%) 
(N=42) 
≥1 AE  234 (99.2)  36 (90.0)  153 (100.0)  42 (100.0)  
≥1 treatment-related AE  188 (79.7)  0 (0.0) 124 (81.0)  39 (92.9)  
≥1 Grade 3 or 4 AE  207 (87.7)  26 (65.0)  141 (92.2)  37 (88.1)  
≥1 Grade 3 or 4 treatment-related 
AE 
125 (53.0)  0 (0.0) 90 (58.8)  29 (69.0)  
≥1 Grade 5 (leading to death) AE  56 (23.7)  23 (57.5)  38 (24.8)  9 (21.4)  
≥1 Grade 5 (leading to death) 
treatment-related AE  
12 (5.1)  0 (0.0) 10 (6.5)  4 (9.5)  
≥1 SAE  188 (79.7)  30 (75.0)  118 (77.1)  27 (64.3)  
≥1 treatment-related SAE  87 (36.9)  0 (0.0) 56 (36.6)  14 (33.3)  
≥1 AE leading to discontinuation 110 (46.6)  0 (0.0) 68 (44.4)  11 (26.2)  
≥1 treatment-related AE leading to 
discontinuation 
22 (9.3)  0 (0.0) 20 (13.1)  5 (11.9)  
≥1 AE leading to dose reduction only  8 (3.4)  0 (0.0) 2 (1.3)  2 (4.8)  
≥1 AE leading to study drug dose 
interruption only  
116 (49.2)  0 (0.0) 61 (39.9)  4 (9.5)  
≥1 AE leading to study drug dose 
reduction and interruption  
13 (5.5)  0 (0.0) 7 (4.6)  0 (0.0) 
Key: AE, adverse event; AML, acute myeloid leukaemia; AZA, azacitidine; BSC, best supportive care; CCR, 
conventional care regimens; CI, confidence interval; IC, intensive chemotherapy; LDAC, low-dose 
cytarabine; SAE, serious adverse event. 
Notes: AE refers to treatment-emergent adverse events. Adverse events included events that started (1) 
between the date of first dose of study drug and 28 days after the date of last dose of study drug for 
azacitidine and LDAC (2) between the date of first dose of study drug and 70 days after the date of last 
dose of study drug for IC (3) between the date of randomisation and the date of discontinuation from the 
treatment period for BSC only. Adverse events that started outside the treatment-emergent period and 
assessed as related to study drug was considered treatment-emergent. 
Source: Celgene Submission, Table 26, p. 86 
 Page 58 of 145 
 
Table 16: Grade 3 to 4 Treatment emergent adverse events occurring in ≥10% of 
patients in any treatment group 









Preferred term No. % No. % No. % No. % 
Febrile 
neutropenia 
66 28.0 11 27.5 46 30.1 13 31.0 
Neutropenia 62 26.3 2 5.0 38 24.8 14 33.3 
Thrombocytopenia 56 23.7 2 5.0 42 27.5 9 21.4 
Pneumonia 45 19.1 2 5.0 29 19.0 2 4.8 
Anaemia 37 15.7 2 5.0 35 22.9 6 14.3 
Leukopenia 16 6.8 0 0 13 8.5 6 14.3 
Hypokalaemia 12 5.1 1 2.5 10 6.5 7 16.7 
Key: BSC, best supportive care; CCR, conventional care regimens; IC, intensive chemotherapy; LDAC, low-
dose cytarabine. 




Key efficacy findings from the RCT reported from the submission were as follows: 
Overall survival 
Azacitidine was not significantly superior to CCR in prolonging survival of adults ≥65 years 
with AML with >30% bone marrow blasts. 
Secondary endpoints 
1-year survival rates were 46.5% for azacitidine compared to 34.3% in the CCR arm 
(difference 12.3 %; 95% CI: 3.5, 21.0). 
Measures of haematologic response, duration of remission and remission free survival were 
similar between treatment arms when CCR was combined. When CCR was not combined, it 
appeared (although limited statistical analysis was reported) that IC was superior to 
azacitidine. Participant numbers for the IC arm compared to those originally assigned to IC 
were small (n=44 and n=43 respectively). 
No statistical analyses were presented for the HRQoL data. Appearances from the figures 
suggest that CCR was favourable to azacitidine. 
Adverse events 
Treatment related AEs were common for both azacitidine, LDAC and IC. Unsurprisingly, AEs 
were less common for BSC. 
4.2.3.1 Strengths and limitations 
Strengths 
 Multicentre, appropriately randomised design of the RCT AZA-AML-001 
 Page 59 of 145 
 
 The population recruited to AZA-AML-001 was representative of the typical UK 
patient population  
 The appropriate CCR regimes used as a comparator in AZA-AML-001 compared to 
UK standard practices 
Limitations 
 Underpowered for individual CCR arms 
 The open-label design introduces the risk of bias 
 The use of subsequent therapies following treatment assignment, some of which are 
not used in routine NHS practice, and which were not balanced across treatment 
arms 
 Limited reporting of time-to-treat outcomes (except for OS) 
 Use of statistical analyses which have reduced efficiency when proportional hazard 
assumptions are not met 
4.3 Adjustments of overall survival estimates for subsequent therapy 
In order to address confounding effects of subsequent therapy on overall survival (OS), the 
company’s submission presents post-hoc analyses that adjust for subsequent therapy use. 
Among these, the analyses that censored data at the start of subsequent therapy and 
weighted the remaining data by the inverse of the probability of not being censored, i.e., the 
inverse probability of censoring weights (IPCW) method, play the most prominent role in the 
submission. Other methods of adjustment of OS treatment effects were considered 
elsewhere in the submission (Celgene submission, Section 5.3.5, p. 122), such as the Rank 
Preserving Structural Failure Time Model (RPSFTM) and the Iterative Parameter Estimation 
(IPE), but these were considered inferior to the IPCW. 
The company presented estimates of relative effects for two sets of IPCW analyses. In the 
first set of analyses, adjustment for subsequent treatment was applied to both trial arms (i.e., 
azacitidine and CCR). In the second set of analyses, adjustment for subsequent treatment 
with azacitidine was applied to the CCR arm. 
Celgene adopted the results of the second set for its health economic base case analysis. 
The company justified this choice on the basis of methodological guidelines (Source: 
Celgene submission, Section 4.4.4.3, p. 55): 
For regulatory purposes, an initial IPCW analysis was undertaken in which both 
treatment arms were adjusted. A further IPCW analysis was conducted in line with 
the NICE DSU TSD16 in which adjustments were only made to the comparator 
treatment arm (CCR).51 
 
This reasoning led Celgene to devote little space in its submission to describe the first set of 
IPCW analyses, which adjusted for subsequent therapy in both arms, and to focus on 
detailing the second IPCW analysis, which only adjusted for subsequent azacitidine use in 
the CCR arm. 
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The ERG believes the first set of analyses, which adjust for subsequent AML treatment in 
both trial arms, should have been used for the base case economic analysis instead of the 
IPCW analysis adjusting for azacitidine use in CCR. The ERG believes the company are 
mistaken in their interpretation of the methodological guidelines. The NICE DSU TSD16 
illustrates the application of IPCW to estimate treatment effects in a hypothetical context 
where a policy choice needs to be made among two states of the world, one where a new, 
experimental treatment is available to patients and the alternative state where such 
treatment is not available, and the evidence comes from an RCT where some control 
patients switch to the experimental treatment after randomisation. IPCW adjustment (or 
indeed adjustment by any other suitable method for that matter) of outcome data in the 
control arm would then be warranted. In this example no IPCW adjustment was made in the 
experimental arm because it was assumed that the mix of subsequent therapies used by 
patients in that arm is representative of patterns of care in the state of the world where the 
experimental treatment is made available. In contrast, as acknowledged in the NICE DSU 
TSD16, if the mix of subsequent therapies in any trial arm (whether is the experimental or 
control) is not representative of patterns of care in the state of the world of interest to the 
decision problem, then adjustment for those subsequent treatments is needed. 
Therefore, in the case where, as the cost-effectiveness model submitted by Celgene for this 
appraisal implies (see Section 5), the decision problem involves the evaluation of two 
alternative states of the world where no subsequent active treatment is available, then 
adjustment of outcomes for active treatment switching in both trial arms is warranted. 
Whether the premise that no subsequent active treatment would be available to UK patients 
in routine practice is correct may of course be questioned (see Section 5 for clinical expert 
opinion on this issue obtained by the ERG for this appraisal), but the point here is that 
applying IPCW adjustment for subsequent treatment to the outcome data of the CCR but not 
the azacitidine arm in the AZA-AML-001 trial is inconsistent with the economic model which 
the OS IPCW analysis was designed to inform. 
Since OS differences between the two arms in AZA-AML-001 narrowed over time and the 
statistically insignificant ITT findings in OS were reversed when data were censored at 
subsequent AML treatment initiation (Celgene submission, Section 4.7.2.3, pp. 67–68), 
Celgene undertook further post-hoc analyses to adjust for imbalance in the use of 
subsequent treatment and baseline covariates across trial arms. The following methods 
were explored. 
4.3.1 Cox proportional hazards models 
Three post-hoc Cox proportional hazards models of survival were considered in the clinical 
effectiveness submission, although were not part of scenarios investigated in the economic 
submission: 
 Model 1 was a function of a time varying indicator of subsequent treatment (as a 
main effect and interacted with treatment allocation); 
 Model 2 was a function of baseline covariates alone; 
 Model 3 included covariates in Models 1 and 2. 
Model 3 produced a large treatment effect estimate (HR 0.69, 95% CI: 0.54, 0.88; 
p=0.0027). However, this estimate and those from the other two post-hoc Cox proportional 
hazards models are susceptible to bias. 
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The treatment effect of azacitidine in Model 2 is likely confounded by treatment switching, 
whilst the adjustment for treatment switching in Model 1 and Model 3 implausibly implies the 
following two assumptions: (a) either those who switch have the same prognosis as those 
that do not switch or their prognoses differ but they are evenly distributed across arms; and 
(b) subsequent treatments have the same average effect across arms conditional on 
prognosis. The different mix of subsequent therapies used across azacitidine and CCR arms 
(see Table 48, page 105) and noticeable differences in results between Model 3 and the 
respective IPCW analysis (see Section 4.3.2) suggests that neither assumption (a) nor (b) 
are likely to be borne out by the data. 
4.3.2 Inverse probability of censoring weights (IPCW) method 
The IPCW method was used, adjusting for treatment switching in the CCR arm only. This 
approach sought to account for the possibility that subsequent treatment use did not occur at 
random. Results were presented for a Cox proportional hazards model unadjusted for 
differences in baseline characteristics across treatment arms (unadjusted IPCW Cox 
proportional hazards model; HR AZA versus CCR xxxx, 95% CI: xxxxxxxxxx, and another 
Cox proportional hazards model that included covariates for those baseline characteristics 
(adjusted IPCW Cox proportional hazards model; xxxx, xxxxxxxxxx. The adjusted IPCW Cox 
proportional hazards estimate was used in the base case economic analysis by Celgene 
(see Section 5.2.5, page 73). This estimate only adjusts outcomes in the CCR arm for 
subsequent azacitidine use, which accounted for 32 out of the 74 (43.2%) control subjects 
with subsequent treatment (Source: Celgene submission, Section 4.7.2.3, p. 67). Figure 7 
and Figure 8 show the Kaplan-Meier curves for the ITT and IPCW data, measured in days 
and 15-day periods respectively (Celgene did not provide the figure in days or the individual 
patient data to produce this graph to ERG). The azacitidine curve is the same in the two 
figures, whereas the CCR curve with IPCW lies above that of ITT. 
Figure 7: Overall survival in AZA-AML-001 based on intention-to-treat population 
 
Key: CCR, conventional care regimen; HR, hazard ratio 
Source: Celgene submission, Figure 8, p. 66 
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Figure 8: Overall survival in AZA-AML-001 following adjustment of the CCR arm for 
subsequent treatment with azacitidine using the IPCW method 
 
Key: CCR, conventional care regimen; IPCW, inverse probability of censoring weight 
Note: Based on discrete (15-day period) time-to-event data 
Source: Patient-level data supplied to ERG by Celgene 
The company also reported that “For regulatory purposes, an initial IPCW analysis was 
undertaken in which both treatment arms were adjusted.” (Source: Celgene Submission, 
Section 4.4.4.3., p. 55). Two sets of results for these IPCW Cox proportional hazards models 
of treatment switching in both AZA and CCR treatment arms were presented, one set for a 
model that adjusted for baseline prognostic covariates and another for a model unadjusted 
for those covariates (Source: Celgene submission, Table 21, p. 70). The baseline covariate-
unadjusted IPCW Cox proportional hazards model HR estimate was 0.77 (95% CI, 0.61–
0.98), and the adjusted estimate was 0.71 (95% CI, 0.56–0.90) (Celgene submission: Table 
21, p. 70). 
Although the respective methods are not clearly reported, it appears that these estimates 
adjust for any subsequent treatment in both arms, as opposed to adjusting only for 
azacitidine in the CCR arm as in the IPCW Cox proportional hazards method previously 
described and used by Celgene for its base case economic analysis. As explained in Section 
5, if IPCW methods were indeed used to adjust for any subsequent treatment in both arms, 
the associated results may be the most suitable of those submitted by Celgene to populate 
the model with for the company’s base case economic analysis. However, the submission is 
unclear about what treatments these analyses adjusted for (Source: Celgene, Appendices to 
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In AZA-AML-001, azacitidine was not the only subsequent treatment for AML used in the 
CCR arm, and there were also active treatments after azacitidine in the azacitidine arm (see 
Table 48, page 105). 
4.3.3 Other analyses 
Other analyses submitted by the company separately analysed patients who did and did not 
receive any subsequent therapy. These analyses are by their nature of limited use in 
informing assessments of relative effectiveness, because the differences in outcomes 
between those two groups of patients are likely to confound the effect of treatment with 
individual variation in the propensity to receive treatment, and are not reviewed further. 
Another set of treatment effect estimates were reported for an analysis that censored 
subsequent cytarabine-based therapy in the azacitidine group and subsequent azacitidine in 
the CCR group (HR xxxx; 95% CI: xxxxxxxxx). These results are more in line with the 
assumptions of Celgene’s economic model, which assumes no subsequent active treatment 
after treatment failure is used in the azacitidine and CCR groups. However, as reported by 
the Celgene submission, cytarabine accounted only for 40 (59.7%) of the 67 subjects who 
received subsequent treatment in the azacitidine group (Celgene submission, Section 
4.7.2.3, p. 67). 
Another analysis used an imputation method to adjust for treatment switching (Celgene Post 
hoc statistical methods addendum AZA-AML-001), but since little information was provided 
on the methods and the results of this analysis played no subsequent role in the submission, 
we do not discuss these further. 
4.3.4 Summary and additional issues 
Comparing HR estimates between the baseline covariate-unadjusted IPCW PH, 0.77 (95% 
CI: 0.61–0.98) (Celgene submission, Table 21, p. 70), and the unstratified HR (ITT) 
censoring at switch to AML therapy, 0.75 (95% CI: 0.59–0.95) (Celgene submission, Table 
19, p. 68), suggests sophisticated methods of adjustment for subsequent treatment use that 
account for censoring not-at-random (e.g., IPCW) make little difference versus simple 
methods that assume censoring at random. 
Further, similar HR estimates were found with IPCW Cox proportional hazards versus simply 
estimating Cox proportional hazards treatment effects without subsequent therapy-related 
censoring and a time-varying covariate indicator of subsequent therapy interacted with 
randomly allocated therapy (0.71 versus 0.69). 
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Adjusting versus not adjusting for baseline covariates appears to be the single structural 
factor to which estimates of relative effectiveness are most sensitive, as evidenced by the 
difference in HR estimates between Cox proportional hazards Model 1 versus Model 3 (0.75 
versus 0.69) and the corresponding estimates with IPCW applied to both trial arms (0.77 
versus 0.71). 
The wide range of HR estimates reported by the company relies on the assumption of 
constant proportional hazards, which was statistically tested for the Cox but not for the IPCW 
approaches. No reasons for the absence of tests of the proportional hazards assumption in 
the IPCW analyses were presented in the submission. The methods description presented in 
the cost-effectiveness section of the Celgene submission suggests these tests were not 
performed and does not provide reasons for this omission (see Section 5.3 for our critique of 
methods presented in the cost-effectiveness section of the Celgene submission). 
In Figure A1 (Appendix 2) we present log-log plots for the IPCW analysis adjusting for 
azacitidine use in the CCR arm only (the corresponding data for the IPCW analysis adjusting 
both the azacitidine and CCR arm for subsequent AML therapy use were not provided by the 
company). This suggests that the proportional hazards assumption (i.e., curves being 
parallel) is unlikely to hold after month 20. Statistical test of this assumption using 
Schoenfeld residuals also rejects the assumption (X²=5.82; p=0.016). 
As explained in Section 5.3.6.2 (page 111), the IPCW method applied by Celgene consisted 
of two parts, first a regression analysis to predict the probability of a CCR patient not 
receiving subsequent treatment at each follow-up point (every 15-days), as a function of 
fixed baseline covariates and time-varying covariates that affect both the likelihood of 
treatment switching and overall survival outcomes. In a second step the survival time of CCR 
individuals who switched to azacitidine are censored at the time of switching and the inverse 
of the predicted probability of switching corresponding to uncensored CCR individuals at a 
given follow-up point is used as sampling weight to account for the unobserved outcomes of 
censored individuals in the counterfactual situation that they had not switched treatment. 
This method thus intends to estimate the outcomes that would have been observed in the 
CCR sample had no patients switched to azacitidine, and does so by adjusting for non-
random censoring (i.e., treatment switching) using a predictive model for subsequent 
treatment. 
The validity of overall survival IPCW estimates (and resulting hazard ratios) depends on the 
AZA-AML-001 data conforming to two key assumptions. 
The first key assumption (referred to as the exchangeability assumption) dictates that after 
controlling for the measured predictors common to survival and subsequent azacitidine use, 
subsequent azacitidine users have the same survival prognosis as those who remain in 
CCR. As discussed elsewhere, this assumption only holds under the following three 
conditions: 
 All common predictors are appropriately measured and accounted for in the analysis; 
 The sample of patients available at all follow-up times is sufficiently large to ensure 
that the probability of not switching is positive for every combination of values 
observed for the common predictors over the whole sequence of follow-up points 
(i.e., the positivity condition, Cole and Hernan 200852); 
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 The common predictors cannot perfectly or nearly perfectly predict survival or 
switching to azacitidine. 
Thus, small sample size or perfect common predictors violate the exchangeability 
assumption because the survival outcomes of uncensored CCR patients would not be 
representative of censored individuals, who switched to azacitidine, even if all common 
confounders were appropriately measured and included in the analysis.53 This problem is 
thus aggravated by small sample sizes, highly stratified data due to a large set of predictors 
used to estimate weights, and continuous predictors can generate random non-positivity. 
The second assumption is that the functional forms in which the common predictors enter 
the switching prediction model is correctly specified, so that exchangeability is maximised by 
controlling for selection bias while maintaining positivity.52 
While the ERG could replicate the IPCW hazard ratio estimates reported by Celgene using 
individual patient data provided by the company, it was not provided the data to replicate the 
estimation of IPCW weights, which were estimated in SAS (Celgene appendices to 
submission, Appendix 10). This limited the ability to assess whether the assumptions implied 
by the IPCW method are consistent with the data from AZA-AML-001. Further details are 
provided in Section 5.3.6.2 (page 111). 
Celgene notes that besides the limitations inherent in the IPCW, there was an additional 
limitation (Source: Celgene Post hoc statistical methods addendum AZA-AML-001, pp. 6–7): 
An additional limitation of the post-randomization data in the current study was that 
for subjects who did not receive subsequent therapy, the last visit interval extended 
from the last assessment done at the time of discontinuation from the treatment 
phase of the study to the time of censoring (study closure or lost to follow-up) or 
death. If the subject was alive and in the survival follow-up phase for a long period of 
time then the gap between treatment discontinuation and death or censoring could 
be quite long and represents a time interval during which no additional clinical 
information was collected or available. 
 
This issue is a potentially important one for the company’s IPCW analyses, because it 
suggests that an unknown proportion of patients might have received unrecorded 
subsequent therapy, for which survival outcomes remained unadjusted for. For the IPCW 
analysis that adjusted only outcomes of CCR arm, this implies that the benefit of azacitidine 
may be underestimated. In contrast, in the IPCW analysis that adjusted survival outcomes of 
both trial arms, if patients with improved survival prognosis were to be more likely to have 
received subsequent therapy during the period of unrecorded clinical management activity it 
is possible that unrecorded treatment switching may have produced a larger omitted variable 
bias in overall survival outcomes of azacitidine than CCR, and that the survival benefits of 
azacitidine may be overestimated. 
The implications of these issues are covered further in Section 5 that discusses the cost-
effectiveness analysis submitted by Celgene. 
 Page 66 of 145 
 
4.4 Critique of trials identified and included and of the indirect 
comparison and/or multiple treatment comparison 
As one RCT was identified from the searches and screening,45 indirect comparisons and/or 
multiple treatment comparisons could not be made and were not presented by the company. 
4.5 Critique of other evidence sources 
Celgene provided four further sources (one non-RCT and three trial registries) of evidence 
within their submission. 
4.5.1 Non-randomised evidence 
The single non-RCT relevant to the decision problem identified by Celgene was by Lao et 
al.46 This was a study which included a broader population of >20% blasts, however they 
provided sub-analysis for the population with >30% blasts. Celgene do not report any of the 
findings from this study as they claim the number of people with >30% blasts was small 
(n=12 for azacitidine group versus n=8 for the IC group versus n=22 for BSC group). From 
exploring the Lao et al. study, there is no evidence reported that compares any outcomes 
between the azacitidine group and either IC or BSC for those with >30% blasts. There is 
evidence comparing <30% and 30% or higher BM blasts in the azacitidine arm. 
4.5.2 Registry data 
The company report registry data from three countries: Austria, Spain and France. They 
hoped to conduct matched-adjusted indirect comparison using single-arm data. None of the 
published registry data (Austrian azacitidine registry (NCT01595295); Spanish AMLA 
registry and French compassionate patient named programme) provided information on the 
population with >30% bone marrow blasts, a population requirements for the Scope for this 
report. 
4.6 Conclusions of the clinical effectiveness section 
In spite of poorly designed and reported searches, the company submission identified a 
single RCT trial (AZA-AML-001) that matched the decision problem. Information from this 
study was reported in detail. The RCT was well conducted, although underpowered for each 
of the CCR arms. 
The primary efficacy endpoint for the RCT was an ITT comparison of overall survival for 
patients randomised to azacitidine versus patients randomised to CCR. An improvement 
was demonstrated but it did not reach statistical significance. Statistical significance was 
also not reached for other outcomes assessed and reported. There was some evidence, 
though not statistically significant due to underpowering, that azacitidine was inferior to 
LDAC and IC on a number of outcomes, including response rate and relapse-free survival, 
although azacitidine appeared to be superior in relation to overall survival. 
Post-hoc analyses were presented where overall survival outcomes were adjusted for 
subsequent treatment in CCR, where a significant improvement with azacitidine was found. 
However, these analyses were hampered by the fact that they relied on the assumption that 
treatment effects displayed a proportional hazards pattern, which was not statistically tested 
in the analysis sample. 
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5 Cost-effectiveness 
5.1 ERG comment on company’s review of cost-effectiveness 
evidence 
5.1.1 Objective 
The company conducted a systematic review to identify cost-effectiveness studies from the 
published literature relevant to the decision problem (see Section 3, page 23). 
5.1.2 Search strategies 
5.1.2.1 Economic evaluations 
The company presented a literature search protocol to support its review of cost 
effectiveness. This protocol included systematic searches of key biomedical databases using 
a literature search strategy combined with hand-searching of conference abstracts and 
included studies. The literature searching was last updated in October 2015. 
The bibliographic database searching used a search strategy that took the following form: 
1. (search terms for acute myeloid leukaemia/leukaemia); and 
2. (search terms for Azacitidine, cytarabine, clofarabine, daunorubicin, etoposide, 
fludarabine, idarubicin, mitoxantrone, mercaptopurine, amsacrine, cytotoxic or 
anthracycline or supportive or conventional care or chemotherapy or antineoplastic 
agent); and 
3. (search terms to identify cost analysis, studies reporting economic evaluations or cost 
parameters). 
This search strategy was applied in: MEDLINE and EMBASE (both via OVID), NHS EEDs 
and the HTA library (via the Cochrane Library: OVID interface) and Econlit (OVID). 
The following conference proceedings were hand-searched between 2013 and 2015 
inclusive: 
 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) - 
European, International, Asia-Pac, and Latin American 
 American Society of Clinical Oncology (ASCO) 
 European Society for Medical Oncology (ESMO) 
 Tufts Cost-effectiveness Analysis (CEA) registry 
 WHO International Clinical Trials Registry Platform (ICTRP) 
 HTA Database of the International Network of Agencies for Health Technology 
Assessment (INAHTA) 
 NIHR HTA website 
 Research Papers in Economics (RePEc) website 
 NICE website. 
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The ERG accepts that these literature searches were fit for purpose. 
5.1.2.2 Health-related quality of life 
Celgene did not record a systematic search for studies reporting HRQoL in their original 
submission. In response to a question for clarification, Celgene confirmed that they had 
undertaken a targeted systematic search. This literature search was undertaken in PubMed 
and the HERC database and takes population search terms combined with search terms for: 
QALY or utlilit* (search term is truncated) or EQ-5D. The ERG has been able to replicate 
and validate this search. 
Celgene noted further that HRQoL was recorded for all treatments in the trial that supports 
their submission. Celgene have therefore used this data to parameterise their model arguing 
that it best reflects the quality of life seen in the target population. Given the inherent 
difficulty of measuring HRQoL outcomes in oncology trials and in particular in this clinical 
area, ERG believes that Celgene is likely to have identified the best available source of 
evidence on these outcomes relevant to this assessment. 
5.1.3 Inclusion criteria 
The review included cost-utility studies in the English language, or English abstracts of 
studies from studies written in other languages, relating to adults (>18 years) with AML with 
>30% blasts. In terms of treatments, included studies had to investigate azacitidine 
(intervention) and comparators of including intensive or non-intensive low-dose 
chemotherapy, including: 
 Cytarabine (Ara C)  
 Clofarabine (Evoltra®) 
 Daunorubicin (daunomycin)  
 Etoposide (Etopophos®, Vepesid®)  
 Fludarabine (Fludara®) 
 Idarubucin (Zavedos®)  
 Mercaptopurine (Xaluprine®) 
 Mitoxantrone  
 Amsacrine 
 Hydroxycarbamide (Hydrea) 
or best supportive care (BSC). 
All of these criteria were within the NICE Scope. 
5.1.4 Results 
Of 334 titles identified by the company’s searches, forty eight studies were candidates for 
inclusion based on abstract and title content and its full text screened for possible inclusion. 
Forty studies were excluded after screening their full text, mostly due to the patient 
population investigated; six studies were excluded due to the study design being limited to 
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costs only rather than cost-effectiveness analysis. The remaining eight studies were included 
in the review. 
Of the eight reviewed studies four were published abstracts and the remaining four were full 
journal article publications. Two of the full publications reported studies in populations within 
the NICE score of AML with >30% blasts, one was a study conducted in France,54 and 
another was a study conducted in China.55 The company performed quality assessment of 
the four full publications only, since abstract publication reported insufficient information to 
be assessed. 
Although Celgene did not discuss the results of their quality assessment of the four included 
full publications, the quality checklist (Celgene appendices to submission, Appendix 8) 
makes clear that the studies were of very poor quality in terms of design, since no study was 
designed as an incremental cost-utility analysis, details of modelling methods required to 
extrapolate outcomes from short term efficacy studies to capture all important costs and 
benefits were not provided, and the degree of uncertainty in estimates was not measured. 
None of the studies were conducted in the UK and the one European study identified did not 
provide adequate methodological evidence to be of use to this assessment.    
Only one of the reviewed studies evaluated azacitidine (versus LDAC). This was a study 
conducted in Russia that reported that azacitidine resulted in RUB 909,573 ($32,261 at 2012 
PPP; source: OECD http://www.oecd-ilibrary.org/economics/purchasing-power-parities-for-
gdp-2013-1_ppp-gdp-table-2013-1-en) extra costs and 0.76 additional life years per patient 
than LDAC, for an incremental cost per life year gained of RUB 1,196,808 (£42,449), but 
since it was published as an abstract56 it provided limited information (ICER calculations 
made by ERG from information reported in the publication). Further, its relevance to the 
NICE decision problem is ambiguous since it is not clear whether patients had >30% blasts, 
and it included MDS patients. Moreover, these results did not take account of HRQoL 
outcomes and the costs results may not be transferable due to differences in relative prices 
between UK and Russia. 
5.1.5 Conclusions 
Although no conclusions were provided by the submitted review, ERG concludes that the 
quality of the evidence is poor and in any case unlikely to be relevant to the present 
assessment. 
5.2 Summary of company’s submitted economic evaluation 
5.2.1 Model structure 
A semi-Markov model, proposed by Celgene, is based on AZA-AML-001 study, a literature 
review of clinical guidelines and economic models for AML, and advice from two UK clinical 
oncologists. The structure of the model is described in the submission (Celgene submission, 
Section 5.5.5, pp. 106–108) and shown in Figure 9 below. 
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Figure 9: Structure of the model submitted by Celgene 
 
Source: Celgene submission, Figure 14, p. 107 
The model simulates remission, non-remission, relapse/progressive disease and death in 
AML patients. 
The model starts after patients have completed the first cycle of either AZA or CCR (i.e., 4 
weeks after the start of treatment). Those patients, who have responded to the treatment by 
the end of the first cycle and have complete remission (CR) or complete remission with 
incomplete blood count recovery (CRi), enter the model in “Remission” state; patients with 
partial remission (PR) or stable disease are placed in “Non-remission” state. 
Disease pathways in the subsequent treatment cycles are as follows: 
 Patients in the remission state may continue in remission, relapse or die. 
 Those in the non-remission state may remain in this state, progress to 
“Relapse/Progressive disease” state or die. 
 Patients in the “Relapse/Progressive disease” state may remain in this state or die. 
For every model cycle, the proportion of patients in each health state is estimated using 
RFS, PFS and OS curves in the following way: 
 The proportion of patients in the remission state is based on RFS from AZA-AML-001 
study. In the trial, RFS was estimated from the date of first documented CR or CRi to 
the date of relapse, while OS and PFS were measured from randomisation to event. 
Therefore, in the model, RFS was adjusted to ensure consistency with OS and PFS.  
 The proportion of patients in the non-remission state was estimated from PFS curve 
for patients who have achieved partial response (PR) or stable disease (SD). 
 The proportion of patients in the relapse/progressive disease (PD) state was the 
difference between the proportions in OS state, and RFS and PFS states. 
 The proportion in the “Death” state was a complement of the OS curve. 
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The model cycle length is 4 weeks which corresponds to one treatment cycle of azacitidine, 
and is in line with AZA-AML-001 study. 
The other key structural assumptions are presented in Table 17. 
Table 17: Key assumptions in Celgene's economic model 
Assumption Justification 
Patients are not eligible for HSCT at any point The marketing authorisation extension for 
azacitidine excludes those patients who are 
eligible for HSCT. 
 
Patients in AZA-AML-001 were ineligible for 
HSCT. 
Patients who do not achieve remission in the 
treatment phase do not subsequently achieve 
remission 
Clinical expert advice. Once off treatment and 
not in remission, a patient will not achieve 
remission. 
Once in the PD state, patients either remain in 
PD or die 
Clinical expert opinion and previous TAs in 
similar end-of-life cancers. 
There is no treatment switching Clinical expert opinion. Only a very small 
percentage of patients at this stage of disease 
would be fit for a second treatment after failing 
their first. 
In any cycle, patients can only be in one of the 
health states 
Markov model Structure 
Key: HSCT, haematopoietic stem cell transplantation; BSC, best supportive care; TAs, technology appraisals; 
PD, progressive disease. 
Source: Celgene submission, Table 54, p. 141 
5.2.2 Population 
The model population, parameterised from the AZA-AML-001 trial, represents older patients 
with de-novo or secondary AML with more than 30% bone marrow blasts who were not 
eligible for hematopoietic stem cell transplantation (HSCT), with intermediate- or poor-risk 
cytogenetics (NCCN 2009 criteria), Eastern Cooperative Oncology Group performance 
status (ECOG PS) scores 0–2, and white blood cell count not more than 15×109/L. 
The starting age of the model population was 75 years and the patient’s body surface area 
(BSA) was 1.8 m², based on the mean age and BSA of AML patients from the AZA-AML-001 
trial. 
The model allows cross-over adjusted, cross-over unadjusted and censor-at-switch analyses 
performed for the whole population, IC, LDAC, or BSC patient subpopulations, 
subpopulations with different cytogenetic risk (intermediate and poor), with and without 
myelodysplasia-related changes. The following rationale was given for these subgroups 
(Source: Celgene submission, Section 5.2.1, p. 106): 
Subgroups on cytogenetic risk and myelodysplasia-related changes were chosen 
based upon a current unmet need for an effective option for patients presenting with 
these characteristics and the observed significant (P-values < 0.05) OS benefit of 
azacitidine over CCR in the AZA-AML-001 trial in these subgroups. 
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The results from alternative and subgroup analysis are reported in Section 5.8 of Celgene’s 
submission. 
Celgene presented cost-effectiveness results for two subgroups: patients with poor-risk 
cytogenetics and patients with MDS related changes: 
Since subsequent-treatment adjustment was not possible for these subgroups, 
analysis was performed without adjustment. 
 
5.2.3 Interventions and comparators 
The model, proposed by Celgene, estimates cost-effectiveness of AZA compared to 
conventional care regimens (CCR) comprised of IC+BSC, LDAC+BSC and BSC alone. 
Further details regarding the interventions and comparators were given (Source: Celgene 
submission, Section 5.2.3, pp. 108–109): 
IC: 
- Induction therapy – Cytarabine was administered at a dose of 100–200 
mg/m²/day via continuous IV infusion for a total of 7 days. Anthracycline was 
given in combination with cytarabine for 7 days. 
- Consolidation - Two consolidation cycles for those who responded to the 
treatment, followed by BSC. Those who do not respond to induction therapy 
receive BSC. 
LDAC: Cytarabine at a dose of 20 mg SC [twice daily] for 10 days, every 28 days, 
until disease progression or unacceptable toxicity; patients then receive BSC. 
BSC: Including but is not limited to red cell or whole blood transfusions, fresh frozen 
plasma transfusions, platelet transfusions, antibiotic and/or antifungal therapy, and 
nutritional support). This is continued until death. 
The same BSC is assumed to apply to all patients who have stopped active 
treatment on AZA, IC or LDAC. 
Azacitidine is incorporated at a dose of 75 mg/m²/day SC for 7 days every 28 days. 
In the base case wastage is assumed and vials used are rounded up to the cost of 
the nearest full vial. Vial sharing is tested in the sensitivity analysis (this also applies 
to CCR regimens). 
 
The distribution of patients over IC, LDAC and BSC treatments (18%, 64% and 18%, 
respectively), modelled in the base case, was derived from the pivotal RCT.  It differed 
substantially from the distribution observed in UK clinical practice and reported in the HMRN 
registry (xxx of patients were treated with IC, xxx with LDAC and xxx with BSC). To assess 
the effect of this assumption on the outcome, the manufacturer performed a scenario 
analysis (Celgene submission, Section 5.8.3, pp.154-156) by calculating a weighted average 
ICER from individual CCR and AZA arms, with weights equal to the proportions of patients in 
individual CCR from the HMRN registry. 
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5.2.4 Perspective, time horizon and discounting 
In the model, the perspective on costs was NHS and personal social services perspectives, 
and the perspective on health effects was direct health effects on patients, in accordance 
with the NICE reference case.  
The model time horizon was 10-years, which was considered the life-time horizon of the 
patient population in question. 
For utilities and costs, the manufacturer used the discount rate of 3.5%, in line with the NICE 
reference case. In addition, the model allows analyses with the discount rates of 1.5% and 
6%. 
5.2.5 Treatment effectiveness and extrapolation 
Treatment effectiveness was estimated from the AZA-AML-001 trial and post-hoc analyses 
conducted on the data collected. 
The economic model used the following clinical endpoints: 
 Overall survival (OS), defined as the time from randomization to death from any 
cause; 
 Relapse-free survival (RFS), the time from first documented CR or CRi to relapse, 
death from any cause, or loss to follow-up (for the model this was adjusted to time 
from randomization until relapse or death); 
 Progression-free survival (PFS), defined as the time from randomization to death or 
disease progression (PD) for patients who did not achieve remission (CR or CRi); 
 Event-free survival (EFS), defined as the time from randomization to treatment 
failure, disease progression, relapse after CR or CRi, death from any cause, or loss 
to follow-up). 
EFS was employed to estimate both RFS and PFS, which were obtained (Source: Celgene 
submission, Section 5.3.1., p. 109): 
[…] by disaggregating the data into those who did or did not achieve CR or CRi; then, 
patients with CR or CRi were assessed for death or relapse (i.e., RFS); patients with 
no CR or CRi were instead assessed for death or disease progression (i.e., PFS). 
Response status was also used to allocate utilities and disease management costs; 
in particular, costs for consolidation IC were attributed to patients with CR, CRi, and 
PR. The cost of BSC was allocated to patients with PD after stopping active 
treatment. 
 
In response to an ERG question for clarification regarding the treatment of loss to follow-up, 
Celgene provided further information: 
Specific definitions for event free survival (EFS) and relapse free survival (RFS) 
outcomes are provided below: 
- Loss to follow-up was treated as an event for EFS outcomes when such loss 
occurred without documented treatment failure, progression or relapse from 
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complete remission (CR)/complete remission with incomplete blood count 
recovery (Cri) and alive at last contact. 
- Loss to follow-up was treated as an event for RFS outcomes when such loss 
occurred after documented CR/CRi without relapse from CR/CRi and alive at last 
contact. 
- Loss to follow-up was treated as an event for progression free survival (PFS) 
outcomes when such loss occurred and the variable PDFLAG = 1 (progressive 
disease (PD) being the best IRC assessed response).  
This was a conservative approach, as the worst case scenario (e.g. progression, 
relapse or death) is assumed for subjects who are lost to follow up in the context of 
such a serious disease that requires ongoing medical attention. 
 
The company also referred to definitions in Table 18 and Table 19 reproduced from the 
AML-001 Statistical Analysis Plan document. 
Table 18: Censoring rules for event-free survival 
Situation Date of Event or Censoring Outcome 
Withdrawal and no post-baseline response 
assessments and alive at date of last contact 
Date of randomization Censored 
Death without any adequate response assessment Date of death Event 
Treatment failure, disease progression, relapse after 
CR/CRi, or death 
Earliest of: Event 
Date of treatment failure 
Date of disease progression 
Date of relapse from CR or CRi 
Date of death 
Lost to follow-up without documented treatment 
failure, progression, or relapse from CR/CRi and alive 
at last contact 
Date of last response 
assessment 
Event 
No treatment failure, progression, or relapse from 
CR/CRi and not lost to follow-up 
Date of last response 
assessment of CR, CRi, PR, or 
SD 
Censored 
Key: CR, complete remission; CRi, complete remission with incomplete blood count recovery; PR, partial 
remission; SD, stable disease 
Source: AML-001 Statistical Analysis Plan Dated Jan 31, 2014 
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Table 19: Censoring rules for relapse-free survival 
Situation Date of Event or Censoring Outcome 
Relapse or death after CR/CRi Earliest of: Event 
Date of relapse from CR or CRi 
Date of death 
Lost to follow-up after documented CR/CRi without 
relapse from CR/CRi and alive at last contact 
Date of last response 
assessment 
Event 
CR/CRi without documented relapse and not lost to 
follow-up and alive at last contact 
Date of last response 
assessment 
Censored 
Key: CR, complete remission; CRi, complete remission with incomplete blood count recovery 
Source: AML-001 Statistical Analysis Plan Dated Jan 31, 2014 
Response rates from the trial (after excluding non-confirmable or non-assessable subjects) 
used in the model are shown in Table 20. 
Table 20: Response rates in the AZA-AML-001 trial 
Response Azacitidine response rate CCR response rate 
Remission (CR, CRi) 0.28 0.25 
Non-response (PR, SD, PD, TF) 0.72 0.75 
Key: CR, complete remission; CRi, morphologic complete remission with incomplete blood count recovery; 
PD, progressive disease; PR, partial remission’ SD, stable disease; TF, treatment failure 
Source: Celgene submission, Table 31, p. 109 
Several models were fitted to extrapolate overall survival, progression-free survival and 






For each of these models and outcomes treatment effects were also estimated in the form of 
constant hazard ratios from the coefficient of a binary covariate treatment group indicator 
included in time to event regressions. Because the log-logistic and log-normal are 
accelerated failure time models they do not have associated constant hazard ratios, 
although in the submission (Section 5.3.3, pp. 111, 114, 116, Tables 32–24) the company 
presents a HR estimate from a Cox proportional hazards model as if it was applicable to the 
log-logistic and log-normal extrapolation models. 
The survival model selection process algorithm recommended by the NICE DSU TSD14 was 
employed to identify the best fitting curves (Source: Celgene submission, Section 5.3.2, p. 
110), with a detailed account on curve fitting also given by the company (Source: Celgene 
submission, Section 5.3.3, p. 110-116). 
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For the base case, the manufacturer selected the exponential model for OS, Weibull for RFS 
and Gompertz for PFS. The company adjusted OS outcomes for treatment switching using a 
range of different methodological options. PFS and RFS were not adjusted for treatment 
switching, and Celgene stated that all progression and relapse events in the trial occurred 
before other censoring events (Celgene submission, Section 5.3.3, p. 116), among which 
Celgene does not mention treatment switching. In response to the questions for clarification 
from ERG on why RFS and PFS had not been adjusted for subsequent treatment, the 
company stated that: 
This was due to sample size primarily. The instances in which switching preceded 
the clinical event of interest were few, and the impact of this on the results would be 
very small. 
 
The overall survival, relapse-free survival and progression-free survival used in the model 
are given in Figure 10, Figure 11 and Figure 12 respectively. 
Figure 10: Overall survival used in the company's submitted model 
 
Key: AZA, azacitidine; CCR, conventional care regimens 
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Figure 11: Relapse-free survival used in the company's submitted model 
 
Key: AZA, azacitidine; CCR, conventional care regimens 
Figure 12: Progression-free survival used in the company's submitted model 
 
Key: AZA, azacitidine; CCR, conventional care regimens 
 
5.2.5.1 Treatment switching 
The base case OS estimates were based on an adjustment for subsequent treatment use in 
the CCR arm that censored the data at the time of subsequent treatment initiation and 
weighted the remaining data by the inverse of the probability of not starting subsequent 
therapy, which was separately estimated using a logistic regression model. This method is 
referred to as the inverse probability of censoring weights (IPCW), and was originally 
developed for the analysis of observational data, applying a similar logic to that used to 
estimate population statistics from survey data.57 
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The validity of this method hinges on the untestable assumption that information on all 
determinants of the probability of not using subsequent treatment that are also correlated 
with OS outcomes is measured in the trial and available to include in the logistic model. This 
is unlikely to be the case in any practical application, and the question is therefore to what 
extent any omitted variable bias is likely to be significant. Also, the method may be unstable 
if few individuals remain uncensored in some patient subgroups as defined by the covariates 
in the logistic regression (i.e. low effective sample size). 
The IPCW method was summarised as follows (Source: Celgene submission, Section 5.3.5, 
pp. 124–125): 
Patients who switch treatments are artificially censored at the time of switching, and 
observations for the remaining patients are weighted to adjust for censored patients. 
A pooled logistic model is constructed to predict the probabilities of remaining 
uncensored-by informative censoring (crossover) at each measurement point and 
must include all baseline or post-randomization variables that predict both treatment 
switching and outcome. Briefly, the procedure for estimation using IPCW is as 
follows52, 57: 
1. Panel data are created for the pooled logistic models. The follow-up period is 
partitioned into intervals based on follow-up measurement points (visit dates). At 
each measurement point, time-dependent variables that could predict treatment 
discontinuation, switching, and OS are assessed for all patients. 
2. The probability of remaining uncensored is calculated. A logistic regression 
model is fitted to predict participation at each measurement (remaining uncensored) 
for each subject. The probability of remaining uncensored using baseline risk factors 
of interest (E) is estimated, as is the probability P of remaining uncensored using 
both baseline risk factors of interest (E) and time-dependent covariates (Z). The 
results of this modelling process are summarized to describe the factors associated 
with participation at each procedure. 
3. IPCWs are calculated: the inverse probability weight for remaining 
uncensored (1/P) will consist of the probability for remaining uncensored estimated in 
step 2, using both covariates E and Z. This inverse probability is stabilized by 
multiplying it by the probability for remaining uncensored using covariates. 
4. A standard Cox regression (i.e., in accordance with estimation with no 
crossover) is fitted for the current outcome using 1/P as weights. The set of 
covariates E and any other appropriate adjustment covariates for that outcome may 
also be included in a parametric regression approach. The weighted Cox regression 
is fitted using stabilized weights (S/P). Standard errors are corrected using sandwich 
estimation or bootstrapping methods. 
5. An unweighted version of the Cox regression is fitted for comparison. The 
same models are fitted as in step 3 but without any sampling weights. 
Preliminary reviews of the data suggested that subsequent use of azacitidine often 
closely followed relapse or progression. The model constructed had relatively short 
time periods (15 days) in order to capture this association. This model was 
constructed using the status of patients at 15 day time points. The last time period for 
each study subject usually contained less than 15 days. 
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The “numerator” model in the pooled logistic model consisted of baseline factors and 
the “denominator” model consisted of baseline factors and time-varying covariates. 
This method provides an estimate of the adjusted HR of survival for the CCR arm in 
relation to the azacitidine arm but does not generate an estimate of the survival 
distribution (i.e., does not produce a KM curve). However, a crude estimate of the 
survival distribution can be obtained by applying the estimated HR to the azacitidine 
KM curve; this will result in an estimated CCR survival curve with a similar profile 
(shape) to the azacitidine curve. Similarly, the converse of the HR can be used as an 
estimate of the median of the adjusted survival distribution for CCR – the actual 
estimated values are indicative only and will reflect the estimated distribution based 
on the distribution of the azacitidine KM curve.58 
Baseline characteristics and time-varying variables were captured during the trial and 
were used in step 2 of the IPCW method in order to estimate the probabilities of 
remaining uncensored or having no subsequent use of azacitidine. These variables 
were assessed by a clinician to establish which factors would be considered relevant 
and appropriate for use in the crossover analysis models, and whether any of the 
laboratory variables collected at each visit were relevant for analysis of survival data, 
either as factors that influence the change in treatment or as factors that could affect 
the estimate of survival. 
Statistical tests were then conducted to assess whether there were any statistically 
significant differences between CCR patients who switch and CCR patients who do 
not switch for the list of potential covariates to be included in the model. Means and 
standard deviations were calculated for numerical variables and counts and 
percentages for categorical variables for all patients, but also separately for patients 
who were censored or died. P values were determined using chi-square test for 
categorical variables and Student’s t-test for numerical variables. 
The covariates included initially in the model, are presented in [Table 21]. These 
were summarized by basic summary statistics (number and percentages for 
categorical variables and means and standard deviations for numerical variables). 
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Table 21: Covariates used in the company's IPCW analysis 
Type of variable Variable 
Non time-varying covariates 
Demographic 
characteristics 
Age at informed consent (continuous) 
Age (<75 years, ≥75 years) 
Sex (male or female) 
Geographic region (North America/Australia, Western Europe/Israel, Eastern 
Europe, or Asia) 
Race (Asian, Black or African American, White, Native Hawaiian or other 
Pacific islander, other, n/a) 
Clinical characteristics ECOG performance status at randomization (0–1, 2) 
AML classification (newly diagnosed, histologically confirmed de novo AML; 
AML secondary to prior myelodysplastic disease not treated with azacitidine, 
decitabine, or cytarabine; AML secondary to exposure to potentially 
leukemogenic therapies or agents with the primary malignancy in remission 
for at least 2 years) 
Time since initial AML diagnosis to randomization (< median; ≥ median) 
(derived from time since initial diagnosis and date of signed informed 
consent) 
Baseline comorbidity score 
Prior history of myelodysplastic syndromes (yes or no) 
Cytogenetic risk status (intermediate risk, poor risk) 
Study design Pre-randomization CCR assignment (BSC, low-dose cytarabine, intensive 
chemotherapy) 
International working group response assessment 
Laboratory variables Percentage bone marrow blasts (continuous) according to central review 
Time-varying covariates 




RBC transfusion status (independent or dependent) 
Platelet transfusion status (independent or dependent) 
Adverse events Occurrence of a grade 3/4 adverse event since last visit (yes/no) 
Other Time since last visit (in months; included at each visit) 
Key: ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group; RBC, red blood cell; 
WBC, white blood cell 
Source: Celgene submission, Table 37, p. 125 
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In relation to the statement that “this method provides an estimate of the adjusted HR of 
survival for the CCR arm in relation to the azacitidine arm but does not generate an estimate 
of the survival distribution (i.e., does not produce a KM curve),” the ERG notes that this 
statement is incorrect, because survival curves for both trials arm may be generated from 
the IPCW analysis. The respective figure is produced by ERG in Figure 8 (page 62) using 
individual patient data provided by Celgene. 
ERG also consulted clinical experts on whether there were any variables missing from Table 
21 that may be considered to predict or explain the use of subsequent therapy and at the 
same time be associated with survival prognosis. The clinical experts did not suggest any 
additional variables. 
In arriving at their preferred base case method the company also considered other 
approaches, including not adjusting for treatment switching, censoring at switch, and the 
Rank Preserving Structural Failure Time Model (RPSFTM) and the Iterative Parameter 
Estimation (IPE). Celgene considered the RPSTFM and IPE approaches as involving a 
fundamental assumption (i.e., that the treatment effect of azacitidine is the same for patients 
who received it as initially randomly allocated therapy as for patients who received it as 
subsequent treatment) that is unlikely to be valid. The company stated (Source: Celgene 
submission, Section 5.3.5, p. 123): 
These limits notwithstanding, the IPCW method and results are stronger than the 
alternatives. The use of RPSFT and IPE methods has an underlying assumption of a 
common treatment effect for patients who started treatment with azacitidine and for 
those who switched to azacitidine. This assumption does not hold in this case: 
differences in prognosis between the two groups are likely to lead to a different 
benefit from delayed versus immediate treatment; CCR itself, particularly LDAC and 
IC, is also an active treatment, so the prognosis of a patient switching from CCR will 
not be the same as for a patient receiving azacitidine from the start of the study. 
The similarity of the results for the IPE and RPSFT analyses  is likely because of 
violation of the key assumption, that treatment benefit in terms of OS is the same 
regardless of whether a patient began on azacitidine or switched; this assumption is 
hard to justify given the prognosis for with AML in the trial. 
 
In addition, Celgene reported the attempt to use of two-stage methods,51 which could not be 
implemented due to insufficient numbers of subsequent treatment users in the CCR arm and 
recorded data (Source: Celgene appendices to submission, Appendix 11, Section 4.7). 
Similarly to the IPCW method, the censor-at-switch method dropped the data after the start 
of azacitidine in the CCR trial arm, but unlike IPCW it did not apply any adjustment to the 
remaining data for the differences in probability of censoring (azacitidine) across CCR arm 
patients. Thus, to the extent that the estimates from the two methods differ (provided IPCW 
is validly in this application), would suggest that azacitidine was not given to CCR patients at 
random (as one would expect). As it transpires, Celgene reported hazard ratio estimates 
from Cox proportional hazards models of xxxx for both the IPCW and censor-at-switch 
methods, suggesting that adjusting for non-random subsequent therapy use is not important 
in this case (see also the critique of treatment switching in the clinical effectiveness Section 
4.3). 
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5.2.5.2 Summary of methods of effectiveness estimation and extrapolation 
In response to ERG’s request to confirm the methods used to calculate different survival 
curves in the model, and whether the curves for relapse-free survival and progression-free 
survival were fitted to azacitidine (AZA) and conventional care regimen (CCR) patients with a 
proportional-hazards azacitidine treatment variable, or if these were fitted only to CCR 
patients, Celgene provided the following information: 
The following methods were used to calculate different survival curves. The curves 
for RFS and PFS were fitted only to CCR patients. 
 
Table 22: Methods used to calculate survival curves in the model submitted by 
Celgene 
Arm AZA CCR 
Overall survival 
Underlying data OS from AZA OS from AZA 
Curve fitting Exponential Exponential 
Adjustments — HR of xxxxxx from IPCW 
method (inverse HR) 
Relapse-free survival 
Underlying data EFS for CCR patients achieving 
CR or CRi 
EFS for CCR patients achieving 
CR or CRi 
Curve fitting Weibull Weibull 
Adjustments HR of 0.84 from curve fitting — 
Progression-free survival 
Underlying data EFS for CCR patients not 
achieving CR or CRi 
EFS for CCR patients not 
achieving CR or CRi 
Curve fitting Gompertz Gompertz 
Adjustments HR of 0.85 from curve fitting — 
Key: AZA, azacitidine; CCR, conventional care regimen; CR, complete remission; CRi, complete remission 
with incomplete blood count recovery; EFS, event-free survival; HR, hazard ratio; IPCW, inverse 
probability of censoring weights 
5.2.6 Health-related quality of life 
Health effects were measured in QALYs in accordance with the NICE reference case. 
Utilities were estimated from response status. They were mapped from trial-based EORTC 
QLQ-C30 data using published algorithms (Source: Celgene submission, Section 5.4, p. 
127). Two mapping algorithms were incorporated in the model, one reported by 
Proskorovsky et al. 2014,59 which was used for the base case, and the other by McKenzie 
and Van der Pol, 2009,60 used for a scenario analysis. The algorithms are presented in 
Celgene’s Submission, Table 40 (p. 128) and the corresponding utility values are shown in 
Table 23. 
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Table 23: Summary of utility values for Celgene’s economic evaluation 
Health state Calculation method 




McKenzie and Van der Pol 
2009
60
 (scenario analysis) 
Remission (CR/CRi) 0.7707 0.7400 
Non-remission (PR, SD) 0.7160 0.6574 
Post-progression/relapse (PD) 0.6233 0.5680 
Grade 3+ AEs −0.0240 −0.0207 
Key: AE, adverse event; CR, complete remission; CRi, morphologic complete remission with incomplete 
blood count recovery; PD, progressive disease; PR, partial remission’ SD, stable disease 
Source: Celgene submission, Table 41, p. 129 
The model accounts for disutility associated with overall grade 3 or above treatment-
emergent adverse events (TEAEs) (Source: Celgene submission, Table 41, p. 129). The 
EORTC QLQ-C30 data used to map the EQ-5D utility for TEAEs are from patients who were 
hospitalised with and without grade 3 or higher TEAEs in the AZA-AML-001 trial. 
Adverse event-related QALYs were calculated by (Source: Celgene submission, Section 
5.4.3, p. 129): 
[Multiplying the probability of at least one TEAE occurring] by its duration in days, 
then multiplying the result by the day equivalent of the HSUV. 
 
5.2.7 Resources and costs 
5.2.7.1 Drug acquisition 
Drug utilization was estimated directly from the AZA-AML-001 trial.  
Total drug use per cycle per patient (Table 24) was calculated by multiplying the number of 
vials per day per patient, the cost of one vial (Table 25) and the mean number of treatment 
days per cycle (Table 26). 
The number of vials per day per patient was based on the average daily dose (Table 24) and 
the assumption on vial sharing, i.e., no wastage, full wastage or wastage with 30% 
tolerance.   
For azacitidine, IC and LDAC treatments, the average daily dose was estimated from the 
average daily dose in mg/m² (Table 24) and the average body surface area (BSA) of 1.80 
m². However, according to the CSR, the daily dose for LDAC treatment should have been 
estimated in mg/day (further details are provided in Section 5.3.8, page 122). 
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Table 24: Drug utilisation per cycle (4 weeks) for no wastage scenario 




Days per cycle Total Dose (mg) 
per cycle 
Azacitidine Azacitidine xxxxx xxxx xxxxxx 
IC, induction Cytarabine  122.20 7.10 1,561.72 
Daunorubicin
a 
 49.70 3.00 268.38 
Idarubicin
a 
 11.00 3.00 59.40 
IC, consolidation Cytarabine  120.20 5.00 1,081.80 
Daunorubicin
a 
 49.40 2.00 177.84 
Idarubicin
a
  10.70 2.00 38.52 
LDAC Cytarabine  84.05 10.22 696.65 
Key: IC, intensive chemotherapy; LDAC, low-dose cytarabine 
Notes: a, Use of anthracycline in the trial comprised 50% idarubicin and 50% daunorubicin 
Source: Celgene submission, Table 42, p. 131 
Full wastage (i.e., no vial sharing) was assumed in the base case, and alternative scenarios 
of no wastage and wastage with 30% tolerance (i.e., vial sharing assumed in 30% of cases) 
were explored in sensitivity analyses. 
For drugs with several vial or pack sizes, vial size selection was on the basis of the largest 
available size, rather than smaller vials as required to minimize vial wastage. The number of 
vials for each drug was not reported in the company’s submission, but was available from 
their executable model. 
Drug acquisition unit costs, presented in Table 25, were estimated from British National 
Formulary (BNF).61 
Table 25: Drug acquisition unit costs 
Drug name Vial or pack mg per vial or pack Price (£) per vial/pack 




20 mg/mL; 5 mL vial or 




20 mg/mL; 25 mL vial 





100 mg/mL; 10 mL vial 1000 39 
100 mg/mL; 20 mL vial 2000 77.5 
Daunorubicin (non-
proprietary) 
20 mg vial 20 55 
Idarubicin (Zavedos®) 5 mg vial 5 87.36 
10 mg vial 10 174.72 
Notes: a, Average of two prices 
Sources: Celgene submission, Table 43, p. 132; BNF 2015 
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Table 26: Drug acquisition cost per cycle 
Treatment Total drug cost per cycle per patient (£) 
No wastage Wastage Wastage with 30% tolerance 
Azacitidine xxxxxx xxxxxxx xxxxxx 
IC, induction Cytarabine £77 £105 £77 
Daunorubicin
a
 £738 £825 £738 
Idarubicin
a
 £1,038 £1,048 £1,038 
IC, consolidation Cytarabine £54 £75 £54 
Daunorubicin
a
 £550 £489 £489 
Idarubicin
a
 £673 £699 £673 
LDAC Cytarabine £34 £48 £34 
Key: IC, intensive chemotherapy; LDAC, low-dose cytarabine 
Notes: a, Average of two prices 
Source: Celgene submission, Table 44, p. 132 
The total cost of drug acquisition was estimated from the per-cycle cost of drugs and setting 
the maximum number of treatment cycles equal to the average number of treatment cycles 
shown in Table 27. 
Table 27: Mean number of treatment cycles in the AZA-AML-001 trial 
Treatment Mean number of cycles per patient 
Azacitidine 8.80 














LDAC Cytarabine 5.21 
BSC 3.60 
Key: BSC, best supportive care; IC, intensive chemotherapy; LDAC, low-dose cytarabine 
Notes: a, 1:1 ratio was assumed for patients on daunorubicin and idarubicin 
Source: Celgene submission, Table 45, p. 133 
5.2.7.2 Drug administration 
Health-care resource use (HCRU) for each model state is reported in Celgene’s submission, 
Section 5.5.3 (p. 133). 
Unit costs for health professionals, used in the model, are from Personal Social Service 
Research Unit (PSSRU) and NHS reference costs (Table 28). 
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Table 28: Unit costs for each item of healthcare resource use 
Staff type Unit costs available 2013/2014 (costs including 
qualifications given in brackets) 
Cost per minute 




Nurse advanced (includes lead specialist, clinical nurse 
specialist, senior specialist). £51 (£58) per hour; £80 (£90) 
per hour client contact cost 
£1.33 
Consultant Consultant: medical, £101 (£140) per contract hour £1.68 
Day Care Nurse Nurse, day ward (includes staff nurse, registered nurse, 
registered practitioner), £34 (£41) per hour; £84 (£100) per 





Registrar group, £40 (£60) per hour (48 hour week); £34 
(£51) per hour (56 hour week); £48 (£71) per hour (40 hour 
week) 
£0.80 
District Nurse Community nurse (includes district nursing sister, district 
nurse), £43 (£50) per hour; £57 (£66) per hour of patient‐
related work. 
£0.95 
Doctor Associate specialist, £97 (£124) per hour (40 hour week). 
An associate specialist is a doctor who has trained and 
gained experience in a medical or surgical specialty but has 
not become a consultant. 
£1.62 
Jnr. Doctor Foundation house officer 2, £29 (£41) per hour (48 hour 
week); £25 (£35) per hour (56 hour week); £35 (£49) per 
hour (40 hour week) 
£0.58 
Pharmacist Hospital pharmacist, £42 (£48) per hour; £84 (£96) per cost 
of direct clinical patient time (includes travel); £60 (£68) per 
cost of patient‐related activities. 
£1.40 
Oncology nurse  Nurse team leader (includes deputy ward/unit manager, 
ward team leader, senior staff nurse),  £42 (£48) per hour; 
£104 (£120) per hour of patient contact 
£1.73 
Inpatient stay for 
IC (cost/day) 
Average of "Elective Inpatients - Excess Bed Days",  "Non-
Elective Inpatients - (Long Stay) Excess Bed Days", "Day 
Case", "Non-elective Inpatients - Short Stay", "Regular Day 
or Night Admissions" 
£714.64 
Key: CNS, clinical nurse specialist; SpR, specialist registrar; PSSRU, Personal Social Services Research 
Unit; IC, intensive chemotherapy 
Sources: Celgene submission, Table 48, p. 136; PSSRU Unit costs of health and social care 2014
62
; NHS 
Reference costs  
The frequency (Table 29) and mean time in minutes of health professionals involved during 
different health states (Table 30) were estimated from a healthcare resource use 
questionnaire developed by Celgene (Celgene’s appendices to submission, Appendix 12). 
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Remission Stable disease Progressive 
disease 
AZA CCR AZA CCR AZA CCR AZA CCR 
CNS 
Haematologist 
2.77 2.38 1.66 0.87 2.08 2.37 2.03 2.62 
Consultant  2.58 3.52 0.92 1.13 1.29 1.66 2.03 1.60 
Day Care Nurse 7.75 2.35 5.54 0.95 6.00 3.41 3.69 3.47 
Day Care SpR 1.66 5.16 1.11 2.07 1.66 2.85 2.95 2.95 
District Nurse 0.62 5.39 0.31 5.61 0.62 6.33 0.62 0.59 
Doctor 0.85 4.95 1.23 2.21 1.54 3.04 0.92 0.88 
Jnr. Doctor 0.23 17.11 0.62 21.75 2.54 17.31 2.77 2.64 
Pharmacist  2.77 3.09 2.77 1.78 2.95 1.37 0.31 0.42 
Oncology nurse  0.62 2.17 0.31 0.05 0.62 0.50 0.62 0.59 
Inpatient day 3.16 13.91 0.25 0.90 2.30 9.20 1.73 2.61 
Key: AZA, azacitidine; CCR, conventional care regimens; CNS, clinical nurse specialist; SpR, specialist 
registrar 
Source: Celgene submission, Table 46, p. 134 






Remission Stable disease Progressive 
disease 
AZA CCR AZA CCR AZA CCR AZA CCR 
CNS 
Haematologist 
34.20 25.51 26.40 25.85 33.00 37.23 24.40 34.20 
Consultant  25.60 20.33 20.80 16.29 24.00 16.97 20.80 25.60 
Day Care Nurse 40.72 22.99 18.40 3.91 26.83 27.55 33.00 40.72 
Day Care SpR 22.00 19.82 22.00 17.79 22.00 19.08 22.00 22.00 
District Nurse 15.00 13.87 15.00 4.26 15.00 17.31 15.00 15.00 
Doctor 12.67 13.00 12.67 9.79 12.67 12.10 9.00 12.67 
Jnr. Doctor 9.00 16.01 15.00 0.94 20.00 10.76 12.67 9.00 
Pharmacist  13.50 25.64 13.50 0.71 13.50 19.68 6.00 13.50 
Oncology nurse  6.00 11.68 4.00 0.00 6.00 4.55 6.00 6.00 
Inpatient day 1,440 1,440 1,440 1,440 1,440 1,440 1,440 1,440 
Key: AZA, azacitidine; CCR, conventional care regimens; CNS, clinical nurse specialist; SpR, specialist 
registrar 
Source: Celgene submission, Table 47, p. 135 
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Monitoring and testing requirements for different disease states are captured in the same 
questionnaire (Celgene appendices to submission, Appendix 12). The number of drug 
monitoring tests per cycle is shown in Table 31, and the unit costs in Table 32. 




Remission Stable disease Progressive 
disease 
AZA CCR AZA CCR AZA CCR AZA CCR 
Bone marrow 
aspirates 
0.92 1.25 0.15 0.21 0.42 0.35 0.15 0.16 
Bone marrow 
biopsies 
0.50 0.41 0.00 0.00 0.04 0.08 0.00 0.03 
Peripheral blood 
smears 
1.08 1.01 0.77 0.59 0.77 0.83 0.77 0.74 
Blood tests 9.23 13.29 1.85 3.53 6.54 7.82 7.23 8.33 








0.92 0.80 0.15 0.16 0.15 0.19 0.15 0.13 
Serum blood 
chemistry 
8.46 12.00 1.69 3.53 6.38 7.72 6.92 7.74 
Key: AZA, azacitidine; CCR, conventional care regimens; DNA, deoxyribonucleic acid; RNA, ribonucleic acid 
Source: Celgene submission, Table 49, p. 137 
Table 32: Unit costs for drug monitoring tests 
Laboratory and disease 
monitoring tests 
HRG (Description) Cost per 
test 
Bone marrow aspirates DAPS04 (Clinical Biochemistry, National average 
cost) 
£1.18 
Bone marrow biopsies DAPS04 (Clinical Biochemistry, National average 
cost) 
£1.18 
Peripheral blood smears DAPS05 (Haematology, National average cost) £3.00 
Blood tests DAPS05 (Haematology, National average cost) £3.00 
DNA and RNA extractions for 
molecular testing 
DAPS04 (Clinical Biochemistry, National average 
cost) 
£1.18 
Extractions for cytogenetic testing DAPS01 (Cytology, National average cost) £7.77 
Serum blood chemistry DAPS04 (Clinical Biochemistry, National average 
cost) 
£1.18 
Key: DNA, deoxyribonucleic acid; HRG, healthcare resource group; RNA, ribonucleic acid 
Source: Celgene submission, Table 50, p. 137; NHS reference costs 2013–14 
Red blood cell and platelet transfusions were also included in the model (Table 33). 
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AZA CCR AZA CCR AZA CCR AZA CCR 
Red blood 
cells 
3.62 3.40 0.15 0.72 3.00 3.05 4.55 4.78 £121.85
63
 
Platelets 4.54 3.63 0.15 0.48 3.92 3.46 5.70 5.85 £193.15
64
 
Key: AZA, azacitidine; CCR, conventional care regimens 
Source: Celgene submission, Table 51, p. 138 
5.2.7.3 Adverse events 
The cost of managing AEs was calculated as a cost per patient, based on the arithmetic 
average cost for managing grade 3 or 4 TEAEs in the AZA-AML-001 trial such as anaemia, 
neutropenia, febrile neutropenia, thrombocytopenia, pneumonia, and worsening AML (not 
qualifying as a progression or relapse event); the cost are shown in Table 34. 
Table 34: Costs of managing adverse events (≥ grade 3) 






£341.69 SA08J (Other Haematological or Splenic Disorders, 
with CC Score 0-2)
a
 
Thrombocytopenia £316.46 SA12K (Thrombocytopenia with CC Score 0-1)
a
 
Pneumonia £143.64 WF01A Service Code 300 (Consultant-led outpatient 






£377.01 SA25M (Acute Myeloid Leukaemia with CC Score 0-1)
a
 
Grade ≥ 3 TEAEs £310.36 Average 
Key: CC, complications and comorbidities; TEAE, treatment-emergent adverse event 
Notes: a, Unit day case cost; b, National unit cost 
Sources: Celgene submission, Table 52, p. 139; National schedule of reference costs 2013-14 
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5.2.8 Cost-effectiveness results 
Base-case results are shown in Table 35. Estimated cost per QALY reported by Celgene is 
£20,648. 
Table 35: Base case results of the company's model 
Arm Total Incremental ICER (cost 
per QALY) 
Costs LYG QALYs Costs LYG QALYs 
CCR £40,608 0.9041 0.6365 — — — — 
Azacitidine xxxxxxx 1.1820 xxxxxx xxxxxx 0.2779 xxxxxx £20,648 
Key: ICER, incremental cost-effectiveness ratio; LYG, life years gained; QALYs, quality-adjusted life years; 
CCR; conventional care regimens 
Disaggregated results are shown in Table 36, Table 37 and Table 38. 
Table 36: Health outcomes (QALYs) by health state in the company's model 





RFS xxxxxx  0.2312  xxxxxx  xxxx 
PFS xxxxxx  0.2725  xxxxxx  xxxx 
PD xxxxxx  0.1328  xxxxxx  xxxx 
Total xxxxxx  0.6365  xxxxxx  xxxx 
Key: CCR, conventional care regimens; PD, progressive disease; PFS, progression-free survival; QALY, 
quality-adjusted life year; RFS, relapse-free survival 
Notes: Figures may not add due to rounding 
Table 37: Costs by health state in the company's model 





RFS xxxxxxx £6,503 xxxxxx xxxx 
PFS xxxxxxx £22,235 xxxxxxx xxxx 
PD xxxxxx £6,260 xxxxxx xxx 
Terminal care xxxxxx £5,609 xxxx xxx 
Total xxxxxxx £40,608 xxxxxx xxxx 
Key: CCR, conventional care regimens; PD, progressive disease; PFS, progression-free survival; RFS, 
relapse-free survival 
Notes: Figures may not add due to rounding 
 Page 91 of 145 
 
Table 38: Costs by component in the company's model 





Drug acquisition xxxxxxx £370 xxxxxxx xxxx 
Drug 
administration 
xxxxxx £23,316 xxxxxxxx xxxxx 
Tests to monitor 
disease 
xxxx £157 xxxx xxx 
Transfusion xxxxxx £4,624 xxxx xxx 
Management of 
AEs 
xxxx £269 xx xxx 
BSC/Monitoring 
costs 
xxxxxx £6,260 xxxxxx xxx 
Terminal care xxxxxx £5,609 xxxx xxx 
Total xxxxxxx £40,608 xxxxxx xxxx 
Key: AEs, adverse events; BSC, best supportive care; CCR, conventional care regimens; PD, progressive 
disease; PFS, progression-free survival; RFS, relapse-free survival 
Notes: Figures may not add due to rounding 
5.2.8.1 Subgroup analyses 
Celgene presented cost-effectiveness results for two subgroups: patients with poor-risk 
cytogenetics (Table 39) and patients with MDS related changes (Table 40). For these 
subgroups, analysis was performed without adjustment for subsequent active treatment. 
Table 39: Results for patients with poor-risk cytogenetics 
Arm Total Incremental ICER (cost per QALY) 
Costs LYG QALYs Costs LYG QALYs 
CCR £46,683 0.6607 0.4567 — — — — 
Azacitidine xxxxxxx 1.1855 xxxxxx xxxxxx 0.5248 xxxxxx £20,227 
Key: ICER, incremental cost-effectiveness ratio; LYG, life years gained; QALYs, quality-adjusted life years; 
CCR; conventional care regimens 
Source: Celgene submission, Table 63, p. 158 
Table 40: Results for patients with MDS related changes 
Arm Total Incremental ICER (cost per QALY) 
Costs LYG QALYs Costs LYG QALYs 
CCR £50,098 0.9459 0.6583 — — — — 
Azacitidine xxxxxxx 1.4050 xxxxxx xxxxxx 0.4591 xxxxxx £19,175 
Key: ICER, incremental cost-effectiveness ratio; LYG, life years gained; QALYs, quality-adjusted life years; 
CCR; conventional care regimens 
Source: Celgene submission, Table 64, p. 158 
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5.2.9 Sensitivity analyses 
Celgene performed deterministic and probabilistic sensitivity analyses to estimate the effect 
of uncertainty in model parameters on the ICER. 
5.2.9.1 Univariate sensitivity analyses 
One-way SA is a form of deterministic sensitivity analysis in which one parameter value is 
varied while keeping all other parameter values constant, to investigate the impact of 
individual parameters on the base case ICER. 
In the model, the base case values of the following parameters were varied by ±20% or 
around a confidence interval (for HRs) to evaluate this impact:  
 Drug utilization costs; 
 Drug administration costs; 
 Drug monitoring cost (transfusion and tests); 
 BSC/palliative care costs; 
 HRs; 
 Safety; 
 Response rate; 
 Health state utility values. 
A tornado diagram demonstrating the results of the univariate sensitivity analyses is shown 
in Figure 13. 
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Figure 13: Tornado diagram of company’s deterministic sensitivity analyses 
 
Key: AZA, azacitidine; CCR, conventional care regimens; CR, complete remission; CRi, complete remission 
with incomplete blood count recovery; HR, hazard ratio; ICER, incremental cost-effectiveness ratio; OS, 
overall survival; PFS, progression-free survival; PD, progressive disease; RFS, relapse-free survival; 
SD, stable disease; TEAE, treatment-emergent adverse events 
Source: Celgene submission, Figure 34, p. 152 
5.2.9.2 Probabilistic sensitivity analysis 
The manufacturer performed second-order Monte Carlo simulations by randomly drawing 
from all predefined parameter distributions simultaneously and computed incremental costs 
and health outcomes for the random variates. The results were plotted as X-Y scatter plot 
and cost-effectiveness acceptability curves where the “willingness to pay” is plotted against 
the proportion of runs that resulted in incremental cost-effectiveness ratios below this 
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willingness to pay. The parameter distributions used for the probabilistic sensitivity analysis 
are reported in Table 41. 
Table 41: Distributions used in the company’s probabilistic sensitivity analysis 
Beta distribution Gamma distribution 
 Response rate 
 HSUVs 
 HSUVs for adverse events 
 Incidence of adverse events 
 Patients’ weights and heights 
 Drug usage and number of treatment cycles 
 Healthcare resource use 
Key: HSUV, health state utility value 
Source: Celgene submission, Table 59, p. 148 
Point estimates and 95% uncertainty intervals from PSA are reported in Table 42. Cost-
effectiveness acceptability curves are shown in Figure 14, and show that at cost-
effectiveness thresholds of £20,000, £30,000 and £50,000 per QALY, azacitidine was cost-
effective versus CCR in 69.9%, 90.8% and 99.6% of iterations respectively. 
Table 42: Results of the company's submitted probabilistic sensitivity analysis 
Arm Total (95% CI) Incremental ICER 
(cost per 
QALY) 





















xxxxxx 0.2751 xxxxxx £17,423 
Key: AZA, azacitidine; CCR, conventional care regimens; CI, confidence interval; ICER, incremental cost-
effectiveness ratio; LYG, life-years gained; QALY, quality-adjusted life year 
Source: Celgene submission, Table 60, p. 149 
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Figure 14: Cost-effectiveness acceptability curves in the company's probabilistic 
sensitivity analysis 
 
Key: AZA, azacitidine; CCR, conventional care regimens; QALY, quality-adjusted life year 
Source: Celgene submission, Figure 33, p. 151 
5.2.9.3 Scenario analyses 
Celgene presented the results of the following scenario analyses (Source: Celgene 
submission, section 5.8.3, p. 154): 
KM curves for RFS, PFS and OS 
OS data unadjusted for treatment-switching 
OS using the censor at switch population 
EQ-5D based on the mapping algorithm from McKenzie et al 
Vial Sharing 
Vial sharing in 30% of cases 
1 year and 5 year time horizons 
Discount rate at 1.5% and 6% 
Individual treatment arms with adjustment for subsequent therapies 
Individual treatment arms without adjustment for subsequent therapies 
 
Celgene also conducted a scenario analysis in which the proportion of patients assigned to 
each CCR arm was estimated from HMRN registry data (IC, xxx; LDAC, xxx; BSC, xxx). A 
weighted average ICER was calculated by multiplying the total costs and QALYs from the 
individual CCR and azacitidine arms (azacitidine results from individual arms not CCR 
population) by these proportions and then summing the resulting totals. 
The results of the scenario analyses are shown in Table 43. 
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Table 43: Results of the company's scenario analyses 




 Costs LYG QALYs 
Base case xxxxxx 0.2779 xxxxxx £20,648 
KM curves for RFS, PFS and OS xxxxxx 0.1485 xxxxxx £32,393 
OS data unadjusted for treatment-switching xxxxxx 0.3630 xxxxxx £11,537 
OS using the censor at switch population xxxxxx 0.8309 xxxxxx £10,397 
EQ-5D based on the mapping algorithm 
from McKenzie et al.
60
 
xxxxxx 0.2779 xxxxxx £22,243 
Vial sharing xxxxxxx 0.2779 xxxxxx -£13,300 
Vial sharing in 30% of cases xxxxxxx 0.2779 xxxxxx -£9,323 
Time Horizon 1 year xxxxxx 0.0791 xxxxxx £30,305 
5 year xxxxxx 0.2673 xxxxxx £20,860 
Discount Rate 1.50% xxxxxx 0.2861 xxxxxx £20,604 
6% xxxxxx 0.2685 xxxxxx £20,704 
Individual treatment arms 
with adjustment for 
subsequent therapies 
IC xxxxxxxx 0.3759 xxxxxx -£52,184 
LDAC xxxxxx 0.2729 xxxxxx £25,136 
BSC xxxxxxxx 0.2095 xxxxxx -£169,672 
Individual treatment arms 
without adjustment for 
subsequent therapies 
IC xxxxxxxx 0.2449 xxxxxx -£85,266 
LDAC xxxxxx 0.2600 xxxxxx £41,671 
BSC xxxxxxxx 0.3386 xxxxxx -£50,300 
Use of individual treatment arm proportions 
from the HMRN registry with adjustment for 
subsequent therapies 
xxxxxxxx 0.2665 xxxxxx -£57,756 
Use of individual treatment arm proportions 
from the HMRN registry without adjustment 
for subsequent therapies 
xxxxxxx 0.2874 xxxxxx -£20,218 
Key: BSC, best supportive care; EQ-5D, EuroQol Five Dimensions; HMRN, Haematological Malignancy 
Research Network; IC, intensive chemotherapy; ICER, incremental cost-effectiveness ratio; KM, Kaplan-
Meier; LDAC, low dose cytarabine; LYG, life years gained; OS, overall survival; PFS, progression-free 
survival; QALY, quality-adjusted life year; RFS, relapse-free survival 
Note: a, Negative ICER indicates that azacitidine is dominant 
Source: Celgene submission, Table 62, p. 156 
5.2.10 Model validation and face validity check 
The manufacturer performed the following model validation and verification. 
Model structure and assumptions were assessed at four levels (Source: Celgene 
submission, Section 5.9.1, p. 159): 
An internal clinical validation was performed by PRMA Consulting’s Senior Medical 
Director, Professor Deborah Saltman. 
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PRMA Consulting’s senior management and expert health economists performed an 
internal validation. 
The validity of the model was confirmed by Professor Stephen Palmer, an external 
technical advisor with extensive experience of NICE HTAs. 
Externally, two UK clinical oncologists validated the model structure and key 
assumptions; one of them also validated HCRU inputs (types of HCRU involved) and 
model outputs on effectiveness.  
The model was also reviewed by the Celgene team. 
 
Technical validity was ensured by performing model checks reported in Table 44. 
Table 44: Checklist used to check the model inputs and results 
Check Purpose 
Set discount rate to 0 To confirm that discounted and non-discounted results are 
equal 
Set main HSUVs to 0 To confirm that QALYs are zero, or can be explained by utility 
decrements associated with adverse events 
Set all HSUVs to 1 To confirm that LYs are equal to QALYs, or that any difference 
can be explained by utility decrements associated with adverse 
events 
Set drug costs to 0 To confirm that drug costs are zero 
Set admin costs to 0 To confirm that administration costs are zero 
Set all non-drug costs to 0 To confirm that non-drug costs are zero 
Manually confirm tornado diagram 
calculations by changing user-
altered cells 
To confirm that that tornado diagram calculations are correct 
Key: HSUV, health state utility value; LY, life-year; QALY, quality-adjusted life-year 
Source: Celgene submission, Table 65, p. 159 
The OS for patients in CCR arm, predicted by the model, has been compared to UK real 
world data from the HMRN registry. Figure 15 provides a comparison for all patients and 
Figure 16 for those patients with poor-risk cytogenetics. Celgene’s submission states 
(Source: Celgene Submission, Section 5.9.3., p.160-161): 
It can be seen that the model predicts slightly better outcomes than have been seen 
for patients treated with CCR in UK clinical practice. When adjustment is made for 
subsequent therapies, the survival curves move closer to that seen in the real world. 
This further emphasises that CCR survival in AZA-AML-001 could have benefited 
from patients switching treatment to receive azacitidine which they currently cannot 
do in clinical practice in the UK. The similar curve shapes suggest the model is 
replicating real life experience plausibly and that the results of AZA-AML-001 can be 
interpreted with a degree of comfort once adjustments have been made for 
subsequent treatments. 
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Figure 15: Comparison of CCR overall survival predictions to Haematological 
Malignancy Research Network data 
 
Key: CCR, conventional care regimens; HMRN, Haematological Malignancy Research Network 
Source: Celgene submission, Figure 35, p. 160 
Figure 16: Comparison of CCR overall survival predictions for patients with poor-risk 
cytogenetics to Haematological Malignancy Research Network data 
 
Key: CCR, conventional care regimens; HMRN, Haematological Malignancy Research Network 
Source: Celgene submission, Figure 36, p. 161 
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5.3 Critique of company’s submitted economic evaluation by the ERG 
5.3.1 Critical appraisal checklists 
Table 45: NICE reference case 





The Scope developed by 
NICE 
Y  
Comparator Therapies routinely used 
in the NHS, including 
technologies regarded as 
current best practice 
U The ERG believe that subsequent 
treatments after initial treatment 
with azacitidine, IC and LDAC 
should have been allowed in the 
model, which assumed that the no 
subsequent AML treatment was 
given and patients were managed 
by BSC instead.    
Perspective on 
outcomes 
All health effects on 
individuals 
Y                                                                                                                          
Perspective on 
costs 
NHS and PSS Y  





Time horizon Lifetime Y At the mean age, 75, of patients at 
the start of the effectiveness study 
and economic model the 10-year 
horizon used in the analysis covers 




Based on a single study U Based on evidence from a single 
trial (AZA-AML-001) since 
systematic review of clinical 
effectiveness found no relevant 
studies. The searches for the 
systematic review were judged to 




QALYs Y  
Source of data for 
measurement of 
HRQL 
Reported directly by 
patients and/or carers 
Y Based on data collected with a 
disease specific questionnaire 




for valuation of 
changes in HRQL 
Representative sample 
of the public 
Y EQ-5D survey mapped from 
disease specific single trial data 
using a published mapping 
algorithm  
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resource use and 
costs 
 Y Unit costs reflect the perspective 
adopted. However, resource use 
was based on experts’ opinion on 
expected quantities of resource 
utilisation by disease state and 
initial treatment; it is unclear why 
those quantities are different across 
initial arms in the progressive 
disease state when all patients are 
assumed to receive best supportive 
care only.  
Discount rate 3.5% p.a. for costs and 
health effects 
Y  
Equity weighting An additional QALY has 
the same weight 
regardless of the other 
characteristics of the 
individuals receiving the 
health benefit 
Y    
Key: BSC, best supportive care; HRQL, health-related quality of life; IC, intensive chemotherapy; LDAC, low-
dose cytarabine; N, no; p.a., per annum; QALY, quality-adjusted life year; U, unclear; Y, yes 
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Has the correct patient 
group/population of interest been 
clearly stated? 
Y  
Is the correct comparator used? N The ERG believes that subsequent therapy after 
azacitidine and CCR (IC and LDAC) is likely to 
be used in the UK, but the model assumed only 
BSC was given after the initial treatments being 
compared. 
Is the study type reasonable? Y  
Is the perspective of the analysis 
clearly stated? 
Y UK NHS PSS 
Is the perspective employed 
appropriate? 
Y NHS Reference Costs 
Is the effectiveness of the 
intervention established? 
Y The trial on which the model is based, AZA-AML-
001 establishes the effectiveness of azacitidine 
relative to CCR in general and the subgroup of 
people eligible only to BSC in particular. 
Has a lifetime horizon been used for 
analysis, if not has a shorter time 
horizon been justified? 
Y The model ran for 10 years. Although this is 
shorter than lifetime given the average patient 
starting age of 75, most people would be 
expected to die by the end of the modelled time 
horizon. 
Are the costs and consequences 
consistent with the perspective 
employed? 
Y All costs are presented from the UK NHS & PSS 
perspective 
Is differential timing considered? Y All future costs and benefits are discounted with 
a 3.5% rate. 
Is incremental analysis performed? Y  
Is sensitivity analysis undertaken 
and presented clearly? 
N Probabilistic sensitivity analyses is reported, 
although it inadequately assesses variations in 
structural uncertainty due to clinical effectiveness 
outcomes not adhering to the maintained 
assumption of the base case relative treatment 
effects (i.e., proportional hazards). 
Key: BSC, best supportive care; CCR, conventional care regimen; HRQL, health-related quality of life; IC, 
intensive chemotherapy; LDAC, low-dose cytarabine; N, no; Y, yes 
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Table 47: Philips checklist66 
Dimension of quality Critical 
appraisal 
Comments 
Structure   
S1 Statement of 
decision 
problem/objective 
Y To evaluate the cost-effectiveness of azacitidine in older 
patients with de-novo or secondary AML with > 30% bone 
marrow blasts who were not eligible for hematopoietic 
stem cell transplantation (HSCT), with intermediate- or 
poor-risk cytogenetics, Eastern Cooperative Oncology 
Group performance status (ECOG PS) scores 0–2, and 
white blood cell count ≤ 15×10
9
/L 
S2 Statement of 
scope/perspective 
Y NHS & PSS perspective was implemented. Cost and 
benefit inputs were consistent with this. Scope of the 
model stated. 
S3 Rationale for 
structure 
U Unclear; see next comment 
S4 Structural 
assumptions 
N Generally, the ERG is not convinced by some of the 
structural assumptions. These are explored in Section 5 of 
this report. The model structure is not consistent with 
routine practice in relation to use of subsequent 
treatments nor with the adjustment for treatment switching 
methodology used to derive the hazard ratios that 
populated the model (i.e., adjustment was only made of 
CCR arm -and only for subsequent azacitidine treatment-; 
subsequent treatment use in the azacitidine arm in AZA-
AML-001 was not adjusted). 
S5 Strategies / 
comparators 
Y Azacitidine was compared with CCR, which itself was a 
composite of different preselected treatments according to 
patient health status and patient and physician preference  
S6 Model type Y A semi-Markov model. The choice of model type is 
adequate. 
S7 Time horizon Y The model ran for 10 years. At the average typical age of 
this patient population, 75 years, by the end of this period 
most patients are expected to have died. 
S8 Disease states / 
pathways 
Y Four disease states were modelled two depending on the 
initial response: Remission (CR/CRi) or Non-remission 
(PR, SD), Post-Progressive disease/relapse and Death. 
S9 Cycle length Y Cycle length is 4 months. Clinical opinion sought by the 
ERG indicated that this cycle length should be appropriate 
to capture the events and outcomes most influential on 




Data   
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Dimension of quality Critical 
appraisal 
Comments 
D1 Data identification U The evidence on relative effectiveness was sourced from 
AZA-AML-001, which is likely to provide the best available 
evidence. However, it is possible that other 
complementary sources of relevant effectiveness 
evidence may have been missed due to poor quality of 
methods used for systematically searching bibliographic 
databases. Searches of costs and cost-effectiveness 
studies were appropriate. 
D2 Pre-model data 
analysis 
U No information given  
D2a Baseline data Y Baseline data used in the model presented similar 
characteristics to those from the source of effectiveness 
data, the AZA-AML-001 study, which includes 3.9% of 
patients with < 30% blasts. 
D2b Treatment effects N The ERG feel that the treatment effects may be biased, 
since a) they are based on overall survival outcomes in 
the azacitidine arm that are unadjusted for treatment 
switching, unlike OS outcomes in the comparator arm, and 
b) the untested and implausible assumption of constant 
proportional hazards. 
D2c Quality of life 
weights (utilities) 
N HRQoL was recorded in AZA-AML-001 using a validated 
disease specific questionnaire (EORTC QLQ30). These 
outcomes were measured every two cycles; clinical 
experts consulted by ERG advised that this is unlikely to 
miss the effects of important acute health events on 
quality of life. EQ-5D utilities were derived from these 
disease specific measures using published mapping 
algorithms. The model grouped together the effect of 
adverse events and may have thus failed to account for 
the effects of repeated adverse events. However, this 
limitation is likely to have limited effect on results.  
D3 Data incorporation N Parameter values in the submission are well referenced. A 
number of errors in cell referencing and formulas were 
found. An error was found in the way parameter values for 
the number of treatment cycles was inputted in the model, 
which resulted in a large underestimation in costs of drug 
administration, monitoring tests, transfusions and the 
company’s drug ICER  
D4 Assessment of 
uncertainty 
N A range of sensitivity analyses was presented, but 
important sources of uncertainty were left unexplored or 
unaccounted for. 
D4a Methodological N The main analysis (based on IPCW approach) of overall 
survival outcomes was not informed by specification tests. 
The analysis of Progression Free Survival was based on 
the Cox proportional hazards assumption, which was 
tested and found to be inconsistent but nevertheless used 
by the company in their base case analysis.  
D4b Structural N Structural uncertainty associated with the untested 
assumption of proportional hazards (PH) in the effect on 
overall survival was not assessed. Neither the effect of 
using non-PH to estimate the effect on relapse free 
survival was investigated. 
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Dimension of quality Critical 
appraisal 
Comments 
D4c Heterogeneity Y Subgroup analysis was undertaken in the model. 
D4d Parameter Y Univariate deterministic and multi-way probabilistic 
sensitivity analyses were performed. 
Consistency   
C1 Internal consistency N Even though Celgene claim to have sought validation for 
the Excel model, the model did not match the number of 
treatment cycles observed in the single trial that was the 
source for the relative effectiveness estimates in the 
model. The model is in any case inconsistent by design 
with the same source, since the former assumed no 
subsequent therapy use in the azacitidine treatment group 
whereas the latter allowed active subsequent treatments 
in the respective arm.   
C2 External consistency U Only expert opinion was sought for external validation. 
Key: BSC, best supportive care; CCR, conventional care regimen; CR, complete remission; CRi, complete 
remission  with incomplete blood count recovery; HRQL, health-related quality of life; IC, intensive 
chemotherapy; IPCW, inverse probability of censoring weights method; LDAC, low-dose cytarabine; N, 
no; PH, proportional hazards; PR, partial remission; PSS, personal social services; SD, stable disease; 
Y, yes 
5.3.2 Model structure 
This four-state model structure has the advantage of being simple and transparent. One 
possible drawback of the model simplicity is that some states are too broadly defined to 
capture important differences in costs and quality of life between the treatments being 
compared. For example, it is questionable whether using the same health state to measure 
costs and health related quality of life for patients who experience relapse or disease 
progression after initial remission and patients with disease progression after initial non-
remission may mask important differences in outcomes between treatments. However, 
clinical experts consulted by the ERG suggested that combining the Post-Progressive 
Disease and the Relapsed states into a single health state in the model had clinical face 
validity. 
The main limitation of the model structure was the assumption that no subsequent active 
treatment was given after the initial azacitidine or CCR treatment. The model assumption 
that only BSC would be given following initial treatment is questionable since, as advised by 
clinical expert opinion, patients treated under azacitidine would be likely to receive LDAC (IC 
as subsequent therapy would not be likely). Similarly, patients under CCR, specifically IC, 
could be eligible to receive and able to benefit from LDAC. 
The absence of all subsequent treatment in the model is also inconsistent with the AZA-
AML-001 trial, from which the clinical effectiveness data used in the model was derived. As 
seen in Table 48, a number of subsequent treatments were used in the trial after azacitidine 
and the CCR treatments.
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Table 48: Subsequent therapies used in AZA-AML-001 by randomly allocated therapy 
Azacitidine treatment group CCR treatment group, Best 
supportive care only 
CCR treatment group, Intensive 
chemotherapy 




Freq. % Subsequent 
treatment 
Freq. % Subsequent 
treatment 





 9 13.43 Azacitidine 4 66.67 Azacitidine 5 27.78 Azacitidine 22 43.14 
Cytarabine 37 55.22 Cytarabine 1 16.67 Cytarabine 9 50.00 Cytarabine 12 23.53 




4 22.22 Hydroxycarbamide 6 11.76 
Hydroxycarbamide 10 14.93       Mercaptopurine 5 9.80 





4 5.96          
Total 67 100.00 Total 6 100.00 Total 18 100.00 Total 51 100.00 
Notes:
 
a, The ERG believes this may be a coding error in the company data; b,
 
Includes one instance each of: ‘Chemotherapeutics’,’Erismodegib’, ‘Gemtuzumab ozogamicin’ 
and ‘investigational drug’; c, Includes one instance each of: ‘Decitabine’, ‘Hydroxycarbamide’, ‘Mercaptopurine’, and ‘Tioguanine’; d, Includes one instance each of: 
‘Clofarabine’, ‘Decitabine’, ‘Etoposide’, Gemtuzumab ozogamicin’, ‘investigational drug’ and ‘Tioguanine’
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5.3.3 Population 
The model considered in the base case a cohort of patients with mean age 75, 59% of whom 
are male, weighing 71 kg and with a Body Surface Area of 1.80 m². In terms of the pre-
selected CCR treatments, the distribution used was that of AZA-AML-001 (BSC, 18%; 
LDAC, 64%; IC, 18%) but results from sensitivity analyses using the alternative distribution 
in the HMRN registry (BSC, xxx; LDAC, xxx; IC, xxx) were also submitted for this 
assessment. The clinical experts consulted by the ERG advised that the distribution of 
patients amongst CCR treatments in these registry data was different to their local practice 
but they thought it plausible that the registry data reflected routine UK practice and they had 
no alternative data. 
A footnote to Table 1 of the study report by Dombret et al. 2015,45 states that “Patients were 
randomly assigned on the basis of local pathology assessment of baseline BM blast count, 
which was subsequently reviewed by the central pathologist; in a small number of cases, 
baseline blast count was <30% upon central review.” In the data provided by Celgene, 
baseline blast count data were grouped in bands, 0 to 5%, 5 to <25%, 25 to <50%, and 50-
100%, and 3.9% (19/488) of the sample had baseline blast count <25%. 
5.3.4 Interventions and comparators 
The specification of evaluated treatments was consistent with randomly allocated treatments 
specified in AZA-AML-001. The number of cycles of treatment and the doses were intended 
to mirror those in the trial. However, the way parameter values for the number of treatment 
cycles were implemented in the model was incorrect, resulting in a mean number of 
treatment cycles in the azacitidine group of 5.6 instead of the intended 8.8, in the CCR group 
IC of 1.86 instead of 2 (initiation and consolidation) and 4.4 when estimating drug acquisition 
costs and 5.3 when calculating the costs of drug administration, tests and transfusion 
instead of 6.10 in the CCR group LDAC. 
In addition, the description of the CCR IC regimen in the economic section of the submission 
(Section 5.2.3, p. 72), states that one-cycle of induction with IC was followed by “two 
consolidation cycles for those who responded to the treatment, followed by BSC. Those who 
do not respond to induction therapy receive BSC”. In effect, the model applied costs for up to 
two consolidation cycles to the group of patients who achieved CR/CRi after induction and 
did not relapse (i.e., were in Remission) and to the group of those who did not achieve 
CR/CRi after induction but whose disease did not progress (i.e. were in non-Remission). 
As discussed before, subsequent therapies were not allowed in the model, despite their use 
in AZA-AML-001. It is possible that the use of subsequent treatments in the trial may have 
resulted in a number of treatment cycles that may not correspond with the number of 
treatment cycles that would be expected in a situation such as that modelled by Celgene, 
where subsequent therapy is unavailable.  
In any case it is questionable that the sequence of treatments studied in the model (i.e., AZA 
followed by BSC and CCR followed by BSC) is realistic and the relative effectiveness 
parameter values used in the model themselves reflect a treatment pathway different to that 
of the model, especially for the azacitidine intervention, whose estimated relative survival 
effectiveness was not adjusted for the effects of subsequent treatments in the RCT data 
source as discussed in Section 5.3.6. 
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5.3.5 Perspective, time horizon and discounting 
The NHS and PSS perspective was used, in line with the NICE reference case. Given the 
mean age of the modelled cohort and the limited life expectancy of its patient population, the 
10-year time horizon is likely to capture practically all important differences in costs and 
health benefits as almost all patients would have died within such period. Discounting was 
also applied to costs and QALYs as in the NICE reference case. 
5.3.6 Treatment effectiveness and extrapolation 
5.3.6.1 Extrapolation of overall, progression-free and relapse-free survival and 
effectiveness estimates of progression-free and relapse-free survival 
The choice of parametric curves for extrapolation of OS, PFS and RFS, was based on a 
comparison of goodness of fit statistics associated with the candidate parametric models. 
However, only models that implied proportional hazards treatment effects were considered 
(i.e., exponential, Weibull and Gompertz). Other parametric models, in particular log-logistic 
and log-normal models, i.e., accelerated failure time models, which allow increasing event 
rates over time at the start of follow-up and decreasing event rates at later times, were not 
considered. 
According to the submission, Celgene’s decision only to consider PH models found support 
in the statistical tests of the assumption for the OS and PFS, but not in the tests results of 
RFS data. The company states that (Source: Celgene submission, Section 5.3.3, p. 112): 
Figure 17 [of the company’s submission] shows the log-log plot for RFS hazards; 
unlike OS and PFS, these indicate that the PH assumption is weak, and a Cox 
regression run with an interaction between treatment group and ln(time) showed a 
statistically significant effect of the interaction (p-value of 0.011); however, the PH 
assumption overall has been retained for consistency. 
 
It is unclear what consistency means in this statement, but it appears the PH assumption 
was imposed in the extrapolation and estimation of treatment effects on relapse because PH 
was not rejected in the analysis of OS and PFS, which is a methodology that is likely to be 
flawed. 
The submission elaborates on the company’s methodological practice stating that “HRs are 
also used still for RFS in the model because the shape of the RFS curves, both overall and 
for treatment groups and subgroups, are not well suited for independent regression models 
(for illustration of this: there is no indication visually that independent regression models 
would better characterise observed RFS for extrapolation)”. It is unclear what this statement 
tries to convey. In any case, Celgene had better options to their chosen biased approach. 
The company could have fitted a separate curve to the RFS data of each trial arm, instead of 
forcing a common parametric shape on those curves. Also more flexible models could have 
been estimated than those supporting the proportional hazard assumption, which although 
convenient was not indispensable in this or any similar analysis. 
The analysis of OS in the submission is also flawed. Although the company reported results 
of a statistical test (for statistically significant interaction of the treatment group variable and 
the logarithm of time) and visual inspection of log-log plots that supported the PH 
assumption, these diagnostic checks were only applied to data that was unadjusted for 
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treatment switching, i.e., had no IPCW weights applied. The company did not perform 
diagnostic tests on the data underlying the IPCW Cox PH estimates that were ultimately 
used for the base case economic analysis. We elaborate on this problem below. 
Unlike OS and RFS, PFS was the only time-to-event outcome where tests for the 
proportional hazard assumption supported the PH assumption. These included statistical 
tests on the interaction of the treatment group indicator and the logarithm of time (p<0.187, 
Source: Celgene submission, Section 5.3.3, p. 114), as well as visual inspection of log-log 
plots. Celgene also documented the goodness of fit statistics in support of their choice of 
parametric curve (i.e., Gompertz). 
The set of statistics used to inform Celgene’s choice of time-to-event curves for the base 
case analysis (Celgene submission, Section 5.3.4, pp. 120–121), are reproduced below in 
Table 49 and Table 50. These are goodness of fit statistics for candidate parametric models 
fitted to each arm for each of the three effectiveness outcomes (OS, PFS and RF). Table 49 
refers to ITT data whereas Table 50 refers to results of analyses that censor-at-switch to 
AML therapy data in both arms. The Weibull provides the best, most parsimonious 
parametric fit to the RFS data (i.e., lowest AIC and BIC statistics). The best fit to the PFS 
data was the exponential for the azacitidine arm and Gompertz for the CCR, although 
differences in goodness of fit between models were smaller than those for RFS or OS data. 
The best parametric fit to the OS data is not that clear for azacitidine, but for the CCR 
Gompertz appears best for ITT and censor-at-switch data. 
Table 49: Goodness of fit for OS, RFS, and PFS parametric functions (ITT data) 
Parametric 
model 
OS RFS PFS 
Azacitidine 
(n = 241) 
CCR 
(n = 247) 
Azacitidine 
(n = 67) 
CCR 
(n = 62) 
Azacitidine 
(n = 112) 
CCR 
(n = 111) 
AIC BIC AIC BIC AIC BIC AIC BIC AIC BIC AIC BIC 
Weibull 752 759 799 806 100 104 133 138 353 359 373 378 
Gompertz 752 759 793 800 108 113 137 141 353 359 372 378 
Exponential 750 754 802 806 149 151 149 151 351 354 374 376 
Key: AIC, Akaike information criterion; BIC, Bayesian information criterion; CCR, conventional care regimens; 
ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival 
Note: Figures in bold indicate best fitting model according to criteria referred to by the column heading 
Source: Celgene submission, Table 35, p. 120 
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OS RFS PFS 
Azacitidine 
(n = 241) 
CCR 
(n = 247) 
Azacitidine 
(n = 67) 
CCR 
(n = 62) 
Azacitidine 
(n = 112) 
CCR 
(n = 111) 
AIC BIC AIC BIC AIC BIC AIC BIC AIC BIC AIC BIC 
Weibull 674 681 694 701 103 108 137 141 344 349 344 349 
Gompertz 674 681 684 691 113 117 141 145 342 348 342 347 
Exponential 676 680 700 704 150 152 150 152 342 345 344 347 
Key: AIC, Akaike information criterion; BIC, Bayesian information criterion; CCR, conventional care regimens; 
OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival 
Note: Figures in bold indicate best fitting model according to criteria referred to by the column heading 
Source: Celgene submission, Table 36, p. 121 
The range of models evaluated by Celgene was too restrictive, as these are all models with 
constant or monotonic hazards that are assumed to be proportional between the two 
treatments. Since, as discussed above and in the submission, RFS failed the proportional 
hazards test, fitting separate Weibull curves, as the company did for its base case analysis 
and ERG verified in the Excel model files, is still likely to bias the extrapolation of RFS 
outcomes. In fact, seeking to fit a rigid statistical model to limited RFS data (n=67 in 
azacitidine and n=62 CCR at randomisation) and PFS (n=112, and n=111, respectively) 
lacks justification because during the observed trial period most people relapse and 
progressed (Figure 17 and Figure 18 respectively). 
Figure 17: Kaplan-Meier estimate of relapse-free survival in AZA-AML-001 
 
Key: AZA, azacitidine; CCR, conventional care regimens 
Source: Celgene submission, Figure 16, p. 113 
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Figure 18: Kaplan-Meier estimate of progression-free survival in AZA-AML-001 
 
Key: AZA, azacitidine 
Source: Celgene submission, Figure 18, p. 115 
The inadequacy of the statistical analysis may be illustrated by comparing the estimated time 
to event curves used by Celgene in their base case analysis, combining PFS with RFS and 
contrasting it with OS. Figure 19 below illustrates the problem for the CCR arm. By cycle 69, 
that is, just after the start of the sixth year after first receiving treatment the estimated curves 
imply that there are more patients in the treated cohort who are either in Remission or non-
remission (stable disease) than there are patients alive. Ironically, Celgene’s consistent 
choice of parametric extrapolation curves that implied PH (possibly including their choice of 
overall survival curve) led them to use survival models that are mutually incompatible. 
It is tempting to disregard the problem depicted in Figure 19 by thinking that the crossing of 
curves occurs only when less than 1% of patients are still alive. However, the crossing itself 
is a sign that the estimated time spent by patients in the different states of the model (and 
the associated base case results) may be severely biased. In fact, it is easy to see why the 
two curves in Figure 19 have incompatible shapes: the OS curve assumes a constant 
hazard (which appears as a straight line in the figure due to log scale metric used for the Y 
axis), whilst the RFS was modelled using a Weibull function with a shape parameter 
estimate of 1.7 (Celgene Excel model sheet ‘CCR parameters’ cell HF42), which implies an 
increasing hazard; the shape of these two curves would be mutually compatible as time 
passes, but not accompanied by the Gompertz function used for PFS since its estimated 
negative parameter of -0.03 (Celgene Excel model ‘CCR parameters’ cell HF30) implies a 
(small) proportion of people never die, which is what ultimately drives the crossing of the 
curves. 
 Page 111 of 145 
 
Figure 19: Survival curves used in Celgene’s base case (Y-axis in logarithmic scale) 
 
Key: OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival 
Source: Produced by the ERG using Celgene’s decision model 
As a consequence the ERG believes that using Kaplan-Meier nonparametric curves as 
observed in the AZA-AML-001 trial provide the best source data with which to populate PFS 
and RFS model parameters, while minimising the structural uncertainty of the cost-
effectiveness results. 
As for OS, it is not clear to the ERG whether the data underlying these assessments of 
parametric curves are censored at switch to some or all subsequent treatment use, and to 
CCR only or both arms. Analyses based on censoring for switching in both arms, possibly 
adjusting for non-random treatment switching may be required to obtain valid estimates of 
survival benefits, and the choice of parametric extrapolation need not restrict to proportional 
hazards functions without statistically testing for such assumption in the data. Therefore, the 
ERG undertook further analyses of individual patient data provided by the company; these 
analyses are presented in the next section, where the justification for extrapolating using 
parametric curves is also considered. 
5.3.6.2 Critique of adjustment of overall survival for subsequent treatments 
This section is focused on the IPCW method used by Celgene to derive its primary estimates 
of relative effectiveness. The other methods explored in the submission either faced 
problems of face-validity (the RPSFTM and IPE methods), were not feasible (the two-stage 
method, which required a second baseline), or appeared only as an appendix (Celgene Post 
hoc statistical methods addendum AZA-AML-001) without details of their application to the 
present assessment or results. 
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As discussed in Section 5.2.5.1 (page 77), the validity of the IPCW method, which originated 
in the literature of causal effects estimation using observational data, is limited by its 
requirement that data for all relevant confounders related to treatment switching and 
mortality are included in the analysis, and tends to perform poorly in small samples or 
applications with rare events. In an RCT context where the method could take advantage of 
high quality prognostic information to adjust for observed confounding in treatment switching, 
the IPCW method is hampered by the small size of available samples of patient data. 
Consequently, IPCW was not used by Celgene to estimate OS effectiveness by CCR 
preselected therapy. 
Indeed, the company stated (Source: Celgene submission, Section 5.3.5, p. 123): 
subgroup adjustment was not feasible because of limited data on switching; however, 
a clinical expert consulted during this analysis stated that questions can be raised 
about the clinical generalizability of the results in subgroups [This refers to 
controlling/adjusting for the three treatment groups within CCR, as well as for 
cytogenetic risk or MDS subgroups, as clarified by Celgene in response to questions 
by ERG], because clinicians can identify potential switching candidates based on 
observed performance, and recommended focusing on the adjusted data for overall 
patients. 
 
Similarly, in response to the request by ERG to clarify the reason for not adjusting event-free 
survival, relapse-free survival and progression-free survival for treatment switching, the 
company answered that “This was due to sample size primarily. The instances in which 
switching preceded the clinical event of interest were few, and the impact of this on the 
results would be very small.” 
Celgene provided the ERG with the individual patient data for replicating the IPCW 
estimation of the Cox proportional hazard ratios used in the company’s base case cost-
effectiveness analysis. ERG was able to replicate those results (Table 51). The ERG was 
unable, however, to replicate the estimation of IPCW weights, which were provided by the 
company but without the dataset used to estimate them. Thus the ERG can only comment 
on the quality of the analyses of OS with the IPCW weights as given, without being able to 
assess whether the statistical model used to estimate these weights is of good quality. This 
is a relevant issue given the relatively small sample available for analysis and the large 
number of groups of patients as defined by the covariates used in the IPCW model, which 
according to the SAS code (Celgene appendices to submission, Appendix 10) and Table 52, 
included four binary and one three-level fixed baseline variables, three binary time-varying 
covariates, and one variable indicating the 76 15-day periods of observation, for a  total of 24 
× 31 × 22 = 192 possible subgroups at each of the 76 follow-up times. It is unlikely that the 
validating condition (see Section 4.3.2, p. 61) of there being a positive probability of not 
being censored at each and every follow-up point and for every combination of values 
observed for the covariates in the IPCW model, might have been met in this sample, and this 
became less likely as time passed in the trial. 
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Table 51: Results of the IPCW models 
Model HR (95% CI) P value
a
 
Unadjusted xxxxxxxxxxxxxxxxxx xxxxx 
Adjusted xxxxxxxxxxxxxxxxx xxxx 
Key: HR, hazard ratio; IPCW, inverse probability of censoring weight 
Notes: a, P value calculated using a log-rank test 
Source: Celgene submission, Table 38, p. 126 
Table 52: List of covariates used for calculating stabilised weights in the IPCW model 


















Key: AML, acute myeloid leukaemia; CR, complete remission; CRi, complete remission with incomplete blood 
count recovery; ECOG, Eastern Cooperative Oncology Group 
Source: Celgene appendices to submission, Appendix 11, Table 14 
The IPCW estimate of OS effect, which was selected for the company’s base case cost-
effectiveness analysis, is based on the assumption of proportional hazards. Celgene 
acknowledge this limitation (Source: Celgene Submission, Section 5.3.5., p. 122): 
A further limitation of the IPCW approach is that it does not produce counterfactual 
survival data directly; in order to use adjusted CCR data in subsequent survival 
analysis and economic modelling, counterfactual data are required. The survivor 
function approach, in which the CCR hazard function is calculated using the 
observed azacitidine hazard function and using the inverse of the IPCW-adjusted 
HR, changed the shape of the CCR survival curve relative to the observed data. On 
the face of it, this is problematic – as well as altering the shape of the CCR survival 
curve, the method forces hazards to be proportional – but it must be acknowledged 
that the purpose of the analyses is to produce counterfactual data, which may result 
in counterfactual hazard functions (i.e., different KM curve shapes) and not just 
counterfactual hazards from curves whose shapes do not change. 
 
It is not clear, however, why Celgene did not test for the proportional hazard assumption 
using the IPCW adjusted data. In their OS analysis, they overlooked the possibility of 
graphically and statistically testing for the constant proportional hazards assumption. They 
seemed to ignore the fact that the survival curve of the CCR arm under the IPCW 
adjustment is observed; in Figure 20, we plot the CCR OS Kaplan-Meier curve for the CCR 
arm after adjustment for IPCW. In contrast, Figure 21 depicts the curve used by Celgene in 
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their base case analysis. The Kaplan-Meier curve for the azacitidine arm is one and the 
same since it was not subject to adjustment for treatment switching by the company. This 
suggests that forcing the proportional hazards assumption on the OS curves is likely to result 
in different estimates of survival benefits from those obtained by fitting separate parametric 
curves, of possibly different shapes, to the OS data from each of the two trial arms. For the 
base case, Celgene used a hazard ratio estimated from a Cox proportional hazards analysis 
adjusted for baseline covariates. The ERG undertook diagnostic tests of the proportional 
hazards assumption on the adjusted Cox PH OS curves by comparing the cumulative log-log 
plot of the azacitidine and CCR arms directly as well as testing for time and treatment effect 
interactions and Schoenfeld residuals (see details in Appendix 2). The results of these tests 
suggest the constant proportional hazards assumption is not supported by the data. 
Figure 20: Overall survival curves in AZA-AML-001 following adjustment of the CCR 
arm for subsequent treatment with azacitidine using the IPCW method 
 
Key: CCR, conventional care regimens; IPCW, inverse probability of censoring weight; ITT, intention-to-treat 
Note: Based on discrete (15-day period) time-to-event data 
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Figure 21: Overall survival from AZA-AML-001 adjusted using hazard ratio from the 
IPCW method 
 
Key: CCR, conventional care regimens; HR, hazard ratio; IPCW, inverse probability of censoring weight 
Source: Celgene submission, Figure 25, p. 127 
Celgene stated that progression and relapse events in the trial occurred before other 
censoring events and few cases of progression and relapse occurred after subsequent 
therapy use in CCR (Source: Celgene responses to NICE questions for clarification). This 
suggests that adjustment of PFS and RFS using the IPCW method would not have been 
practicable due to very small numbers, but the company could have applied simple 
censoring at switch adjustments on curves to verify that indeed subsequent therapy use was 
not important for the results, as the company suggests. 
In any case, these adjustments for treatment switching are inconsistent with the economic 
model for which they were intended. The Celgene model assumes no subsequent therapy 
use was available after either azacitidine or CCR (Celgene submission, Section 5.6.2, p. 
161). In contrast, the clinical effectiveness analyses conducted by Celgene only adjusted for 
subsequent treatment with azacitidine in CCR arm, thus ignoring the use of subsequent 
treatments in the azacitidine arm of AZA-AML-001 (the source of the clinical effectiveness 
data), as well as any active subsequent treatments other than azacitidine used in the CCR 
arm. 
In defence of their methodology, Celgene referred to the methodological recommendations 
in the NICE DSU TSD1651 as indicating that the NICE preferred approach is to adjust 
treatment switching in the comparator (CCR arm) but not the intervention (azacitidine arm). 
As discussed in Section 4.3 (page 59), this is an incorrect interpretation of NICE DSU 
TSD16, which clearly recommends that in situations where, as in the present case, the 
decision problem involves the evaluation of two alternative states of the world where no 
subsequent active treatment is available, then adjustment of outcomes for active treatment 
switching in both trial arms is warranted. Whether the assumption that no subsequent active 
treatment would be available to UK patients in routine practice is plausible may of course be 
questioned, but the point here is that applying IPCW adjustment for subsequent treatment to 
 Page 116 of 145 
 
the outcome data of the CCR but not the azacitidine arm in the AZA-AML-001 trial is 
inconsistent with the economic model which the overall survival IPCW analysis was 
designed to inform. 
To remedy the contradiction between the model structure, on the one hand, and the 
methodology underlying the OS treatment effect estimates, on the other, two options were 
available to the ERG. One was to correct the model to include the costs of subsequent 
treatments used in the AZA-AML-001 and left unadjusted for in the statistical analysis that 
produced the base case OS treatment effect estimates. This option was not feasible 
because the required data on the dates of start and end of subsequent treatments as well as 
treatment dosages and frequencies of administration were not available to ERG. The 
alternative of adjusting the estimates of relative effectiveness for subsequent AML treatment 
use in both arms of AZA-AML-001 was feasible, since the company provided results of such 
analysis using IPCW (Celgene submission, Table 21, p. 70). A limitation of this option was 
that statistical tests to validate these analyses were not reported, and the Kaplan-Meier or 
individual patient data required to perform them were not available to ERG either (not all the 
required data were available in the individual patient data that Celgene provided for ERG 
use). Ideally, testing for the Cox PH assumption would be performed and, if rejected, 
treatment effects estimated using a different model. 
The only option available to ERG was to base the test of the proportional hazards 
assumption on OS data censored-at-switch, which had similar Kaplan-Meier plots as the OS 
IPCW weighted data in the CCR arm, and resulted in small differences in hazard ratio 
estimates (Celgene appendices to submission, Appendix 11). The data provided by Celgene 
did not allow ERG to extend the IPCW analysis to adjust for subsequent AML therapy to 
both treatment groups. However, the company provided the data to perform censor-at-switch 
analysis for any subsequent AML therapy use in both trial arms, as well as testing for the 
proportional hazards assumption in the data. Fitting a range of parametric curves including 
proportional (exponential, Weibull, Gompertz, Bathtub) and non-proportional hazard 
parametric models (log-normal and log-logistic) to OS data from each trial arm separately 
resulted in the following goodness of fit statistics and test statistics for nested models (i.e., 
whether the simple exponential model could be supported by the results of more complex 
proportional hazards models). 
 Page 117 of 145 
 
Table 53: Goodness of fit and test statistics for OS parametric functions (patients 
censored at switch for any subsequent therapy in both arms) 
Parametric 
model 
Unadjusted for baseline covariates Adjusted for baseline covariates
a
 
Azacitidine (n=241) CCR (n=247) Azacitidine (n=241) CCR (n=247) 
AIC BIC p
b
 AIC BIC p
b
 AIC BIC p
b
 AIC BIC p
b
 
Weibull 676 687 0.050 696 707 0.008 638 708 0.858 642 713 0.708 
Gompertz 676 687 0.057 686 697 <0.001 638 708 0.810 641 711 0.202 
Exponential 678 685  702 709  636 702  641 707  
Bathtub 678 689  706 716  640   645   
Log-logistic 676 686  684 694  637 707  643 714  
Log-normal 678 688  678 689  641 711  644 714  
Key: AIC, Akaike information criterion; AML, acute myeloid leukaemia; CCR, conventional care regimens; 
ECOG, Eastern Cooperative Oncology Group; OS, overall survival 
Notes: a, Covariates included in adjustment: age, sex, ECOG, cytogenetic risk, % blast group, CCR therapy 
preselect group, comorbidities, AML days, platelet transfusion status, geographical region; b, p-value 
from Z-test on shape coefficient (versus null hypothesis of exponential distribution); Figures in bold 
indicate best fitting model according to criteria referred to by the column heading 
According to AIC, there is no difference in performance between unadjusted models of 
azacitidine, since all lie within a 2-unit difference of one another.67 For unadjusted analyses 
of CCR, the models consistent with PH are not supported by the data, except for the 
Gompertz, because they perform worse than the model with the minimum AIC, the log 
normal, by more than 10 units.67 BIC rewards parsimonious models relative to AIC, since the 
former penalises the inclusion of each additional covariate in the model by 5.5 points 
whereas the latter does it by 2. Thus, the exponential, which uses one fewer parameter than 
the other models, moves up the BIC performance ranking to be the best unadjusted model fit 
to azacitidine OS data, but still ‘strongly’ underperforms the unadjusted model that best fits 
the CCR data, the log-normal model, since it has more than 10 additional points.68 The best 
performing unadjusted model for the CCR arm that is consistent with the PH assumption is 
the Gompertz, but its 8 additional points over the log normal model may be considered 
‘strong’ evidence against it and in favour of the log-normal model.68 Although the accelerated 
failure time models (the log normal and log-logistic) perform better than other models they 
imply implausible predictions as detailed in Appendix 2. In contrast, an exponential 
unadjusted model fitted separately to each arm produces life expectancy estimates of 17.09 
versus 12.36 months for azacitidine and CCR, respectively. 
As for models that adjusted for baseline covariates, the exponential is the optimal model for 
both azacitidine and CCR arms, although all other models except the log-normal show 
comparable AIC and BIC performance. The adjusted exponential model fitted to both arms 
results in a HR of 0.64 and has a predicted difference in OS of 3.64 months, in favour of 
azacitidine; details are presented in the Appendix 2. Figure 22 presents the ITT Kaplan-
Meier data and the fitted adjusted exponential OS model to data censored at switch to 
subsequent AML therapy in both trial arms. 
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Figure 22: Overall survival in AZA-AML-001 – ITT Kaplan-Meier data and adjusted 
exponential model fitted to censor-at-switch (any AML therapy) data 
 
Key: AML, acute myeloid leukaemia; Aza, azacitidine; CCR, conventional care regimens; ECOG, Eastern 
Cooperative Oncology Group; ITT, intention-to-treat; K-M, Kaplan-Meier 
Note: Adjusting covariates: age, sex, ECOG, cytogenetic risk, CCR therapy preselect group, comorbidities, 
AML days, platelet transfusion status, geographical region were effects-coded so that baseline is an 
estimated overall mean in the sample; % blast group <25% adjusted using 1 vs. 0 indicator (see 
Appendix 2) 
Source: ERG analysis using censored-at-switch to subsequent AML therapy (in both trial arms) individual patient 
AZA-AML-001 data provided by Celgene 
Although the frequency of subsequent therapy use was similar in both groups, overall 
(azacitidine 28% versus CCR 30%), and by subgroups (see Table 54, Source: Celgene’s 
response to questions for clarification), patients who used subsequent treatments did so 
earlier in CCR than azacitidine (273 versus 322 days post-randomisation; Source: ERG 
extraction from individual patient data provided by Celgene). The xxxxx difference between 
unadjusted censor-at switch (HR 0.72, Source: ERG analysis using individual patient data 
provided by Celgene) and unadjusted IPCW (HR xxxx, Celgene submission, p. 70, Table 21) 
for subsequent AML treatment in both arms, suggests the censor-at-switch estimate is 
biased in favour of azacitidine, and thus may be considered a conservative choice of 
estimates given the effect on results of other changes adopted by the preferred ERG base 
case analysis. Figure 22 depicts the adjusted fitted exponential survival curves alongside the 
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Table 54: Number of patients who switched treatments in AZA-AML-001 
Patient subgroup Number of patients who did not 
receive subsequent AML therapy 
Number of patients who 
received subsequent AML 
therapy 
All patients xxxxxxxxx xxxxxxx 
xxxxxxxxx xxxxxxx 
Comparator: IC xxxxxxxxxx xxxxxxx 
xxxxxxx xxxxxx 
Comparator: LDAC xxxxxxxx xxxxxxx 
xxxxxxxxxx xxxxxxxx 


















Key: AML, acute myeloid leukaemia; AZA, azacitidine; BSC, best supportive care; CCR, conventional care 
regimen; IC, intensive chemotherapy; LDAC, low-dose cytarabine; MDS, myelodysplastic syndrome 
The ERG believe that baseline covariate-adjusted censor-at-switch methods coupled with 
parametric curves fitted to each arm offer a practical, transparent alternative to IPCW with 
similar performance in this application. While the censor-at-switch assumption that 
subsequent treatment occurs at random is likely biased, in the current case the alternative of 
adjusting for non-random treatment switching with the IPCW was not feasible due to the the 
ERG lacking the data required to assess or replicate the model used to estimate the IPCW 
weights. In any case, given the relative magnitudes of costs and QALYs presented in 
Section 6 (page 130), the degree of uncertainty in effectiveness parameters is unlikely to 
matter for the economic results. 
As a conservative approach, the ERG’s preferred base case analysis adopted the 
exponential OS HR estimates adjusted for baseline covariates used by the IPCW method, 
including sex, age, ECOG status, preselected CCR treatment, time since initial AML 
diagnosis, comorbidity score, in data censored at switch to any subsequent AML treatment 
from both trial arms in the dataset provided by Celgene to ERG. The resulting HR estimate, 
0.64, is more favourable to azacitidine than the respective estimates from applying IPCW to 
subsequent azacitidine use in CCR only, xxxx and xxxx (Celgene’s base case), IPCW to any 
AML in both arms arms, 0.77 and 0.71, and the ITT value of 0.85.45 
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It must be noted that the adjusted censored at switch analysis performed by the ERG in 
obtaining its preferred estimate of OS effectiveness was not extended to subgroup analyses, 
since the small sample is likely to lead to bias due to overfitting when adjusting for baseline 
covariates. The subgroup analyses were thus based on the original censor-at switch 
exponential OS curves estimates used by the company in their model. 
5.3.7 Health-related quality of life 
A number of problems were found with the assessment of health related quality of life in the 
economic analysis. However, based on univariate sensitivity analyses presented by Celgene 
and conducted by ERG, the bias originating from this element of the model has an 
insignificant influence on the ICER. 
In line with RCT studies in this field, health related quality of life was measured at the start of 
every other cycle in AZA-AML-001 using a disease specific HRQoL measure, the EORTC 
QLQ-C30. Since EQ-5D outcomes were not measured in the trial, peer-reviewed mapping 
algorithms were identified and used by Celgene in accordance with NICE methodological 
guidance.41 
Three potential limitations of this analysis were identified by ERG. One related to the 
possibility that because HRQoL was measured every 56 days in AZA-AML-001, the effects 
of some important acute adverse clinical events, especially treatment-related ones, may 
have been missed by the data collection. Advice sought from clinical experts suggests that 
no obvious important events would have been expected to be missed by the quality of life 
study supporting the Celgene submission. 
Another potential issue was missing data. Celgene reported that longitudinal statistical 
analysis using mixed methods were employed to assess HRQoL (Celgene Submission, 
Section 4.7.5.8, p. 77), and in response to clarification questions by ERG, the company 
stated that: 
A mixed effect model repeat measurement (MMRM) model was developed for the 
EORTC QLQ-C30 Fatigue domain with the inclusion of a fixed-effect covariate 
indicating whether a transfusion had taken place up to 5 days before health related 
quality of life (HRQL) assessment. This analysis was undertaken because blood 
transfusions are likely to affect fatigue, but this relationship would not have been 
explored by previous analyses.   
Additional MMRM models were developed for the secondary HRQL domains 
(Dyspnoea, Physical Functioning and Global Health Status/ quality of life (QoL)) that 
included RBC or platelet transfusion up to 5 days before the HRQL assessment as a 
factor. 
The statement ‘A mixed model analysis failed to reveal any statistically significant 
differences in the impact of treatment on all domains between treatment arms’ 
references the  post-hoc MMRM analysis controlling for the impact of red blood cell 
(RBC) or platelet transfusion received up to 5 days before HRQoL assessment.  It 
was hypothesized by the clinical study team that transfusions administered shortly 
before HRQoL assessment may have an effect on fatigue, and this effect would not 
have been captured in the initial model.  The results of the MMRM analysis for the 
Fatigue domain without this additional covariate were significant in favour of CCR.  
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No significant differences were observed for the secondary domains.  Full 
presentation of both results can be located in the CSR section 11.4.1.2.10.7.   
All MMRM analyses were based on the assumption that data are missing at random.  
A post-hoc sensitivity analysis utilizing a pattern-mixture model was conducted to 
explore the impact of the missing-at-random assumption.  Results of this analysis 
aligned with the MMRM results for Physical Functioning, Dyspnoea and Global 
Health Status/QoL, with no differences between treatment groups at p<0.05, while 
results favoured CCR for the Fatigue domain (P=0.025). 
 
The ERG is satisfied that the statistical analyses of HRQoL conducted by Celgene were 
thorough and conducted following best methodological practice. As is typical with patient 
reported outcome studies conducted alongside RCT in this clinical area, missing data is a 
problem due to the high drop-out rates and item non-response, and analytical methods 
employed by Celgene have tried to address it. However, the results of this analysis were 
crudely applied in the cost-effectiveness model, as explained next. 
The third limitation was the way the effect of adverse events was implemented in the model, 
which treated disutility effects of adverse events differently from their cost impacts. The ERG 
asked the company to explain why the adverse events which are costed on page 130 of the 
company’s submission appear to differ from the adverse events for which disutilities are 
measured (page 129 of the company’s submission). The company replied:  
HRQL analysis from the trial was more restricted in terms of measuring and mapping 
from EORTC QLQ-C30 scores during an AE in the trial; costing on the other hand 
used rates of AEs, disaggregated by type, from the main clinical study report, and 
hence were more detailed. 
Thus, in the model, AE disutilities are a single figure that are aggregated at the trial-
analysis level; AE costs on the other hand are aggregated within the model itself, 
calculated from rates and unit costs for AEs. 
 
The QALY impact of AEs was modelled as the probability of at least one TEAE of Grade > 3 
per 100 person-years multiplied by the utility of grade > 3 TEAEs. In the model, the effect of 
AEs on QALYs in azacitidine have been modelled for a maximum of 8.8 treatment cycles, 
which is effectively less than the mean 8.8 in the trial, while for CCR as a whole they were 
counted for a maximum number of cycles of 5.1 which is more than the mean number of 2 
cycles with IC. These calculations are likely to overestimate the additional costs of CCR 
relative to azacitidine but this bias had a small effect on the results given other issues 
identified by the ERG in the model. 
These features of the model are likely to lead to bias in estimating the costs and QALYs 
differences between the azacitidine and CCR treatment groups, as they conflated different 
types of adverse events and inaccurately measured repeated or continued episodes of AEs. 
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5.3.8 Resources and costs 
5.3.8.1 Drug costs 
The ERG identified some errors in the calculation of drug costs. The most important error 
was that the model incorrectly applied the mean number of cycles reported in the trial.45 In 
order to obtain the mean 8.8 number of azacitidine cycles, a maximum number of 19 cycles 
needs to be set given the distribution of the modelled cohort between the Remission and 
Non-remission states (the proportion of cohort members in the relapse/PD state and Death 
states do not consume azacitidine medication). Instead Celgene applied a maximum of 8.8 
(rounded down to the closest integer, 8) number of treatment cycles effectively accounting 
for a mean number of azacitidine cycles in the model less than 6 as opposed to the intended 
8.8. Likewise the correct maximum number of cycles for LDAC in CCR is 10 cycles (the 1.6 
cycles used for IC in CCR modelled by Celgene is practically correct). In correcting the 
probabilistic sensitivity analysis ERG chose SE 3 for azacitidine, 1 LDAC and (0.06 for IC as 
used by Celgene’s base case is correct), to calibrate the respective model outputs to the 
reported figures for mean minus one standard error in the number of cycles reported by 
Dombret et al. 2015.45 As documented below, correcting this error of implementation to 
calibrate the model outputs with the summary statistic reported by the trial increases the 
ICER from a level around £20,000 to £84,000 per QALY gained. 
A mistake was also found in the calculation of dosing. Celgene incorrectly estimated daily 
dose of cytarabine (‘HRU_costs’!C115:C117) assuming mg/m² instead of using mg/day as in 
the CSR. However, this error does not affect acquisition costs, since the inflated dose is still 
less than the size of a vial, but has a small effect on ICERs for the ‘no wastage’ analyses. 
More importantly, the costs of drug acquisition and administration, monitoring tests, and 
transfusions in CCR were based on a formula with reference to the azacitidine number of 
cycles (8.8) instead of the number of cycles of CCR treatments (2 cycles, 1 initiation and 1 
consolidation cycle in IC, and 6.1 in LDAC). 
The ERG also corrected an error in how the model calculated the costs of drug 
administration, monitoring tests and transfusions in the first (induction/pre-response) cycle 
for both azacitidine (Model AZA sheet AB23:AD23 and Model CCR sheet AB23:AD23). In 
the first cycle, the model accounts for costs of two cycles for these costs, unlike for drug 
acquisition costs (AA23 in Model CCR and Model AZA sheets), which only accounts for the 
initial cycle. This has the effect of loading the costs of two cycles of treatment to all patients, 
since the survival curves in the model assume all are alive and under treatment while 
awaiting the initial evaluation of response. For IC this implies one induction cycle and one 
consolidating cycle thus overestimating the mean number of consolidation cycles reported in 
the trial of 1.45 
5.3.8.2 Health resource utilisation and unit costs 
The quantities of resource use for medical staff costs, drug monitoring tests and outpatient 
procedures (including transfusions), and inpatient hospitalisations by health state and initial 
treatment (azacitidine, IC, LDAC or BSC) were derived from expert opinion. Apart from drug 
monitoring testing and outpatient procedures during Remission and Non-remission phases 
(i.e., while the initial treatments are being administered or when treatment has recently been 
withdrawn or concluded), it is not clear the rationale for having different resource use 
quantities within the same health state for the different treatments being compared. Models 
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of health state transitions that use generic health states, where health status entirely 
determines  health related quality of life and costs and where treatment is irrelevant (apart 
from explicit treatment-related events), are more transparent and arguably robust to bias. In 
terms of resource use none of the health states are generic, and only adverse events-related 
costs are independent of initial treatment. 
Without a clear clinical rationale, asking expert opinion about costs in the 
Relapse/progressive disease phase contingent on initial treatment, despite the model 
assumption that all patients in this phase are managed under BSC only, is susceptible to 
framing bias in surveyed responses. This issue is apparent in the health resource use 
questionnaire used by Celgene and presented in its submission Appendix 12. Furthermore, 
in this model, variation of costs in Relapse/progressive disease across initial treatments are 
not accompanied by a corresponding variation in utilities, which implies resources are being 
used without noticeable effects on quality of life. 
Most notably in the differences in resource use quantities is the amount of inpatient days per 
4-week cycle of 1.73 in azacitidine versus 2.61 in CCR (Celgene Submission, Table 46, p. 
134). At the Intensive Care per inpatient day cost used by Celgene of £714, inpatient costs 
differences between groups accumulate at a rate of £628 per month per patient in 
Relapse/PD. The CCR per cycle inpatient days figure breakdown by treatment is, as 
presented in the Excel model file, 1.66, 0.95 and 0.00, for IC, LDAC and BSC (sheet ‘Default 
values’ cells I283, M283, Q283). While heterogeneity by pre-selected CCR therapy is to be 
expected it is unclear why the weighted average across subgroups should differ between 
azacitidine and CCR in Relapse/PD managed with BSC.    
The ERG believes that costs in the Relapse/PD phase should be equal across treatment 
arms and pre-selected therapy arms, which significantly increases the ICER for azacitidine 
versus CCR. Appendix 3 presents the costs per cycle in PD/Relapse under BSC, which were 
applied to the PD/Relapse state across all arms and therapies within CCR to reflect the 
assumption that all patients are in the same health state and managed equally. 
Another limitation was that the costs of managing AEs in patients from azacitidine and CCR 
groups were estimated as the product of the probability of at least one TEAE of Grade > 3 
per 100 person-years and the average cost of managing grade 3 or 4 TEAEs observed in 
the AZA-AML-001 trial. The average cost was calculated as arithmetic average of the 
treatment costs of anaemia, neutropenia, febrile neutropenia, thrombocytopenia, pneumonia 
and worsening AML. Furthermore, it was assumed that the most frequent TEAEs of grade 3 
or 4 and their incidence rates in azacitidine and CCR groups are the same. 
In the executable model, the costs of managing AEs in azacitidine and CCR patients have 
only been accounted as a one-off initial cost, which is at odds with the way the associated 
quality of life effects were implemented in the model (see Section 5.3.7). 
5.3.9 Cost-effectiveness results 
The deterministic base case ICER presented by Celgene is £20,648 per QALY. Comparison 
of Tables 56 on QALYs and 57 on Costs results in the submission, (Celgene Submission, 
Tables 56 and 57, p. 146-147), reproduced below, points to RFS and Relapse/PD as the 
phases in the model where the largest outcome differences between treatment groups 
appear. While in the RFS phase azacitidine is associated with a xxx increase in utilities over 
CCR that is accompanied by a xxxx increment in costs. As for the Relapse/PD phase these 
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figures are xxx and xxx. Consistent with our critique in Section 5.3.6.1 these results may be 
biased as they are derived from extrapolations of RFS data based on parametric functions 
that invalidly imply proportional hazards, and which determine the length of Relapse/PD 
phase given that OS duration was determined separately from PFS and RFS duration. 
Further, as discussed in the previous section and in Sections 5.3.8.1 and 5.3.8.2, the 
estimation of costs in RFS is incorrect due to invalid account for the number of treatment 
cycles and counting two cycles instead of one in the first model cycle. 
Table 55: Summary of QALYs by health state in company base case 








RFS xxxxx 0.231 xxxxx xxxxx xxx 
PFS xxxxx 0.273 xxxxx xxxxx xxx 
PD xxxxx 0.133 xxxxx xxxxx xxx 
Total xxxxx 0.637 xxxxx xxxxx xxxx 
Key: QALY, quality-adjusted life-year, CCR; conventional chemotherapy regimens, RFS; relapse free 
survival, PFS; progression free survival PD, progressive disease 
Source: Celgene Submission, Table 56, p.146 
Table 56: Summary of costs by health state in company base case 








RFS xxxxxxx £6,503 xxxxxx xxxxxx xxxx 
PFS xxxxxxx £22,235 xxxxxxx xxxxxxx xxxx 
PD xxxxxx £6,260 xxxxxx xxxxxx xxx 
Terminal care xxxxxx £5,609 xxxx xxxx xxx 
Total  xxxxxxx £40,608 xxxxxx xxxxxx xxxx 
Key: CCR; conventional chemotherapy regimens, RFS; relapse free survival, PFS; progression free survival 
PD, progressive disease 
Source: Celgene Submission, Table 57, p.147 
In addition, the PD costs assume healthcare resource utilisation associated with BSC, 
whereas, as discussed in Section 5.3.6.2, estimates of relative overall survival effectiveness 
and thus duration of the PD phase were estimated on AML-AZA-001 study data that were 
affected by the use of subsequent AML active therapy, to a larger extent in the azacitidine 
than the CCR arm. 
5.3.10 Sensitivity analyses 
When sampling uncertainty in the parameter values used in the base case were accounted 
for, the probabilistic sensitivity analysis resulted in an ICER of £17,423 per QALY, which is 
lower than the base case deterministic ICER of £20,648 per QALY. Taken at face value 
these different results between the deterministic and PSA results would suggests that there 
are important nonlinearities in the model that make PSA results more adequate estimates of 
cost-effectiveness than the deterministic values. However, the ERG found a number of 
problems as discussed before in this critique, which invalidate both the deterministic and 
PSA results. The ERG has corrected some errors in the implementation of the model and 
estimates of some parameter values populating it, as presented below in Table 57. 
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Despite the limitations identified in the model from which Celgene derived their base case 
cost-effectiveness results, its analysis of the most influential individual parameter values 
provides guidance as to which elements may need special consideration in assessing the 
validity of results. As described in Section 5.2.9.1 (page 92), ICER results are most sensitive 
to variation in the costs of drug administration in CCR, followed by the hazard ratio of OS, 
with acquisition costs of AZA, administration costs of AZA and the HR of RFS being the 
fourth, fifth and sixth most influential parameters. In these parameters ERG found flaws 
either in model implementation or parameter estimation, as discussed above. To illustrate 
the importance of this, Celgene reports that a 20% increase in the value of these parameters 
is associated with an increase of their base case results of 155%, 44%, 113%, 98% and 
78% (Celgene submission, Table 61, p. 153). 
Of particular interest is the subgroup analysis of patients who would be candidates for LDAC 
under the control situation. In this group Celgene’s scenario analysis is reported to result in 
an ICER of £25,136 per QALY with IPCW adjustment for treatment switching in the control 
arm. However, some 28% of the azacitidine arm subjects received subsequent active 
treatment but their health outcomes and costs were not adjusted for the effect of subsequent 
lines of treatment. This caveat is also relevant for the comparison of patients pre-selected for 
BSC and for IC controls, where according to results presented by Celgene, azacitidine 
generates more QALYs and has lower costs relative to BSC and IC. However, as explained 
next, the results of this subgroup analyses did not collectively pass a fundamental validation 
test. 
Celgene provides the results of a scenario where the distribution of patients by pre-selected 
CCR treatment is that observed in clinical practice from HMRN registry data (xxx IC, xxx 
LDAC, xxx BSC) instead of the original trial case mix (18%, 64% and 18%, respectively). 
The ICERs change from £20,648 to -£57,756 per QALY, i.e., to the result that azacitidine is 
both more effective and less costly than CCR. Although an improvement in cost-
effectiveness of azacitidine is to be expected when applying a distribution of the patient 
population with a larger proportion of patients in poorer health condition and thus eligible to 
receive BSC under CCR, as in AZA-AML-001 the largest detectable difference was found 
precisely in those patients, these are unexpectedly large results. ERG replicated these 
results to a small degree of discrepancy (-£57,968 versus -£57,656 per QALY), using the 
weighted average method described by Celgene in its submission (Celgene submission, 
Section 5.8.3, p. 155). However when ERG tried to replicate the base case results using the 
same method we obtained and ICER of -£17,960 per QALY (azacitidine dominant), quite a 
different result from the base case model result of £20,648 per QALY. This suggests that the 
method used by Celgene to calculate an alternative ICER based on HMRN data may not be 
compared with that used in the base case. It must be noted that this discrepancy is despite 
both the subgroup analysis by CCR pre-selected treatment and the analysis of the overall 
sample using the same OS effectiveness estimates, i.e., the exponential extrapolation using 
the adjusted IPCW HR estimate of xxxx. 
The inability to replicate the base case results using the weighted average method described 
in the Celgene submission poses a severe limitation to ERG’s ability to correct the most 
important flaws of the model submitted by Celgene. This is because the error incurred by the 
company in implementing the number of treatment cycles described in Section 5.3.8.1 (page 
122) may only be corrected, within their model, by separately calculating costs and QALYs 
for each CCR pre-selected treatment subgroup and combining results using weighted 
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averages of costs and of QALYs using the patient distributions in AZA-AML-001, in the same 
way as the company did for their sensitivity analysis of the HMRN patient population. Our 
corrected results presented in Section 6 (page 130) are subject to this caveat. 
5.3.11 Model validation and face validity check 
5.3.11.1 Internal validity 
We conducted two assessments of internal validity of the model submitted by Celgene. First, 
we compared the mean number of treatment cycles produced by the model in the azacitidine 
arm with the reported mean number of cycles in AZA-AML-001.45 As discussed in Section 
5.3.8.1 we found that the model underestimated the mean number of treatment cycles, and 
this was due to an error of implementation in that the maximum number of treatment cycles 
allowed by the model was 8 (after rounding 8.8 to the lowest integer), thus overlooking the 
fact that a proportion of the modelled cohort would have made a transition to Relapse/PD 
and therefore be receiving no treatment within those first 8 cycles. Similar but more severe 
underestimation problems applied to the active treatments in the CCR arm. 
The second validity check compared the overall survival outputs from the model with the 
respective outcome in the original trial report, for the azacitidine arm. In this case the model 
overestimated the observed data; the median overall survival was approximately 11.5 in the 
model base case (exponential distribution) versus 10.4 months in the Kaplan-Meier OS 
curve in AZA-AML-001 (Figure 1A of Dombret et al. 201545). Incidentally, the model output 
was closer to the median OS obtained by censoring data at switch to subsequent AML 
therapy, i.e., 12.1 months (Figure 1B of Dombret et al. 201545). 
5.3.11.2 Model implementation checks 
We conducted a list of model checks, including black-box tests (varying inputs and checking 
for the anticipated impact on outputs) and checking individual formulae in the model. We 
highlight below problems identified by this and a subsequent process that sought to replicate 
model results in the submission. 
In calculating the costs of drug administration, monitoring tests and transfusions 
corresponding to stable disease (“Model CCR” and “Model AZA” columns AB:AD), the 
company subtracted a portion of these costs equal either to the differences between the 
proportion of patients in the modelled cohort who were in Non-remission and the proportion 
of patients who were in remission at each cycle, or to zero, whichever of the two quantities 
was higher. This was found to have no rational basis and was not explained nor described in 
the submission. 
The model was also subject to verification tests, where individual parameters’ values in the 
model were varied and results compared to a priori expectations. Further, the ERG identified 
an error in the formulae referencing the Kaplan-Meier curves for PFS and RFS in the “KM” 
worksheet (DD:DI columns). This is correction was important in the light of ERG’s preference 
for using Kaplan-Meier time to event curves to model the evolution in these outcomes, as 
described in the next section. 
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5.4 Exploratory and sensitivity analyses undertaken by the ERG 
5.4.1 Corrected base case 
The ERG identified a number of implementation errors in the model submitted by Celgene 
and corrected them, as shown in Table 57. 
Table 57: Corrections to the implementation of Celgene's model 
Celgene’s model ERG’s corrections 
The costs of drug administration, tests and transfusions in LDAC patients 
were estimated for 8 model cycles, as for azacitidine, instead of 6.1 
cycles reported in the submission (AB, AC and AD in ‘Model CCR’). 
Corrected to incorporate 
changes in the mean 
number of treatment 
cycles for LDAC patients 
Transfusion costs pre-response in CCR arm were modelled using  the 
corresponding costs for azacitidine group (‘Model CCR’!AD23) 
Corrected 
Transfusion costs in cycles 2+ in CCR arm were modelled incorrectly: the 
cost of transfusion in remission state was assumed to be equal to the 
transfusion costs in patients with stable disease (‘Model 
CCR’!AD24:153). 
Corrected 
Cytarabine daily dose for LDAC assumed mg/m² (resulting in 71.82 
mg/day) instead of 39.9 mg/day reported in CSR. However, it has no 
effect on costs in the base case and has a minimal effect on ICER in 
scenario analyses for no wastage and wastage with 30% tolerance (‘HRU 
costs’!C115:117). 
39.9 mg/day of 
cytarabine in LDAC 
patients 
Kaplan-Meier OS, PFS and RFS curves for the overall sample were 
incorrectly referenced to the IC curves in the KM worksheet (DD:DI 
columns) 
Corrected 
Costs of tests and transfusions in PD state were not modelled by 
Celgene 
Corrected 
Celgene assume the drug administration costs for IC patients after cycle 
3 
Corrected 
“BSC only” patients are assumed to incur drug administration costs Corrected 
Wastage with 30% tolerance was coded incorrectly Corrected 
The number of treatment cycles for which drug administration, monitoring 
tests and transfusions costs were accounted was two in the first 
treatment cycle (AB23, AC23 and AD23 in Model AZA and Model CCR), 
in contrast to drug acquisition costs for which only one cycle was 
accounted in the first cycle (AA23 in Model AZA and Model CCR sheets). 
Corrected 
Key: CCR, conventional care regimen; CSR, clinical study report; ERG, Evidence Review Group; ICER, 
incremental cost-effectiveness ratio; LDAC, low-dose cytarabine; OS, overall survival; PFS, progression-
free survival; RFS, relapse-free survival 
5.4.2 ERG preferred base case 
The corrections to the implementation were followed by a series of changes made to the 
model parameter values to reflect what ERG considers the best values to reflect current UK 
practice and model logic. The results of these changes are presented as a sequence of 
cumulative changes in Section 6. 
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5.4.2.1 Calibrating the number of treatment cycles 
The maximum number of treatment cycles of azacitidine treatment was set to 19, in order to 
match the 8.80 mean number of cycles in the respective arm of AZA-AML-001.45 Similarly 
the maximum number of treatment cycles of LDAC was set to 10 to match the respective 
mean reported in the trial of 6.1 cycles of treatment. The IC was set to a maximum of two 
cycles as specified in the trial protocol and reported in the submission. 
5.4.2.2 Equalising costs of relapse and progressive disease across treatments 
The frequency and amount of use of medical staff, monitoring and outpatient procedures and 
hospitalisations used by patients managed under BSC in the progressive disease/relapse 
state as estimated from clinical opinion surveyed by Celgene was applied to IC and LDAC 
preselected CCR patients and azacitidine patients that were in the progressive disease or 
relapse health state. Appendix 3 details the costs used in PD/Relapse by ERG for its 
preferred base case analysis. 
5.4.2.3 Adjusting overall survival in both arms for subsequent active treatment 
The ERG set the OS curves to the Censor At Switch analysis mode in Celgene’s model, 
keeping the exponential functional form adopted in Celgene’s base-case. This choice was 
associated with a hazard ratio of 0.72, which corresponded to the analysis that was 
unadjusted for baseline covariates. Given the high ICERs that were obtained after the 
preceding revisions in Sections 5.4.2.1 and 5.4.2.2, the effect of adopting the smaller hazard 
that resulted from censored at switch analysis that adjusted for baseline covariates was 
investigated in exploratory analyses. 
5.4.2.4 Fitting separate parametric survival curves to relapse-free survival and 
progression-free survival in each arm 
Since finding the optimal fitting functional form for RFS and PFS is highly uncertain as 
discussed in this report, the ERG adopted the observed non-parametric Kaplan-Meier curves 
from the trial for these outcomes. The rationale for this choice is further strengthened by the 
fact that the Kaplan-Meier curves are almost completely observed by the end of the 
observation period at 37 months and extrapolation is not necessary. Neither is it obvious that 
adjusting those survival curves for any observed confounders is practicable or indeed 
desirable. 
5.4.2.5 Adjusting overall survival for baseline covariates 
The effect of using the OS hazard ratio estimate of 0.64 from the exponential model adjusted 
for baseline covariates, which found support in statistical tests conducted by the ERG, was 
investigated. 
5.4.3 Exploratory analyses 
The ERG sought to perform some exploratory assessment of the subgroup analysis by 
preselected CCR treatment, while acknowledging that for PFS and RFS outcomes, the 
sample sizes make subgroup-specific time to event data highly unreliable. Thus in these 
analyses subgroup specific differences in OS outcomes were allowed using censor-at-switch 
data, while keeping common PFS and RFS curves across the three subgroups. 
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5.5 Conclusions of the cost-effectiveness section 
The ERG identified several issues with the company’s submitted economic evaluation. 
The model assumed that no patients would receive active treatment following 
discontinuation of first-line treatment. In the AZA-AML-001 trial underpinning the analysis, 
29% of participants received active second-line treatment. Advice from clinical experts 
suggests that active second-line treatment is considered for some patients in the NHS. 
The model assumed proportional hazards for all time-to-event outcomes, even though this 
was not supported for overall survival and relapse-free survival by results from the AZA-
AML-001 trial. 
Overall survival in the AZA arm was not adjusted for subsequent active treatment, resulting 
in an inconsistency between the modelled health outcomes and costs, since only the costs 
of best supportive care were modelled following azacitidine. 
Implementation issues were identified in the model. The most significant of these was an 
error in the calculation of the duration of first-line treatment which resulted in an 
underestimate of the drug acquisition and administration costs in both arms. 
The ERG also identified that there were significant differences in the cost associated with the 
Relapse/progressive disease state between the AZA and CCR arm, even though all patients 
(in both arms) are expected to be receiving BSC at this point. 
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6 Impact on the ICER of additional clinical and economic 
analyses undertaken by the ERG 
The ERG’s preferred base case ICER is £169,606 per QALY (see Table 58 and Table 59). 
Corrections to implementation errors in the model increased the ICER from the base case 
£20,648 to £62,518 per QALY (analysis A). 
Analyses B to G are the additional changes made to reach the ERG’s preferred base case. 
Of these, two independently lead to significant increases in the ICER: calibrating the number 
of treatment cycles to match the mean number of cycles in AZA-AML-00145 increases the 
ICER to £131,698 per QALY; setting the costs of relapse/progressive disease equal across 
the arms increases the ICER to £159,352 per QALY. Two independently lead to reductions 
in the ICER: adjusting overall survival for treatment switching in both arms reduces the ICER 
to £47,482 per QALY; adjusting overall survival for baseline covariates reduces the ICER to 
£39,145 per QALY. Using Kaplan-Meier relapse-free survival has little impact on the ICER 
(£63,569 per QALY). Using Kaplan-Meier progression-free survival increases the ICER to 
£75,471 per QALY. 
 Page 131 of 145 
 
Table 58: Corrected base case and elements of ERG preferred base case 
Analysis Outcome Azacitidine CCR Difference 
Celgene base 
case 
Costs xxxxxxx £40,608 xxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £20,648 




Costs xxxxxxx £45,954 xxxxxxx 
QALYs xxxxx 0.637 xxxxxx 
ICER (cost per 
QALY gained) 
  £62,518 






Costs xxxxxxx £50,064 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £131,698 
A + C = A and 







Costs xxxxxxx £68,688 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £159,352 








Costs xxxxxxx £52,225 xxxxxxx 
QALYs xxxxx 0.728 xxxxx 
ICER (cost per 
QALY gained) 
  £47,482 
A + E = A and 
Kaplan-Meier 
RFS curves for 
each trial arm  
e
 
Costs xxxxxxx £46,221 xxxxxxx 
QALYs xxxxx 0.636 xxxxx 
ICER (cost per 
QALY gained) 
  £63,569 
A + F = A and 
Kaplan-Meier 
PFS curves for 
each trial arm  
e
 
Costs xxxxxxx £45,753 xxxxxxx 
QALYs xxxxx 0.635 xxxxx 
ICER (cost per 
QALY gained) 
  £75,471 








Costs xxxxxxx £36,028 xxxxxx 
QALYs xxxxx 0.391 xxxxx 
ICER (cost per 
QALY gained) 
  £39,145 
Key: CCR, conventional care regimen; ERG, Evidence Review Group; ICER, incremental cost-effectiveness 
ratio; PD, progressive disease; PFS, progression-free survival; QALY, quality-adjusted life year; RFS, 
relapse-free survival 
Notes: a, See Table 57; b, See Section 5.4.2.1; c, See Section 5.4.2.2; d, See Section 5.4.2.3; e, See Section 
5.4.2.4; f, See Section 5.4.2.5 
 Page 132 of 145 
 
Table 59: Derivation of the ERG's preferred base case 
Analysis 
a
 Outcome Azacitidine CCR Difference 
Celgene base 
case 
Costs xxxxxxx £40,608 xxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £20,648 
A = Corrected 
base case 
Costs xxxxxxx £45,954 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £62,518 
A + B Costs xxxxxxx £50,064 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £131,698 
A + B + C Costs xxxxxxxx £72,798 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £238,674 
A + B + C + D Costs xxxxxxxx £91,847 xxxxxxx 
QALYs xxxxx 0.728 xxxxx 
ICER (cost per 
QALY gained) 
  £171,511 
A + B + C + D + E Costs xxxxxxxx £92,676 xxxxxxx 
QALYs xxxxx 0.727 xxxxx 
ICER (cost per 
QALY gained) 
  £174,205 
A + B + C + D + E 
+ F 
Costs xxxxxxxx £98,046 xxxxxxx 
QALYs xxxxx 0.724 xxxxx 
ICER (cost per 
QALY gained) 
  £246,488 
A + B + C + D + E 
+ F + G = ERG 
preferred base 
case 
Costs xxxxxxx £41,161 xxxxxxx 
QALYs xxxxx 0.390 xxxxx 
ICER (cost per 
QALY gained) 
  £169,606 
Key: CCR, conventional care regimens; ERG, Evidence Review Group; ICER, incremental cost-effectiveness 
ratio; QALY, quality-adjusted life year 
Note: a, See Table 58 
6.1 Exploratory analyses 
Exploratory subgroup analyses by preselected CCR treatment using the changes A–F 
described in Table 58 by the ERG produce ICERs above £100,000 per QALY for all 
subgroups (Table 60). An adjustment for baseline covariates, which is not reliable due to the 
small sample sizes available within each group, would be expected to reduce these figures 
but they would remain around the £100,000 per QALY value. 
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Analysis PFS and 
RFS 






to CCR arm for 
switching to 
azacitidine 
IC xxxxxxxx xxxxxx -£52,184 
LDAC xxxxxx xxxxxx £25,136 





ITT IC xxxxxxxx xxxxxx -£85,266 
LDAC xxxxxx xxxxxx £41,671 






switch for any 
active AML 
treatment 
IC xxxxxxx xxxxxx £210,767 
LDAC xxxxxxx xxxxxx £276,260 





ITT IC xxxxxxx xxxxxxx £122,722 
LDAC xxxxxxx xxxxxx £408,492 
BSC xxxxxxx xxxxxx £80,952 
Key: AML, acute myeloid leukaemia; BSC, best supportive care; CCR, conventional care regimens; ERG, 
Evidence Review Group; IC, intensive chemotherapy; ICER, incremental cost-effectiveness ratio; IPCW, 
inverse probability of censoring weight; ITT, intention-to-treat; LDAC, low-dose cytarabine; OS, overall 
survival; PFS, progression-free survival; PH, proportional hazards; QALY, quality-adjusted life year; 
RFS, relapse-free survival 
Notes: a, Includes corrections and changes as described in Table 59 except for component ‘G’ (i.e., not 
including adjustment for baseline covariates); b, Negative ICERs indicate azacitidine is dominant 
6.2 Univariate sensitivity analyses 
The univariate sensitivity analysis with the base case preferred by ERG is presented in the 
tornado analysis of Figure 23; plausible variation of parameter values results in ICERs above 
£130,000 per QALY. 
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Figure 23: Tornado diagram of ERG’s preferred base case deterministic analysis 
 
Key: AZA, azacitidine; CCR, conventional care regimens; CR, complete remission; CRi, complete remission 
with incomplete blood count recovery; ERG, Evidence Review Group; HR, hazard ratio; ICER, 
incremental cost-effectiveness ratio; OS, overall survival; PD, progressive disease; PFS, progression-
free survival; PR, partial response; RFS, relapse-free survival; SD, stable disease; TEAE, treatment 
emergent adverse event 
6.3 Probabilistic sensitivity analysis 
A probabilistic sensitivity analysis was conducted for the ERG’s preferred base case (Table 
61). An ICER of £182,151 per QALY was obtained, which is similar to the deterministic ICER 
of £169,606 per QALY. Figure 24 presents the cost-effectiveness acceptability curves from 
the probabilistic sensitivity analysis in the ERG’s preferred base case. At a willingness to pay 
threshold of £100,000 the probability of azacitidine being cost-effective is less than 40%. 




Admin costs  (AZA)
Utility: Remission (CR/CRi)
Remission (CR, CRi) (AZA)
Utility: Non-remission (PR, SD)




Disutility, any grade > 3 TEAEs
Test costs (AZA)
Test costs (CCR)
Acquisition cost (CCR cycle 1)
Acquisition cost (CCR cycle 4 - progression)
Acquisition cost (CCR cycle 2+)
Terminal care costs
AE cost of grade 3 or 4 TEAEs
HR PFS
HR RFS
ICER from lower variation ICER from upper variation
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Table 61: Cost-effectiveness results for ERG’s preferred base case probabilistic 
sensitivity analysis 
Arm Total Incremental ICER (cost 
per QALY) 
Costs LYG QALYs Costs LYG QALYs 
CCR £41,063 0.5478 0.3911 — — — — 
Azacitidine xxxxxxx 0.8186 xxxxxx xxxxxxx 0.2708 xxxxxx £182,151 
Key: CCR; conventional care regimens; ERG, Evidence Review Group; ICER, incremental cost-effectiveness 
ratio; LYG, life years gained; QALYs, quality-adjusted life years  
Figure 24: Cost-effectiveness acceptability curves from ERG’s preferred base case 
probabilistic sensitivity analysis 
 
Key: AZA, azacitidine; CCR, conventional care regimens; ERG, Evidence Review Group; QALY, quality-



























Willingness to pay (£) per QALY
AZA CCR
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7 End of life 
The NICE Guide to the methods of technology appraisal41 indicates that while in the 
reference case all QALYs are regarded as being of equal weight, the Appraisal Committee 
can consider QALY weighting in the case of life-extending treatment at the end of life. 
Celgene included an assessment of three criteria (all of which should be met for end of life 
consideration), and this is reproduced accompanied by ERG comments in Table 62. 
Table 62: Assessment of end-of-life criteria 
Criterion Data available (Celgene) ERG comment 
The treatment is 
indicated for patients 
with a short life 
expectancy, normally 
less than 24 months 
Median OS reported in the 
literature ranges between 1.5 
months (aged >65 years) and 
2 months (aged >55 years)
18, 19
  
Median OS in AZA-AML-001 trial is 6.5 
months without azacitidine treatment. 
Restricted mean survival at 30 months is 
estimated to be 10.55 months (Appendix 
4). 
 
Azacitidine is also indicated for 
intermediate-2 and high-risk 
myelodysplastic syndromes, CMML with 
10–29% marrow blasts without 
myeloproliferative disorder and AML with 
20–30% blasts and multi-lineage 
dysplasia. The results of the AZA-001 
trial in this population suggest median 




There is sufficient 
evidence to indicate that 
the treatment offers an 
extension to life, 
normally of at least an 
additional 3 months, 
compared with current 
NHS treatment 
Median OS based on the 
primary endpoint was 10.4 
months in the azacitidine 
group and 6.5 months in the 
CCR group, providing an OS 
benefit of 3.8 months with 
azacitidine. As reported in 
Section 4.7 [of Celgene’s 
submission], various pre-
defined analyses 
demonstrated that treatment 
with azacitidine provided a 
statistically significant survival 
benefit versus CCR 
Extension to life should be assessed 
considering differences in mean overall 
survival in addition to median OS. ERG 
analyses based on restricted mean 
survival at 30 months suggest an 
extension to life of 1.8–2.5 months 
(depending on how treatment switching 
is handled – see Appendix 4). 
 
The estimated improvement in restricted 
mean OS is greatest for patients pre-
selected to BSC, although comparisons 
to individual CCR are subject to 
uncertainty. 
The treatment is 
licensed or otherwise 
indicated for small 
patient populations 
The estimated total population 
for all licensed indications in 
England is 3,354, consisting of 
1,026 covered by the proposed 
new indication and 2,328 for all 
existing indications. See 
additional detail provided [in 
Celgene submission, Section 
4.13.2, pp. 97–98] 
No comment. 
Key: AML, acute myeloid leukaemia; BSC, best supportive care; CCR, conventional care regimen; CMML, 
chronic myelomonocytic leukaemia; ERG, Evidence Review Group; OS, overall survival; NHS, National 
Health Service. 
Source: Celgene submission, Table 28, p.97 
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The NICE guide also indicates that the Committee will need to be satisfied that the estimates 
of the extension to life are robust, and that the assumptions used in the reference case 
economic modelling are plausible, objective and robust. 
The ERG considers that the estimates of extension to life are not robust. The company’s 
estimate based on median overall survival difference is not robust as it is does not reflect the 
convergence of survival curves seen in AZA-AML-001. Overall survival benefit was also the 
primary endpoint of AZA-AML-001 and this did not reach statistical significance. Estimates of 
overall survival are affected by adjustments for baseline imbalances and for subsequent 
active treatment. 
The ERG conducted additional analyses of the restricted mean overall survival at 30 months 
(see Appendix 4) and found that the survival gain was less than three months on average for 
azacitidine versus CCR. 
The ERG also considers that the assumptions used in the company’s economic modelling 
were not plausible or robust. In Section 6 (page 130) the ERG show the results of correcting 
these assumptions and implementation errors. The ERG’s preferred base case ICER is 
considered to be more plausible, objective and robust. 
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8 Overall conclusions 
The ERG believes that by limiting the comparators in the decision problem to a combined 
CCR comparator, there is the possibility of azacitidine being recommended or not 
recommended inappropriately for certain patients (according to the most appropriate CCR 
for them). Although it is claimed that these patients cannot be reliably and objectively 
identified, they are at least sufficiently identifiable for CCR regimens to be assigned both in 
routine clinical practice and in the pivotal RCT. In the absence of high-quality clinical 
effectiveness data on the clinical value of azacitidine versus individual conventional care 
regimens, clinical decision making may be made more challenging if azacitidine is 
recommended for all elderly AML patients with >30% blasts. 
Of the key changes made to the economic model by the ERG in arriving at their preferred 
base case (ICER £169,606 per QALY), the following might be considered to be differences 
of opinion between the company and the ERG: 
 Adjustment of overall survival in the azacitidine and CCR arms for subsequent active 
treatment – the company only adjusted survival in the CCR arm (for subsequent 
treatment with azacitidine), while the ERG has adjusted survival in both arms for any 
active treatment for AML; 
 Equalising costs per month spent in the Relapse/progressive disease state – the 
company assumed significant incremental costs in the CCR arm despite all patients 
in the model receiving best supportive care only in this state; their assumption is 
based on a questionnaire-based survey of clinicians, but expert opinion solicited by 
the ERG does not support this assumption; 
 Replacing parametric survival models for relapse-free and progression-free survival 
with Kaplan-Meier curves to avoid imposing a proportional hazards assumption – the 
company used a proportional hazards assumption “for consistency” although they 
acknowledged it was in contradiction of the data. 
The ERG considers that the changes made to the modelled treatment duration cannot be 
considered matters of opinion and are corrections to implementation errors. After correcting 
solely for these implementation issues, an ICER of £131,698 per QALY was obtained. 
The base case analysis preferred by the ERG has the limitation that the sum of the cohort 
proportions in PFS and RFS exceeds the proportion alive by the third cycle in the model. 
Celgene included an adjustment in the model to eliminate such anomalies, but nevertheless 
this remains a deficiency of the model structure. The ERG has not attempted to correct this, 
due to the difficulties of fitting plausible parametric models to the PFS and RFS data (as 
discussed in this critique) and adjusting for baseline covariates, given the small samples 
available for analysis. 
8.1 Implications for research 
8.1.1 Clinical effectiveness 
Further research is needed to establish the effectiveness of azacitidine in elderly AML 
patients with >30% blasts. This research should be powered to detect clinically meaningful 
improvements in survival between azacitidine and individual conventional care regimens. 
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The statistical analyses planned for the research should account for the likelihood of non-
proportional hazards and for treatment switching, with adequate data collection to support 
multiple plausible statistical models. 
8.1.2 Health-related quality of life (HRQoL) 
This research should also collect HRQoL data measured using a generic (as opposed to 
condition-specific) and validated instrument, which allow outcomes to be valued using 
preferences from the general public (preferably EQ-5D) and is preferred for economic 
analyses. Significant efforts should be made to collect HRQoL data across all patients and 
across all time points to reflect the full range of quality of life experienced by patients. 
8.1.3 Healthcare resource use 
Further research (likely separate from the research above) is required to accurately estimate 
healthcare resource use in elderly AML patients with >30% blasts within the NHS. For 
conventional care regimens this should be based on routine clinical practice. For azacitidine, 
this may involve a pilot study, or, if azacitidine receives a positive recommendation from 
NICE, prospective collection of healthcare resource use data, and collection of data relating 
to the most clinically appropriate alternative treatment for each patient. 
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Azacitidine for treating acute myeloid 
leukaemia with more than 30% bone marrow 
blasts 
Addendum 
This addendum updates and replaces Section 6 “Impact on the ICER of additional clinical 
and economic analyses undertaken by the ERG”. 
An error was identified in the ERG’s estimate of the baseline overall survival curve adjusted 
for baseline covariates. This has been corrected and the effect on the results has been 
reflected in the new Section 6. The ERG has also made certain clarifications within the 
section and has conducted additional exploratory analyses. 
6 Impact on the ICER of additional clinical and economic 
analyses undertaken by the ERG 
The ERG’s preferred base case ICER is £273,308 per QALY (see Table 58 and Table 59). 
Corrections to implementation errors in the model increased the ICER from the base case 
£20,648 to £62,518 per QALY (analysis A). 
Analyses B to G are the additional changes made to reach the ERG’s preferred base case. 
Of these, two independently lead to significant increases in the ICER: calibrating the number 
of treatment cycles to match the mean number of cycles in AZA-AML-00145 increases the 
ICER to £131,698 per QALY (analysis B); setting the costs of relapse/progressive disease 
equal across the arms increases the ICER to £159,352 per QALY (analysis C). 
The primary focus of analysis D is to change the way overall survival is modelled by 
censoring for treatment switching in both arms. As a side effect (due to the model wiring) this 
also results in changes to the modelling of relapse-free and progression-free survival, again 
to censor for treatment switching in both arms. The effect of this analysis is to reduce the 
ICER to £47,482 per QALY. 
Analysis E replaces the parametric proportional hazards progression-free survival curves 
with Kaplan-Meier curves and increases the ICER to £75,471 per QALY. 
Using Kaplan-Meier curves for relapse-free survival (analysis F) has little impact on the 
ICER (£63,569 per QALY). 
Adjusting overall survival for treatment switching (censoring at switch in both arms) and 
baseline covariates (analysis G) increases the ICER to £65,188 per QALY. The reason the 
ICER for analysis G is higher than the ICER for analysis D is that analysis G does not have 
the side effects on relapse-free and progression-free survival and so azacitidine patients 
spend longer in the progressive disease model state with high costs and low utility. 
Table 58: Corrected base case and elements of ERG preferred base case 
Analysis Outcome Azacitidine CCR Difference 
Celgene base 
case 
Costs xxxxxx £40,608 xxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £20,648 




Costs xxxxxxx £45,954 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £62,518 






Costs xxxxxxx £50,064 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £131,698 
A + C = A and 







Costs xxxxxxx £68,688 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £159,352 








Costs xxxxxxx £52,225 xxxxxxx 
QALYs xxxxx 0.728 xxxxx 
ICER (cost per 
QALY gained) 
  £47,482 
A + E = A and 
Kaplan-Meier 
RFS curves for 
each trial arm  
e
 
Costs xxxxxxx £46,221 xxxxxxx 
QALYs xxxxx 0.636 xxxxx 
ICER (cost per 
QALY gained) 
  £63,569 
A + F = A and 
Kaplan-Meier 
PFS curves for 
each trial arm  
e
 
Costs xxxxxxx £45,753 xxxxxxx 
QALYs xxxxx 0.635 xxxxx 
ICER (cost per 
QALY gained) 
  £75,471 








Costs xxxxxxx £44,818 xxxxxxx 
QALYs xxxxx 0.622 xxxxx 
ICER (cost per 
QALY gained) 
  £65,188 
Key: CCR, conventional care regimen; ERG, Evidence Review Group; ICER, incremental cost-effectiveness 
ratio; PD, progressive disease; PFS, progression-free survival; QALY, quality-adjusted life year; RFS, 
relapse-free survival 
Notes: a, See Table 57; b, See Section 5.4.2.1; c, See Section 5.4.2.2; d, See Section 5.4.2.3, also note that 
PFS and RFS are adjusted as a side effect; e, See Section 5.4.2.4; f, See Section 5.4.2.5 
Table 59: Derivation of the ERG's preferred base case 
Analysis 
a
 Outcome Azacitidine CCR Difference 
Celgene base 
case 
Costs xxxxxxx £40,608 xxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £20,648 
A = Corrected 
base case 
Costs xxxxxxx £45,954 xxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £62,518 
A + B Costs xxxxxxx £50,064 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £131,698 
A + B + C Costs xxxxxxxx £72,798 xxxxxxx 
QALYs xxxxx 0.637 xxxxx 
ICER (cost per 
QALY gained) 
  £238,674 
A + B + C + D Costs xxxxxxxx £91,847 xxxxxxx 
QALYs xxxxx 0.728 xxxxx 
ICER (cost per 
QALY gained) 
  £171,511 
A + B + C + D + E Costs xxxxxxxx £92,676 xxxxxxx 
QALYs xxxxx 0.727 xxxxx 
ICER (cost per 
QALY gained) 
  £174,205 
A + B + C + D + E 
+ F 
Costs xxxxxxxx £98,046 xxxxxxx 
QALYs xxxxx 0.724 xxxxx 
ICER (cost per 
QALY gained) 
  £246,488 
A + B + C + D + E 
+ F + G = ERG 
preferred base 
case 
Costs xxxxxxxx £71,138 xxxxxxx 
QALYs xxxxx 0.621 xxxxx 
ICER (cost per 
QALY gained) 
  £273,308 
Key: CCR, conventional care regimens; ERG, Evidence Review Group; ICER, incremental cost-effectiveness 
ratio; QALY, quality-adjusted life year 
Note: a, See Table 58 
6.1 Exploratory analyses 
The ERG explored the extreme case that no healthcare costs are incurred in the 
Relapse/PD state, which resulted in an ICER of £73,953 per QALY. 
In another scenario, in which no inpatient hospitalisations occur in the Relapse/PD state, the 
resulting ICER was £105,611 per QALY. This scenario may be relevant if 100% of inpatient 
days in the Relapse/PD phase are incurred due to terminal care; it seems plausible to ERG 
that the cost estimate of terminal care of £5,705 in the Celgene model could already account 
for most hospital costs in PD, and therefore assuming zero inpatient costs may be a 
plausible scenario. 
The base case analysis preferred by ERG included costs of monitoring tests and 
transfusions for the whole duration of the Remission and Non-remission phases of the model 
(as well as for the Relapse/PD phase). This was viewed as a correction of Celgene’s 
analysis, which only measured these costs up to the time the patient stopped treatment. The 
ERG explored the effects of adopting Celgene’s assumption: the ICER changed from 
£273,308 to £260,190 per QALY. Celgene’s assumption is unlikely to be correct with respect 
to transfusions as acknowledged by Celgene’s own definition of BSC (Source: Celgene 
submission, Section 4.3.5, p. 49, and Section 5.2.3, p. 108): 
BSC: Including but is not limited to red cell or whole blood transfusions, fresh frozen 
plasma transfusions, platelet transfusions, antibiotic and/or antifungal therapy, and 
nutritional support). This is continued until death. 
 
Other scenarios included revising the costs of monitoring tests and transfusions during 
Relapse/PD to values estimated by a clinical expert consulted by ERG, whereby two units 
each of red blood cell transfusions and adult doses of platelet transfusions are given on 
average per 4 week cycle, whilst no bone marrow aspirates or biopsies nor extractions for 
cytogenetic testing, four blood tests, and two each of peripheral blood smears and serum 
blood chemistry are given during PD. The resulting ICER was £257,211 per QALY. 
Exploratory subgroup analyses by preselected CCR treatment using the changes A–F 
described in Table 58 by the ERG produce ICERs above £100,000 per QALY for all 
subgroups (Table 60). Exploratory subgroup analyses were also conducted by preselected 
CCR treatment using changes A, B and D–F (i.e., leaving in place Celgene’s assumptions 
regarding costs in Relapse/PD), with the result that for patients preselected to intensive 
chemotherapy an ICER of £73,728 per QALY was obtained, while for other patients the 
ICER remained over £100,000 per QALY. An adjustment for baseline covariates, which is 
not reliable due to the small sample sizes available within each group, would be expected to 
increase the ICERs overall. 










Analysis PFS and 
RFS 









to CCR arm for 
switching to 
azacitidine 
IC xxxxxxxx xxxxxx -£52,184 
Gompertz 
and Weibull 
LDAC xxxxxx xxxxxx £25,136 
Exponential 
and Weibull 










Exponential IC xxxxxxxx xxxxxx -£85,266 
Gompertz LDAC xxxxxx xxxxxx £41,671 







switch for any 
active AML 
treatment 
IC xxxxxxxx xxxxxx £352,918 
LDAC xxxxxxx xxxxxx £282,589 







switch for any 
active AML 
treatment 
IC xxxxxxx xxxxxx £73,728 
LDAC xxxxxxx xxxxxx £131,349 







IC xxxxxxx xxxxxx £414,304 
LDAC xxxxxxx xxxxxx £500,493 
BSC xxxxxxx xxxxxx £137,449 
Key: AML, acute myeloid leukaemia; BSC, best supportive care; CCR, conventional care regimens; ERG, 
Evidence Review Group; IC, intensive chemotherapy; ICER, incremental cost-effectiveness ratio; IPCW, 
inverse probability of censoring weight; ITT, intention-to-treat; LDAC, low-dose cytarabine; OS, overall 
survival; PFS, progression-free survival; PH, proportional hazards; QALY, quality-adjusted life year; 
RFS, relapse-free survival 
Notes: a, Negative ICERs indicate azacitidine is dominant; b, Includes corrections and changes as described in 
Table 59 except for component ‘G’ (i.e., not including adjustment for baseline covariates); c, Not 
including component ‘C’ (i.e., retaining Celgene’s estimates for costs in Relapse/PD) 
To assess the validity of these analyses, the ERG derived an ICER for the whole population 
using a weighted average of the incremental costs and QALYs across the three CCR 
therapy preselected subgroups. The resulting ICER was £269,714 per QALY, compared to 
an ICER of £246,488 per QALY using changes A–F for the whole population (Table 59). This 
is a discrepancy of less than 10%. 
6.2 Univariate sensitivity analyses 
The univariate sensitivity analysis with the base case preferred by ERG is presented in the 
tornado analysis of Figure 23; plausible variation of parameter values results in ICERs above 
£200,000 per QALY. 
Figure 23: Tornado diagram of ERG’s preferred base case deterministic analysis 
 
Key: AZA, azacitidine; CCR, conventional care regimens; CR, complete remission; CRi, complete remission 
with incomplete blood count recovery; ERG, Evidence Review Group; HR, hazard ratio; ICER, 
incremental cost-effectiveness ratio; OS, overall survival; PD, progressive disease; PFS, progression-
free survival; PR, partial response; RFS, relapse-free survival; SD, stable disease; TEAE, treatment 
emergent adverse event 
6.3 Probabilistic sensitivity analysis 
A probabilistic sensitivity analysis was conducted for the ERG’s preferred base case (Table 
61). An ICER of £277,123 per QALY was obtained, which is similar to the deterministic ICER 
of £273,308 per QALY. Figure 24 presents the cost-effectiveness acceptability curves from 
the probabilistic sensitivity analysis in the ERG’s preferred base case. At a willingness to pay 
threshold of £100,000 the probability of azacitidine being cost-effective is less than 5%. 
Table 61: Cost-effectiveness results for ERG’s preferred base case probabilistic 
sensitivity analysis 
Arm Total Incremental ICER (cost 
per QALY) 
Costs LYG QALYs Costs LYG QALYs 
CCR £73,152 0.8863 0.6218 — — — — 
Azacitidine xxxxxxxx 1.3302 xxxxxx xxxxxxx 0.4439 xxxxxxx £277,123 
Key: CCR; conventional care regimens; ERG, Evidence Review Group; ICER, incremental cost-effectiveness 
ratio; LYG, life years gained; QALYs, quality-adjusted life years  
Figure 24: Cost-effectiveness acceptability curves from ERG’s preferred base case 
probabilistic sensitivity analysis 
 
Key: AZA, azacitidine; CCR, conventional care regimens; ERG, Evidence Review Group; QALY, quality-




Azacitidine for treating acute myeloid 





Original text Corrected text 
Section 1.7, p.17 The ERG preferred base case ICER is 
£169,606 compared to the company’s 
base case ICER of £20,648 per QALY.  
The ERG preferred base case ICER is 
£273,308 compared to the company’s 
base case ICER of £20,648 per QALY. 
Section 1.7, p. 17 Adjusting overall survival for baseline 
covariates (reduces ICER from 
£246,488 to £169,606 per QALY). 
Adjusting overall survival for baseline 
covariates (reduces ICER from 
£246,488 to £273,308 per QALY). 
Section 5.3.1, p. 
99 
EQ-5D survey mapped from disease 
specific single trial data using a 
published mapping algorithm. 
EQ-5D survey mapped from disease 
specific single trial data using a 
published mapping algorithm; a second 
published algorithm was used for 
sensitivity analysis. 
Section 5.3.1, p. 
102 
Cycle length is 4 months. Cycle length is 4 weeks. 
Section 5.3.1, p. 
103 
An error was found in the way 
parameter values for the number of 
treatment cycles was inputted in the 
model, which resulted in a large 
underestimation in costs of drug 
acquisition, monitoring tests, 
transfusions and the company’s drug 
ICER 
An error was found in the way 
parameter values for the number of 
treatment cycles was inputted in the 
model, which resulted in a large 
underestimation in costs of drug 
acquisition and administration, 
monitoring tests, transfusions and the 
company’s drug ICER. 
Section 5.3.4, p. 
106 
However, the way parameter values for 
the number of treatment cycles were 
implemented in the model was 
incorrect, resulting in a mean number 
of treatment cycles in the azacitidine 
group of 5.6 instead of the intended 
8.8, in the CCR group IC of 1.86 
instead of 2 (initiation and 
consolidation) and 4.4 when estimating 
drug acquisition costs and 5.3 when 
calculating the costs of drug 
administration, tests and transfusion 
instead of 6.10 in the CCR group 
LDAC. 
However, the way parameter values for 
the number of treatment cycles were 
implemented in the model was 
incorrect, resulting in a mean number 
of treatment cycles in the azacitidine 
group of 5.6 instead of the intended 
8.8, in the CCR group IC of 2.61 
instead of 2 (initiation and 
consolidation), 4.4 when estimating 
drug acquisition costs and 5.3 when 
calculating the costs of drug 
administration, tests and transfusion 




The ERG undertook diagnostic tests of 
the proportional hazards assumption 
on the adjusted Cox PH OS curves by 
comparing the cumulative log-log plot 
of the azacitidine and CCR arms 
directly as well as testing for time and 
treatment effect interactions and 
Schoenfeld residuals (see details in 
Appendix 2). The results of these tests 
suggest the constant proportional 
hazards assumption is not supported 
by the data. 
 
The ERG undertook diagnostic tests of 
the proportional hazards assumption 
on the adjusted Cox PH OS curves by 
comparing the cumulative log-log plot 
of the azacitidine and CCR arms 
directly by Schoenfeld residual test; the 
proportional hazard assumption is not 
rejected at the 5% level, p=0.068, but 
graphical inspection suggest the test 
may not be robust and cast doubt on 
the appropriateness of the assumption 
in these data (see details in Appendix 
2). 
Section 5.3.6.2, 
p.117, Table 53 
Bathtub Adjusted for baseline 
covariates, Azacitidine, AIC 640, BIC 
Bathtub Adjusted for baseline 
covariates, Azacitidine, AIC 648, BIC 
718 
Section 5.3.6.2, 
p.117, Table 53 
Bathtub Adjusted for baseline 
covariates, CCR, AIC 645, BIC 
Bathtub Adjusted for baseline 
covariates, CCR, AIC 646, BIC 716 
Section 5.3.6.2, 
p.117, Table 53 
Bathtub Notes Bathtub
c  








The adjusted exponential model fitted 
to both arms results in a HR of 0.64 
and has a predicted difference in OS of 
3.64 months, in favour of azacitidine; 
details are presented in the Appendix 
2. 
The adjusted exponential model fitted 
to both arms results in a HR of 0.65 
and has a predicted difference in OS of 
3.64 months, in favour of azacitidine; 
details are presented in the Appendix 
2. 
Section 5.3.6.2, p. 
117 
Figure 22 presents the ITT Kaplan-
Meier data and the fitted adjusted 
exponential OS model to data 
censored at switch to subsequent AML 
therapy in both trial arms. 
Figure 22 presents the Kaplan-Meier 
data (censored at switch) and the fitted 
adjusted exponential OS model to data 
censored at switch to subsequent AML 
therapy in both trial arms. 
Figure 22, p. 118 
(Caption) 
Figure 22: Overall survival in AZA-
AML-001 – ITT Kaplan-Meier data and 
adjusted exponential model fitted to 
censor-at-switch (any AML therapy) 
data 
Figure 22: Overall survival in AZA-
AML-001 – Kaplan-Meier data 
(censored at switch) and adjusted 
exponential model fitted to censor-at-
switch (any AML therapy) data 
Figure 22, p. 118 [Figure] [See Figure 22 below] 
Section 5.3.6.2, 
p.119 
As a conservative approach, the 
ERG’s preferred base case analysis 
adopted the exponential OS HR 
estimates adjusted for baseline 
covariates used by the IPCW method, 
including sex, age, ECOG status, 
preselected CCR treatment, time since 
initial AML diagnosis, comorbidity 
score, in data censored at switch to 
any subsequent AML treatment from 
both trial arms in the dataset provided 
by Celgene to ERG. The resulting HR 
estimate, 0.64, is more favourable to 
azacitidine than the respective 
estimates from applying IPCW to 
subsequent azacitidine use in CCR 
As a conservative approach, the 
ERG’s preferred base case analysis 
adopted the exponential OS HR 
estimates adjusted for baseline 
covariates used by the IPCW method, 
including sex, age, ECOG status, 
preselected CCR treatment, time since 
initial AML diagnosis, comorbidity 
score, in data censored at switch to 
any subsequent AML treatment from 
both trial arms in the dataset provided 
by Celgene to ERG. The resulting HR 
estimate, 0.65, is more favourable to 
azacitidine than the respective 
estimates from applying IPCW to 
subsequent azacitidine use in CCR 
only, xxx and xxxx (Celgene’s base 
case), IPCW to any AML in both arms 




only, xxxx and xxxx (Celgene’s base 
case), IPCW to any AML in both arms 






The subgroup analyses were thus 
based on the original censor-at switch 
exponential OS curves estimates used 
by the company in their model. 
The subgroup analyses were thus 
based on the original censor-at switch 
exponential OS curves estimates used 
by the company in their model 
(alongside Kaplan-Meier curves for 
censor at switch PFS and RFS data 
available in the Celgene excel model). 
Section 5.3.7, 
p.120 
The QALY impact of AEs was 
modelled as the probability of at least 
one TEAE of Grade > 3 per 100 
person-years multiplied by the utility of 
grade > 3 TEAEs. In the model, the 
effect of AEs on QALYs in azacitidine 
have been modelled for a maximum of 
8.8 treatment cycles, which is 
effectively less than the mean 8.8 in 
the trial, while for CCR as a whole they 
were counted for a maximum number 
of cycles of 5.1 which is more than the 
mean number of 2 cycles with IC. 
These calculations are likely to 
overestimate the additional costs of 
CCR relative to azacitidine but this bias 
had a small effect on the results given 
other issues identified by the ERG in 
the model. 
The QALY impact of AEs was 
modelled as the probability of at least 
one TEAE of Grade ≥ 3 per 100 
person-years multiplied by the utility of 
grade ≥ 3 TEAEs. In the model, the 
effect of AEs on QALYs in azacitidine 
have been modelled for a maximum of 
8.8 treatment cycles, which is 
effectively a mean of 6.43 in the model 
rather than the mean 8.8 cycles in the 
trial, while for CCR as a whole they 
were counted for a maximum number 
of cycles of 5.1, which resulted in a 
mean of 4.23 treatment cycles instead 
of the mean number of 2 cycles with IC 
in the trial. These calculations are likely 
to overestimate the additional QALY 
losses due to disutility of CCR relative 
to azacitidine treatment but this bias 
had a small effect on the results given 
other issues identified by the ERG in 
the model. 
Section 5.3.8.1, p. 
122 
Likewise the correct maximum number 
of cycles for LDAC in CCR is 10 cycles 
(the 1.6 cycles used for IC in CCR 
modelled by Celgene is practically 
correct). In correcting the probabilistic 
sensitivity analysis ERG chose SE 3 
for azacitidine, 1 LDAC and (0.06 for 
IC as used by Celgene’s base case is 
correct), to calibrate the respective 
model outputs to the reported figures 
for mean minus one standard error in 
the number of cycles reported by 
Dombret et al. 2015.
45
 As documented 
below, correcting this error of 
implementation to calibrate the model 
outputs with the summary statistic 
reported by the trial increases the 
ICER from a level around £20,000 to 
£84,000 per QALY gained. 
Likewise the correct maximum number 
of cycles for LDAC in CCR is 10 cycles 
and  2 cycles  for IC in CCR. In 
correcting the probabilistic sensitivity 
analysis ERG chose SE 3 for 
azacitidine, and 1 for LDAC (0.06 for 
IC as used by Celgene’s base case is 
correct), to calibrate the respective 
model outputs to the reported figures 
for mean minus one standard error in 
the number of cycles reported by 
Dombret et al. 2015.
45
 As documented 
below, correcting this error of 
implementation to calibrate the model 
outputs with the summary statistic 
reported by the trial increases the 
ICER from a level around £60,000 
(Celgene’s corrected base case) to 
around £130,000 per QALY gained. 
Section 5.3.8.2, 
p.123 
Another limitation was that the costs of 
managing AEs in patients from 
azacitidine and CCR groups were 
estimated as the product of the 
probability of at least one TEAE of 
Another limitation was that the costs of 
managing AEs in patients from 
azacitidine and CCR groups were 
estimated as the product of the 
probability of at least one TEAE of 
Grade > 3 per 100 person-years and 
the average cost of managing grade 3 
or 4 TEAEs observed in the AZA-AML-
001 trial. 
Grade ≥ 3 per 100 person-years and 
the average cost of managing grade 3 
or 4 TEAEs observed in the AZA-AML-
001 trial. 
Section 5.3.10, p. 
126 
Our corrected results presented in 
Section 6 (page 130) are subject to 
this caveat. 
However, the ERG corrected base 
case results presented in Section 6 
(page130) were found to be replicable 
by the weighted average method within 
a 5-10% margin of error. 
Section 5.4.2.3, 
p.128 
The ERG set the OS curves to the 
Censor At Switch analysis mode in 
Celgene’s model, keeping the 
exponential functional form adopted in 
Celgene’s base-case. This choice was 
associated with a hazard ratio of 0.72, 
which corresponded to the analysis 
that was unadjusted for baseline 
covariates. Given the high ICERs that 
were obtained after the preceding 
revisions in Sections 5.4.2.1 and 
5.4.2.2, the effect of adopting the 
smaller hazard that resulted from 
censored at switch analysis that 
adjusted for baseline covariates was 
investigated in exploratory analyses. 
The ERG set the OS curves to the 
Censor At Switch analysis mode in 
Celgene’s model, keeping the 
exponential functional form adopted in 
Celgene’s base-case. This choice was 
associated with a hazard ratio of 0.72, 
which corresponded to the analysis 
that was unadjusted for baseline 
covariates. In addition, the Censor At 
Switch analysis in the Celgene model 
alters the estimates of relative effects 
of azacitidine on PFS and RFS, from 
the Celgene base case HR values of 
0.84 and 0.85 to 0.83 and 0.76, 
respectively. Given the high ICERs that 
were obtained after the preceding 
revisions in Sections 5.4.2.1 and 
5.4.2.2, the effect of adopting the 
smaller hazard that resulted from 
censored at switch analysis that 
adjusted for baseline covariates was 
investigated in separate exploratory 
analyses. 
Secton 5.4.2.5, p. 
128 
The effect of using the OS hazard ratio 
estimate of 0.64 from the exponential 
model adjusted for baseline covariates, 
which found support in statistical tests 
conducted by the ERG, was 
investigated. 
The effect of using the OS hazard ratio 
estimate of 0.65 from the exponential 
model adjusted for baseline covariates, 
which found support in statistical tests 
conducted by the ERG, was 
investigated. 
Section 5.4.3, p. 
128 
The ERG sought to perform some 
exploratory assessment of the 
subgroup analysis by preselected CCR 
treatment, while acknowledging that for 
PFS and RFS outcomes, the sample 
sizes make subgroup-specific time to 
event data highly unreliable. Thus in 
these analyses subgroup specific 
differences in OS outcomes were 
allowed using censor-at-switch data, 
while keeping common PFS and RFS 
curves across the three subgroups. 
Since resource use data in the 
Celgene model was obtained from a 
survey of clinical experts’ estimates, 
and because the ERG’s preferred cost 
estimates for Relapse/PD were those 
estimated by Celgene’s experts for the 
BSC (i.e. the most costly) subgroup 
during Relapse/PD, the effect of 
uncertainty from these values on the 
ICER was explored in extreme 
scenarios where costs of Relapse/PD 
were zero and, separately, where no 
inpatient costs were incurred (apart 
from what is already included in the 
model ‘Terminal care’ costs). 
In its preferred base case analysis, 
Celgene measured costs of monitoring 
tests and transfusions only while 
patients were on azacitidine, LDAC or 
IC. The ERG instead included costs for 
these items for the duration of the 
patients in Remission and Non-
Remission states as well as during 
Relapse/ Progressive Disease. The 
ERG explored the effects of adopting 
Celgene’s assumption that no such 
costs would occur after treatment 
active treatment stopped. 
Other scenarios included revising the 
costs of monitoring tests and 
transfusions during Relapse/PD to 
values estimated by a clinical expert 
consulted by the ERG, whereby two 
units each of red blood cell 
transfusions and adult doses of platelet 
transfusions are given on average per 
4 week cycle, whilst no bone marrow 
aspirates or biopsies nor extractions 
for cytogenetic testing, four blood tests, 
and two each of peripheral blood 
smears and serum blood chemistry are 
given during PD.         
In addition, the ERG sought to perform 
some exploratory assessment of the 
subgroup analysis by preselected CCR 
treatment, while acknowledging that for 
PFS and RFS outcomes, the sample 
sizes make subgroup-specific time to 
event data highly unreliable. In these 
analyses subgroup specific differences 
in OS, PFS, and RFS outcomes were 
allowed using censor-at-switch data, 
using the exponential (OS) and 
Kaplan-Meier (PFS and RFS) curves 
provided by Celgene in the Excel 
model for each arm in the three 
subgroups. 
Section 6, pp. 
130–136 
[Section 6 and all included tables (58 to 61) and figures (23 and 24) superseded 
by the ERG Addendum following correction of an error in the final stage of the 
derivation of the ERG preferred base case] 
Section 8, p. 138 Of the key changes made to the 
economic model by the ERG in arriving 
at their preferred base case (ICER 
£169,606 per QALY), the following 
might be considered to be differences 
of opinion between the company and 
the ERG: 
Of the key changes made to the 
economic model by the ERG in arriving 
at their preferred base case (ICER 
£273,308 per QALY), the following 
might be considered to be differences 
of opinion between the company and 
the ERG: 
Section 8, p. 138 The base case analysis preferred by 
the ERG has the limitation that the sum 
of the cohort proportions in PFS and 
RFS exceeds the proportion alive by 
the third cycle in the model. Celgene 
included an adjustment in the model to 
eliminate such anomalies, but 
nevertheless this remains a deficiency 
of the model structure. The ERG has 
not attempted to correct this, due to the 
[This is no longer the case after 
correcting the error in estimating the 
ERG’s adjusted exponential OS 
baseline hazard; Appendix has been 
corrected below] 
difficulties of fitting plausible parametric 
models to the PFS and RFS data (as 
discussed in this critique) and adjusting 
for baseline covariates, given the small 




Figure A1: Log-log plots of OS 
probability adjusted for subsequent 
azacitidine use in the CCR arm using 
the IPCW method – unadjusted for 
baseline covariates 
Figure A1: Log-log plots of OS 
probability adjusted for subsequent 
azacitidine use in the CCR arm using 










[Figure] [See Figure A1 below] 
Appendix 2, 
Section A2.1 
 Append following subsection: 
 
A2.1.2 Schoenfeld residual plots 
 
Figure A2: Schoenfeld residual plots 
and local polynomial regression, 
adjusted for subsequent azacitidine 





Key: CCR, conventional care regimens 
Source: ERG analysis using individual 
patient data provided by Celgene 
Appendices 2–4 [Figure numbering] [Renumber figures] 
Appendix 2, 
Section A2.4 
Model estimated using effects coding 
to obtain average baseline. Mean time 
to death Azacitidine = 0.0973354
-1
 = 
10.27 months; CCR 
=(1.549388×0.0973354)
-1
 = 6.63 
months (HR azacitidine vs. CCR = 
1.549388
-1
 = 0.6454162) 
Model estimated using effects coding 
to obtain average baseline. Mean time 
to death Azacitidine = 0.058019
-1
 = 
17.24 months; CCR 
=(1.549388×0.058019)
-1
 = 11.12 
months (HR azacitidine vs. CCR = 
1.549388
-1
 = 0.6454162) 
Appendix 2, 
Section A2.4 
This model adjusted for baseline 
covariates sex, age, ECOG, 
cytogenetic risk, CCR preselected 
treatment, comorbidity group, AML 
days, platelet transfusion status, 
geographical region, used in Celgene’s 
IPCW analysis (fixed covariates), using 
effects-coding, in order to estimate the 
average baseline (intercept) coefficient 
in the sample. Blast group was not 
effects-coded but included in order to 
adjust for blast group <25 (blastgrp2 
indicates 5-24% blasts; blastgrp4 
indicates blastgrp<5%), so that 
estimated baseline coefficient of 
0.0973354 is average in sample with 
blasts≥25% group. 
This model adjusted for baseline 
covariates sex, age, ECOG, 
cytogenetic risk, CCR preselected 
treatment, comorbidity group, AML 
days, platelet transfusion status, 
geographical region, used in Celgene’s 
IPCW analysis (fixed covariates). The 
predicted baseline hazard rate was 
obtained by evaluating the estimated 
equation and mean valued of the 
covariates for the whole. Blast group 
was not evaluated at 0 in order to 
adjust for blast group <25 (blastgrp2 
indicates 5-24% blasts; blastgrp4 
indicates blastgrp<5%), so that 
estimated baseline coefficient of 




[Stata output from streg command] [Stata output as shown below] 
Figure 22: Overall survival in AZA-AML-001 – Kaplan-Meier data (censored at switch) 
and adjusted exponential model fitted to censor-at-switch (any AML therapy) data 
 
Figure A1: Log-log plots of OS probability adjusted for subsequent azacitidine use in 















































0 1 2 3 4
ln(analysis time)
Azacitidine CCR
Figure A2: Schoenfeld residuals and local polynomial regression, adjusted for 
subsequent azacitidine use in the CCR arm – adjusted for baseline covariates 
 
 
Revised Stata output for streg command (Section A2.4) 
----------------------------------------------------------------------- 
          _t | Haz. Ratio  Std. Err.    z   P>|z|  [95% Conf. Interval] 
-------------+--------------------------------------------------------- 
         ccr | 1.549388  .1874601    3.62  0.000  1.222288    1.964024 
        sex2 | 1.028439  .126573     0.23  0.820  .8080132    1.308996 
     agegrp2 | 1.633048  .2117287    3.78  0.000  1.266597    2.10552 
       ECOG2 | 1.490963  .2070571    2.88  0.004  1.135681    1.957389 
       CYTO2 | 2.117182  .2584642    6.14  0.000  1.666649    2.689505 
   blastgrp2 | .379288   .149469    -2.46  0.014  .1751981    .8211239 
   blastgrp4 | .1908186  .1924331   -1.64  0.100  .0264373    1.377286 
     randpr2 | .3804746  .0875254   -4.20  0.000  .242389     .5972257 
     randpr3 | .4458237  .0697034   -5.17  0.000  .3281557    .6056844 
   comorbis3 | 1.386397  .220576     2.05  0.040  1.014989    1.893712 
        aml1 | 1.033729  .3199961    0.11  0.915  .5635249    1.896272 
        aml2 | 1.181031  .358463     0.55  0.584  .6514894    2.140994 
        aml3 | .933583   .2925007   -0.22  0.826  .5051998    1.725213 
    pltstat2 | .6219478  .0802252   -3.68  0.000  .4830113    .8008489 
     georeg1 | 1.159714  .2316993    0.74  0.458  .7839519    1.715586 
     georeg2 | 2.366019  .4000999    5.09  0.000  1.698549    3.295783 
     georeg3 | 1.194632  .2019344    1.05  0.293  .8577316    1.66386 
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Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts [ID829] 
 
You are asked to check the ERG report from Peninsula Technology Assessment Group (PenTAG) to ensure there are no factual inaccuracies contained 
within it. 
 
If you do identify any factual inaccuracies you must inform NICE by 5pm, Friday 19 February 2016 (changed to Wednesday 24
th
 February 2016) using the 
below proforma comments table. All factual errors will be highlighted in a report and presented to the Appraisal Committee and will subsequently be published 
on the NICE website with the Evaluation report. 
 




Issue 1 Use of CCR as a comparator; not investigating individual treatments 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Throughout the report (example 
Table 1, pg. 24), the ERG have 
It should be stated that: Stating that the company have not 
assessed whether azacitidine 
The company have not adequately 
assessed whether azacitidine 
stated that CCR was used as a 
comparator rather than IC LDAC and 
BSC, and as a result the company 
have not assessed whether 
azacitidine demonstrates clinical and 
cost effectiveness compared with 
each treatment within CCR 
The company have used CCR in 
their base case analysis; however 
they have provided sensitivity 
analyses comparing patients 
receiving each of the treatments 
making up CCR 
demonstrates clinical and cost 
effectiveness compared with each 
treatment within CCR is factually 
inaccurate, and leads the reader to 
conclude that the company have not 
investigated individual treatments.  
demonstrates clinical and cost-
effectiveness compared with each 
treatment within CCR for the 
following reasons: 
1. The pivotal RCT was not 
powered for such 
comparisons. 
2. There are significant 
inconsistencies between the 
results of the company’s 
base case and subgroup 
analyses (ERG report, p. 
125). 
In the stated example the ERG 
considers it is clear that the focus of 
the critique is the base case. The 
ERG report does include the 
subgroup analyses and therefore a 
full reading of the ERG report would 
not lead the reader to conclude that 
the company have not investigated 
individual treatments. 
No action taken. 
Issue 2 Suggestion that the literature review for clinical effectiveness studies was poor 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
On pg. 28, the ERG state “The ERG 
believes the literature searching for 
clinical effectiveness studies was 
poorly conducted and reported“. 
They also state that their own 
Suggested text: 
The methodology used in the 
literature, although less thorough 
than expected, did not miss any 
It is factually inaccurate to suggest 
that the methodology was poor if it 
identified all relevant studies. 
The ERG rejects this proposed 
amendment. The ERG critique 
remains an accurate reflection on the 
quality of the company’s submission 
searches did not identify any 
additional studies. 
studies found by the ERG’s own 
literature search. 
as it relates to study identification. 
No action taken. 
Issue 3 The dropout rates due to an AE look imbalanced for azacitidine (36.9%) compared to the CCR group (26.7%) 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Table 3 pg.36 the ERG state “The 
drop-outs provided by Celgene 
represent the figures reported in the 
RCT. However, neither Celgene nor 
the RCT report the drop outs for the 
three CCR treatments separately, 
therefore it is unknown whether the 
actual treatments that make up the 
CCR are comparatively different to 
azacitidine. The dropout rates due to 
an AE look imbalanced for 
azacitidine (36.9%) compared to the 
CCR group (26.7%)”.  
 
This is a misleading statement. 
Text should state:  
 
Within the single technology 
appraisal (STA) company evidence 
submission document, dated 25 
November 2015, Figure 7, the 
CONSORT diagram for AZA-AML-
001 depicts the disposition of 
subjects in the intent-to-treat (ITT) 
population for the Treatment Phase, 
with each of the three CCR treatment 
arms presented individually.  Also, as 
seen in the STA submission 
document, the duration of therapy is 
considerably longer in the azacitidine 
group compared with the individual 
CCR groups and this must be 
considered when interpreting these 
data. 
 
In Study AZA-AML-001, the median 
duration of treatment for the 
azacitidine group (164.5 days) was 
longer than that observed for the 
BSC-only (65.0 days), low-dose 
cytarabine (98.0 days), or intensive 
chemotherapy (55.5 days) groups. 
The original statement in the ERG 
report is misleading without providing 
text to explain this difference. 
The company is correct to indicate 
that Figure 7 provides the detail 
which the ERG originally said was 
not reported. 
The ERG agrees to change the 
statement in Table 3 to: 
The ERG has no further comments. 
The total treatment exposure 
expressed in person-years was 
higher in the azacitidine group 
(174.9) than in the other groups 
(82.9, 14.1, and 9.6 for low-dose 
cytarabine, intensive chemotherapy, 
and BSC-only groups, respectively). 
 
 
Issue 4 Statement that none of the published registry data provided information on the population with >30% blasts 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
On page 66 of the ERG report, it is 
stated that “None of the published 
registry data (Austrian azacitidine 
registry (NCT01595295); Spanish 
AMLA registry and French 
compassionate patient named 
programme) provided information on 
the population with >30% bone 
marrow blasts, a population 
requirements for the Scope for this 
report.“ 
This statement should be removed. The registry data discussed do 
include information on patients with 
>30% bone marrow blasts; therefore 
the ERG’s statement is factually 
inaccurate. 
The ERG’s intended meaning was 
that results pertaining only to the 
subpopulation with >30% blasts was 
not presented (not that patients with 
>30% blasts were not represented at 
all). However, the ERG 
acknowledges that results were 
presented for a relevant 
subpopulation from the Austrian 
Azacitidine Registry. 
The ERG agrees to replace the 
paragraph with the following: 
Both the Spanish AMLA registry and 
French compassionate patient 
named programme failed to provide 
outcomes  for the specific population 
with >30% bone marrow blasts. 
Instead only the proportion of 
patients with >30% bone marrow 
blasts was reported. Outcomes were 
reported combined irrespective of 
bone marrow blast status.  
The Austrian azacitidine registry 
(AAR, NCT01595295) report 
outcomes for the total patient 
population irrespective of bone 
marrow blasts status. In addition, 
they also report outcomes for those 
with >30% bone marrow blasts and a 
WBC <15g/L receiving azacitidine 
and compare baseline and treatment 
characteristics for these patients to 
the azacitidine arm of the AZA-AML-
001 trial. Baseline and treatment 
characteristics were similar between 
the two groups of patients receiving 
azacitidine except for the following 
differences: 
Baseline characteristics for AML 
classification: AML-NOS was higher 
(63.5 %) in the AZA-AML-001 trial 
than the AAR (24.2%) and for AML-
MRF, the AAR reported higher 
proportions (66.3%) than the AZA-
AML-001 trial (31.1%). 
Outcomes appear to be similar for 
the registry and the AZA-AML-001 
trial. 
For AE, treatment-emergent 
thrombocytopenia and anaemia both 
had significantly higher (47.4% and 
31.6% respectively) incidences in the 
Austrian azacitidine registry than 
from the AZA-AML-001 trial (15.7% 
and 26.3% respectively). 
Issue 5 Statement that the ERG’s preferred base case equalises the costs in the relapse/progressive disease health 
state across the model 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Throughout the report, the ERG 
make reference to their preferred 
base case of setting relapse/PD 
health state costs to be equal across 
the model. For example on pg.15 
they say “The ERG also identified 
that there were significant differences 
in the cost associated with the 
Relapse/progressive disease state 
between the AZA and CCR arm, 
even though all patients (in both 
arms) are expected to be receiving 
BSC at this point.” This is further 
detailed in section 5.3.8.2 on pages 
122-123. 
In Appendix 3 of the ERG report, the 
ERG state that they have applied the 
data for the BSC cohort to all cohorts 
within the relapse/PD state. 
The ERG also state that it is 
questionable that the sequence of 
treatments studied in the model i.e., 
AZA followed by BSC and CCR 
A statement should be added by the 
ERG in relation to their preferred 
base case, that setting setting 
relapse/PD health state costs to be 
equal across the model is not 
reflective of the AZA-AML-001 trial, 
the conclusions drawn by the clinical 
questionnaire designed to elicit 
resource use (from 7 UK clinicians), 
or the clinical opinion given to the 
ERG.  
In addition, it should be noted that 
applying the BSC cohort data to all 
cohorts in the relapse/PD state is 
inappropriate and not representative 
of clinical practice. 
There is inconsistent messaging from 
the ERG; one message of setting 
relapse/PD health state costs to be 
equal across the model, and the 
other than patients would receive 
active treatment after 1
st
 line. 
The combination of the AZA-AML-
001 trial, the conclusions drawn by 
the clinical questionnaire designed to 
elicit resource use (from 7 UK 
clinicians), as well as clinical opinion 
given to the ERG, suggests that 
patient resource use is likely to vary 
after 1
st
 line treatment. 
Applying the BSC cohort data to all 
cohorts in the relapse/PD state is 
inappropriate and not representative 
of clinical practice. 
The proposed statements are not 
appropriate. 
The ERG had to work within the 
limitations of the structure of the 
Celgene model. The ERG’s limited 
aim was to correct the OS 
effectiveness parameter values in 
Celgene’s model to make them 
consistent with the model’s 
assumption that no subsequent 
active therapy would be used in AZA 
or CCR after 1st line treatment; see 
Celgene submission, Section 5.6.2., 
Table 54, p. 141 “Assumption: There 
is no treatment switching. 
Justification Clinical expert opinion. 
Only a very small percentage of 
patients at this stage of disease 
would be fit for a second treatment 
after failing their first.” 
ERG’s corrections do not imply 
endorsement of Celgene’s 
assumptions. The model should have 
followed by BSC) is realistic, 
suggesting subsequent therapy may 
be given in clinical practice (as was 
seen in the AZA-AML-001 trial). In 
addition, the ERG states (pg. 129) 
“Advice from clinical experts 
suggests that active second-line 
treatment is considered for some 
patients in the NHS”. 
allowed for the cost and effects of 
subsequent treatments used in the 
trial which would also be used in 
routine NHS practice, by modelling 
second line treatment. However, 
Celgene’s model assumed that no 
such treatment was available after 
relapse/PD. As stated in ERG’s 
report, Section 5.3.6.2, p. 116. 
“To remedy the contradiction 
between the model structure, on the 
one hand, and the methodology 
underlying the OS treatment effect 
estimates, on the other, two options 
were available to the ERG. One was 
to correct the model to include the 
costs of subsequent treatments used 
in the AZA-AML-001 and left 
unadjusted for in the statistical 
analysis that produced the base case 
OS treatment effect estimates. This 
option was not feasible because the 
required data on the dates of start 
and end of subsequent treatments as 
well as treatment dosages and 
frequencies of administration were 
not available to ERG.” 
Note that setting relapse/PD costs to 
be equal across the model was 
simply done for consistency with the 
model assumptions; i.e. Celgene 
assume that patients in this state are 
all managed by BSC and it was not 
clear why there should be differences 
in costs by initial treatment (i.e. AZA 
vs CCR). Different costs may apply 
to the relapse/PD phase (and ERG 
presented results of varying these), 
but claiming that costs should be 
different between cohorts is 
questionable given the lack of data 
and difficulties of defining these CCR 
preselected subgroups a priori. 
Further, Celgene did not provide any 
evidence in its submission that the 
resource use survey addressed the 
role of the specific subsequent 
treatments used in AZA-AML-001. 
No action taken. 
 
Issue 6 Statement that combined PFS and RFS curves cross OS curve at cycle 69 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
On page 110, the ERG state “The 
inadequacy of the statistical analysis 
may be illustrated by comparing the 
estimated time to event curves used 
by Celgene in their base case 
analysis, combining PFS with RFS 
and contrasting it with OS. Error! 
Reference source not found. below 
illustrates the problem for the CCR 
arm. By cycle 69, that is, just after 
the start of the sixth year after first 
receiving treatment the estimated 
curves imply that there are more 
This statement should be removed. 
This is factually inaccurate. Having 
checked the model, the curves do not 
cross. 
 
A possible reason for the ERG’s 
interpretation may be that they have 
compared the wrong settings: RFS 
and PFS in columns H and I of the 
Model worksheets can exceed OS in 
column J because they are 
comprised from different 
denominators: in fact, OS from 
column J must be compared with 
The ERG stands by its comment. 
The ERG confirms it has considered 
the appropriate columns. The reason 
these curves, as implemented in the 
Excel model, do not cross is that in 
the Excel model Celgene applied an 
adjustment so that when crossing 
would have occurred the survival 
probabilities distributed the OS time 
proportionately to PFS and RFS; e.g. 
in Celgene Model AZA sheet cell L23 
the formula is:   
patients in the treated cohort who are 
either in Remission or non-remission 
(stable disease) than there are 
patients alive.” 










This correction avoids having PFS + 
RFS larger than OS, but does not 
address concerns about the validity 
of Celgene’s chosen parametric 
survival curves for assigning time to 
Remission and Non-remission  
versus relapse/PD states in the 
model. 
No action taken. 
 
Issue 7 The use of censor at switch analyses  
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
On pages 116 to 120, the ERG 
describe using censor at switch 
methodology to model the OS. They 
acknowledge that they did this 
because they were not able to 
perform the IPCW analysis to adjust 
for subsequent therapy for both 
treatment groups.  
The ERG also acknowledge that (pg. 
129) “Advice from clinical experts 
It should be noted along with the 
ERG’s preferred base case ICER 
that the methodology used for 
modelling OS is not optimal, and 
does not fit with the AZA-AML-001 
trial, the conclusions drawn by the 
clinical questionnaire designed to 
elicit resource use (from 7 UK 
clinicians), as well as clinical opinion 
given to the ERG, all of which 
suggest patients could receive 
The ERG’s  base case ICER is 
misleading without acknowledging 
the limitations of the OS modelling 
whenever the base case is 
mentioned. 
 
The ERG’s preferred base case is 
the best possible use of the available 
data given Celgene’s model logic. It 
does not represent ERG’s view of 
what UK routine practice is or an 
endorsement of Celgene’s structural 
assumptions, whose correction was 
beyond the scope of ERG’s STA 
review as defined by NICE. We 
acknowledge this in ERG report 
Section 5.3.6.2, p. 117: “Whether the 
suggests that active second-line 
treatment is considered for some 
patients in the NHS” 
subsequent therapy. assumption that no subsequent 
active treatment would be available 
to UK patients in routine practice is 
plausible may of course be 
questioned, but the point here is that 
applying IPCW adjustment for 
subsequent treatment to the outcome 
data of the CCR but not the 
azacitidine arm in the AZA-AML-001 
trial is inconsistent with the economic 
model which the overall survival 
IPCW analysis was designed to 
inform.”   
Please also see our response to 
Issue 6. 
No action taken. 
 
Issue 8 OS modelling methods and results are unrealistic and misleading  
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
The ERG describes their preferred 
base case for OS modelling (pg. 116-
120), as well as the use of KM data 
for PFS and RFS (pg. 128). 
The ERG state the uncertainty 
around the PH assumption for OS 
(pg.114). 
The ERG’s methodology uses a 
censor-at-switch analysis and does 
It should be noted in the report that 
the ERG’s preferred base case is 
unrealistic as it: 
- Extends OS but uses KM 
data for PFS and RFS 
leading to clinical 
implausibility. In addition, it 
can be seen that, even in 
isolation, the KM data for 
PFS and RFS is not 
Given the ERG’s stated uncertainty 
around the PH assumption with OS, 
the clinical implausibility of the ERG’s 
modelling of OS in relation to PFS 
and RFS, removing subsequent 
therapy and the way the changes in 
the ERG’s base case interact with 
each other, the ERG’s methodology 
is misleading.  
Stating the ERG preferred base case 
The ERG disagrees with Celgene’s 
view. In response to each point in 
proposed amendments: 
ERG chose KM curves for PFS and 
RFS because they are a) as 
observed in the trial and b) non-
parametric, i.e. free from risk of bias 
in fitting a parametric curve, which 
Celgene’s own analysis identified as 
an issue. The resulting PFS and RFS 
not allow for any subsequent therapy; 
this does not represent the view of 
the clinical expert consulted by the 
ERG, the data from the AZA-AML-
001 trial or the clinician questionnaire 
used to calculate HRU by the 
Company. 
Pg. 118 of ERG report: text states 
that their OS modelling is 
“conservative” i.e. it is unrealistically 
increases the ICER, because it is 
biased in favour of AZA for OS.  
PFS and RFS are not increased 
(ERG uses KM data in their base 
case).  
The ERG’s modelling of OS interacts 
with two other influential ERG 
changes 1. Scenario “E”, the use of 
KM data only for RFS and PFS 
(which we have shown is 
inappropriate), and 2. Scenario “B”, 
the calibration of relapse/PD HRU 
and costs. The unrealistic 
combination of these changes is 
misleading. 
appropriate  
- Pushes patients into the PD 
disease state for longer 
which combines with other 
ERG changes such as 
equalised costs and HRU 
across all PD for both arms 
thus biasing against 
azacitidine 
- Suggests no subsequent 
therapy is received after 1
st
 
line therapy despite 
consistent evidence that this 
is unrealistic 
without acknowledging its limitations 
and implausibility clearly is 
misleading to the reader. 
data may have been affected by the 
use of subsequent therapies 
although it appears that at least for 
CCR arm subsequent azacitidine use 
occurred in few instances and their 
effect was negligible (this was 
confirmed by Celgene’s response to 
ERG’s questions for clarification). 
Acknowledging that the ERG’s 
preferred base-case analysis results 
in a longer incremental period in 
relapse/PD under azacitidine than 
those of Celgene’s base case, ERG 
have undertaken considerable 
sensitivity analyses. All of these 
show that the ICER is >£70,000 per 
QALY even when relapse/PD costs 
are zero. 
Please see our response to Issues 5 
& 7. 
No action taken. 
 
 
Issue 9 The use of KM curves from the trial for RFS and PFS within the model 
Description of problem  Description of 
proposed amendment  
Justification for 
amendment 
ERG preferred base case uses KM data for RFS and PFS. Section 5.4.2.4, page 128.  
RFS and PFS KM curves, for all regimens, are not completely observed. The table below provides 
the final survival data from the observed KM curves; in the case of RFS in particular we would 
argue that some modelling is required.  
Identifying the optimal fitting functional form is uncertain, however retaining KM data only 
underestimates benefit in all regimens. 
The ERG’s preferred modelling for OS increases OS compared with the Company’s base case. 
Survival rates in the KM curves are below: 










All patients 0.0149 0.1390 0.0161 0.1014 
IC 0.0938 0.1455 0.0588 0.1604 
LDC 0.0362 0.1128 0.0242 0.0515 
BSC 0.0909 0.2857 0.0588 N/a 
Intermediate risk 0.0266 0.1581 0.0353 0.1039 
Poor risk 0.0266 0.1581 0.0353 0.1039 
With myelodysplasia-related 
changes 0.0845 0.2591 0.0484 0.0879 
Without myelodysplasia-related 
changes 0.0155 0.0917 0.0245 0.1261 
 
 
It should be noted in the 
report that  KM data for 
RFS and PFS are not 
completely observed, and 
that some modelling is 
required. 
It should be noted that the 
ERG’s preferred base 
case increases OS, but 
does not increase PFS or 
RFS, and that there is no 
clinical reason for this. 
It is factually inaccurate to 
suggest the KM data is 
complete for PFS and 
RFS. 
It is misleading and 
clinically implausible to 
extend OS whilst not 




The ERG accepts that its use of KM curves result in underestimation (‘censoring’) of time in the Remission state. However, this affects a minority of patients, 
i.e. those with a CR/CRi response, 28% in AZA and 25% in CCR, and given that the difference in censoring in AZA vs. CCR is 3.76 percentage points 
(0.1390 minus 0.1014) the bias against azacitidine is small and unlikely to be of significance to the results. 
No action taken. 
 
Issue 10 The suggestion that EOL criteria are met based on restricted mean value 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
When assessing whether EOL 
criteria are met, on page 136, table 
62 the ERG state “ERG analyses 
based on restricted mean survival at 
30 months suggest an extension to 
life of 1.8–2.5 months” 
The ERG also state that “Extension 
to life should be assessed 
considering differences in mean 
overall survival in addition to median 
OS” 
The ERG also conclude (pg. 117) 
that the mean predicted difference in 
OS from their base case model is 
3.64 months in favour of azacitidine. 
 
It should be explicitly stated that 
using the restricted mean to 
determine the mean OS gain for the 
target population is inappropriate. 
The restricted mean underestimates 
the mean OS and is therefore not 
representative of the target 
population. 
It should also be stated that the 
median OS gain from the trial, as well 
as the mean OS gain from the cost 
effectiveness model indicate that 
EOL criteria are met. 
It is factually inaccurate to state that 
the extension to OS is not met; the 
restricted mean is not suitable for 
basing the conclusion about the 
extension to life. The median OS 
gain from the AZA-AML-001 is 3.8 
months and the modelled mean OS 
for  corrections individually 
implemented by the ERG each 
produce a mean OS gain of >3 
months. Additionally, the ERG  
conclude (pg. 117) that the mean 
predicted difference in OS from their 
base case model is 3.64 months in 
favour of azacitidine. 
 
Overall survival curves have 
converged by 30 months in the ITT 
analysis (Celgene submission, Figure 
8), and arguably also in the censor-
at-switch analysis (Celgene 
submission, Figure 9). For this 
reason the difference in restricted 
mean survival (observed) is 
considered to be an unbiased 
estimate of the difference in 
unrestricted mean survival 
(unobserved); i.e., the restricted 
mean is a suitable basis for the 
conclusion about the extension to 
life. 
The ERG do not consider it 
necessary to state that restricted 
mean survival is an underestimate of 
unrestricted mean survival since this 
is widely understood and the ERG 
did not suggest anything to contradict 
this. 
The ERG note that even if median 
OS gain is preferred over mean OS 
gain (as estimated using restricted 
mean OS gain), the estimate is not 
robustly over 3 months, with a 95% 
CI of 1.0 to 6.5 months. 
No action taken. 
 
Issue 11 Unexplained model results due to ERG changes 
Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
The combination of ERG changes do 
not explain changes in model results.  
Switching off all of the ERG changes 
results in an ICER of £36,931, not 
£20,648, the original base case. 
The ERG note on the worksheet 
“ERG changes” of the model that 
additional changes relate to Table 32 
of the report; this table contains unit 
costs. It is not clear how the ERG 
have implemented their changes and 
why the ICER with ERG changes 
switched off is different to the 
Company’s base case ICER. 
More explanation of modifications 
made by the ERG 
The ERG amendments cannot be 
checked for accuracy and the 
explanation does not seem to fit with 
the actual change in ICER. The ERG 
changes may interact with the 
changes that are listed. This can be 
seen by comparing Table 58 
(piecewise changes) and Table 59 
(cumulative changes). 
This interaction may be significant 
because of the impact in particular of 
the ERG’s “A” and “B” amendments 
to the model. 
Due to the high number of 
corrections made by the ERG to the 
model submitted by Celgene and due 
to the time constraints, option buttons 
were created only for major 
corrections. The list of corrections to 
the implementation of Celgene's 
model is shown in Table 57 of the 
ERG’s report.  
An additional model correction, made 
by the ERG and discussed in section 
5.3.11.2 of the report (p. 126), was 
implemented in the model as “MAX 
operator” option buttons. 
The duration of monitoring tests and 
transfusions implemented in the 
ERG’s base case is described in 
section 6.1 (p. 134) of our report: 
“The base case analysis preferred by 
ERG included costs of monitoring 
tests and transfusions for the whole 
duration of the Remission and Non-
remission phases of the model (as 
well as for the Relapse/PD phase).” 
In the executable model, all corrected 
cells are highlighted in yellow. 
Action: ERG have produced a full 
listing of corrections to Celgene’s 
model (below) 
 
Full listing of corrections made to Celgene’s model 
The ERG present below a full listing of corrections made to Celgene’s model. Each correction is presented as an individual correction to Celgene’s original 
model, i.e., there is no accumulation of corrections shown. Correct implementation of all of these corrections leads to analysis A (corrected base case). ICERs 
are shown for AZA versus CCR in the deterministic base case. These corrections are listed in order of decreasing ICER. 
 
Correction 1 
Issue In the CCR arm, the patients receiving BSC only are assumed to incur drug administration costs in the Remission and Non-
remission states, although the costs of administering BSC are not included after discontinuation of other active treatments 
until relapse/progression. 
Cells affected ‘Model CCR’!AB23:AB153 
Original formula Revised formula 
Formula in ‘Model CCR’!AB23: 
='PSA inputs'!$D$71+K23*IF(C23<7,'PSA inputs'!$D$72,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$72))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$73,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$73)) 
replaced with:  
=('PSA inputs'!$D$71+K23*IF(C23<7,'PSA inputs'!$D$72,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$72))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$73,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$73))) 
* ('PSA inputs'!$D$16+'PSA inputs'!$D$17) 
Formula in ‘Model CCR’!AB24: 
=K24*IF(C24<7,'PSA inputs'!$D$72,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$72))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$73,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$73)) 
replaced with:  
=(K24*IF(C24<7,'PSA inputs'!$D$72,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$72))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$73,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$73))) 
* ('PSA inputs'!$D$16+'PSA inputs'!$D$17) 
 
(Correct the formulas in the cells below) 
ICER (cost per QALY) £43,676 
 
Correction 2 
Issue In the AZA and CCR arms, costs of tests and transfusions are not modelled for patients in the Relapse/progressive disease 
state. 
Cells affected ‘Model AZA’!AC23:AD153, ‘Model CCR’!AC23:AD153 
Original formula Revised formula 
Formula in ‘Model AZA’!AC23: 
='PSA inputs'!$D$57+K23*IF(C23<7,'PSA inputs'!$D$58,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$58))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$59,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$59)) 
replaced with:  
='PSA inputs'!$D$57+K23*IF(C23<7,'PSA inputs'!$D$58,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$58))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$59,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$59))  
+M23*'PSA inputs'!$D$60 
Formula in ‘Model AZA’!AC24: 
=K24*IF(C24<7,'PSA inputs'!$D$58,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$58))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$59,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$59)) 
replaced with:  
=K24*IF(C24<7,'PSA inputs'!$D$58,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$58))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$59,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$59)) +M24*'PSA inputs'!$D$60 
 
(Correct the formulas in the cells below) 
Formula in ‘Model CCR’!AC23: 
='PSA inputs'!$D$76+K23*IF(C23<7,'PSA inputs'!$D$77,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$77))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$78,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$78)) 
replaced with:  
='PSA inputs'!$D$76+K23*IF(C23<7,'PSA inputs'!$D$77,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$77))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$78,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$78)) 
+M23*'PSA inputs'!$D$79 
Formula in ‘Model CCR’!AC24: 
=K24*IF(C24<7,'PSA inputs'!$D$77,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$77))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$78,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$78)) 
replaced with:  





(Correct the formulas in the cells below) 
Formula in ‘Model AZA’!AD23: 
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$63,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$63))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$64,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$64)) 
replaced with:  
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$63,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$63))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$64,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$64)) 
+M23*'PSA inputs'!$D$65 
Formula in ‘Model AZA’!AD24: 
=K24*IF(C24<7,'PSA inputs'!$D$64,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$64))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$64,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$64)) 
replaced with:  





(Correct the formulas in the cells below) 
Formula in ‘Model CCR’!AD23: 
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$82,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$82))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$83,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$83)) 
replaced with:  
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$82,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$82))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$83,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$83)) 
+M23*'PSA inputs'!$D$84 
Formula in ‘Model CCR’!AD24: 
=K24*IF(C24<7,'PSA inputs'!$D$83,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$83))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$83,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$83)) 
replaced with:  





(Correct the formulas in the cells below) 
ICER (cost per QALY) £37,381 
 
Correction 3 
Issue In the AZA and CCR arms, drug administration, monitoring tests and transfusion costs are double-counted during the 1st 
model cycle. 
Cells affected ‘Model AZA ‘!AB23, AC23 and AD23; ‘Model CCR’! AB23, AC23 and AD23 
Original formula Revised formula 
Formula in ‘Model AZA’!AB23: 
='PSA inputs'!$D$52+K23*IF(C23<7,'PSA inputs'!$D$53,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$53))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$54,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$54)) 
replaced with:  
='PSA inputs'!$D$52 
Formula in ‘Model AZA’!AC23: 
='PSA inputs'!$D$57+K23*IF(C23<7,'PSA inputs'!$D$58,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$58))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$59,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$59)) 
replaced with:  
='PSA inputs'!$D$57 
Formula in ‘Model AZA’!AD23: 
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$63,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$63))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$64,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$64)) 
replaced with:  
='PSA inputs'!$D$62 
Formula in ‘Model CCR’!AB23: 
='PSA inputs'!$D$71+K23*IF(C23<7,'PSA inputs'!$D$72,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$72))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$73,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$73)) 
replaced with:  
='PSA inputs'!$D$71 
Formula in ‘Model CCR’!AC23: 
='PSA inputs'!$D$76+K23*IF(C23<7,'PSA inputs'!$D$77,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$77))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$78,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$78)) 
replaced with:  
='PSA inputs'!$D$76 
Formula in ‘Model CCR’!AD23: 
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$82,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$82))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$83,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$83)) 
replaced with:  
='PSA inputs'!$D$62 
 
ICER (cost per QALY) £35,532 
 
Correction 4 
Issue In the CCR arm, transfusion costs in the Remission state from the 2nd cycle onwards are modelled using the transfusion 
costs for patients with stable disease. 
Cells affected ‘Model CCR’!AD24:153 
Original formula Revised formula 
Formula: 
=K24*IF(C24<7,'PSA inputs'!$D$83,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$83))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$83,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$83)) 
replaced with:  
=K24*IF(C24<7,'PSA inputs'!$D$82,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$82))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$83,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$83)) 
ICER (cost per QALY) £28,147 
 
Correction 5 
Issue In the AZA and CCR arms, monitoring tests and transfusions were modelled only while the patient remained on their initial 
treatment. 
Cells affected ‘Model AZA’!AC24:AD153; ‘Model CCR’!AC24:AD153 
Original formula Revised formula 
Formula in ‘Model AZA’!AC24: 
=K24*IF(C24<7,'PSA inputs'!$D$58,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$58))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$59,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$59)) 
replaced with:  
=K24*'PSA inputs'!$D$58+MAX(L24-K24,0)*'PSA inputs'!$D$59 
 
(Correct the formulas in the cells below) 
Formula in ‘Model AZA’!AD24: 
=K24*IF(C24<7,'PSA inputs'!$D$64,IF(C24>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$64))+MAX(L24-K24,0)*IF(C24<7,'PSA inputs'!$D$64,IF(C24>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$64)) 
replaced with:  
=K24*'PSA inputs'!$D$64+MAX(L24-K24,0)*'PSA inputs'!$D$64 
 
(Correct the formulas in the cells below) 
Formula in ‘Model CCR’!AC24: 




=K24*'PSA inputs'!$D$77+MAX(L24-K24,0)*'PSA inputs'!$D$78 
 
(Correct the formulas in the cells below) 
Formula in ‘Model CCR’!AD24: 




=K24*'PSA inputs'!$D$83+MAX(L24-K24,0)*'PSA inputs'!$D$83 
 
The wrong cell reference in this formula is discussed above. 
 
(Correct the formulas in the cells below) 
ICER (cost per QALY) £26,696 
 
Correction 6 
Issue In the CCR arm, the patients receiving LDAC have costs of drug administration, tests and transfusions estimated based on 
the treatment duration of azacitidine, rather than the treatment duration of LDAC. 
Cells affected ‘Model CCR’!AB23:AD153 
Original formula Revised formula 
Cell reference:  
'PSA inputs'!$D$121 
replaced with:  
'PSA inputs'!$D$158 
ICER (cost per QALY) £26,537 
 
Correction 7 
Issue In the CCR arm, the patients receiving IC are assumed to incur drug administration costs after their treatment is discontinued 
(i.e., after cycle 2). 
Cells affected ‘Model CCR’!AB25:AB153 
Original formula Revised formula 
Formula in ‘Model CCR’!AB25: 
=K25*IF(C25<7,'PSA inputs'!$D$72,IF(C25>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$72))+MAX(L25-K25,0)*IF(C25<7,'PSA inputs'!$D$73,IF(C25>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$73)) 
replaced with:  
=(K25*IF(C25<7,'PSA inputs'!$D$72,IF(C25>'PSA inputs'!$D$121,0,'PSA 
inputs'!$D$72))+MAX(L25-K25,0)*IF(C25<7,'PSA inputs'!$D$73,IF(C25>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$73)))* 
('PSA inputs'!$D$17+'PSA inputs'!$D$18) 
 
(Correct the formulas in the cells below) 
ICER (cost per QALY) £26,333 
 
Correction 8 
Issue In the CCR arm, transfusion costs in the pre-response period were modelled using transfusion costs for patients receiving 
azacitidine. 
Cells affected ‘Model CCR’!AD23 
Original formula Revised formula 
Cell reference:  
'PSA inputs'!$D$62 
replaced with:  
'PSA inputs'!$D$81 
ICER (cost per QALY) £21,742 
 
Correction 9 
Issue In the CCR arm, the daily dose of cytarabine for patients receiving LDAC is estimated assuming calculations using units of 
mg/m²/day, whereas the parameter used in AZA-AML-001 has units of mg/day. 
Cells affected ‘HRU costs’!C115:117 
Original formula Revised formula 
Formula: 
='PSA inputs'!D15*'PSA inputs'!D156 
replaced with:  
'PSA inputs'!D156 
ICER (cost per QALY) £20,648 (only affects scenario analyses) 
 
Correction 10 
Issue In the AZA and CCR arms, the formulae for calculating wastage with 30% tolerance (used in a scenario analysis) are 
incorrect. 
Cells affected ‘HRU costs’!E103, E109, E113, E117, E123, E127, E133, E137 
Original formula Revised formula 
Formula in ‘HRU costs’!E103: 
=IF(E102*(1-'Drug costs'!$L$14)<E101,E101,(E102*(1-'Drug costs'!$L$14))) 
replaced with:  
= 'Drug costs'!$L$14*E101+(1-'Drug costs'!$L$14)*E102 
Formula in ‘HRU costs’!E109: 
=IF(E108*(1-'Drug costs'!$L$14)<E107,E107,(E108*(1-'Drug costs'!$L$14))) 
replaced with:  
='Drug costs'!$L$14*E107+(1-'Drug costs'!$L$14)*E108 
Formula in ‘HRU costs’!E113: 
=IF(E112*(1-'Drug costs'!$L$14)<E111,E111,(E112*(1-'Drug costs'!$L$14))) 
replaced with:  
='Drug costs'!$L$14*E111+(1-'Drug costs'!$L$14)*E112 
Formula in ‘HRU costs’!E117: 
=IF(E116*(1-'Drug costs'!$L$14)<E115,E115,(E116*(1-'Drug costs'!$L$14))) 
replaced with:  
='Drug costs'!$L$14*E115+(1-'Drug costs'!$L$14)*E116 
Formula in ‘HRU costs’!E123: 
=IF(E122*(1-'Drug costs'!$L$14)<E121,E121,(E122*(1-'Drug costs'!$L$14))) 
replaced with:  
= 'Drug costs'!$L$14*E121+(1-'Drug costs'!$L$14)*E122 
Formula in ‘HRU costs’!E127: 
=IF(E126*(1-'Drug costs'!$L$14)<E125,E125,(E126*(1-'Drug costs'!$L$14))) 
replaced with:  
='Drug costs'!$L$14*E125+(1-'Drug costs'!$L$14)*E126 
Formula in ‘HRU costs’!E133: 
=IF(E132*(1-'Drug costs'!$L$14)<E131,E131,(E132*(1-'Drug costs'!$L$14))) 
replaced with:  
='Drug costs'!$L$14*'HRU costs'!E131+(1-'Drug costs'!$L$14)*'HRU 
costs'!E132 
Formula in ‘HRU costs’!E137: 
=IF('ERG changes'!V10 = 2,('Drug costs'!$L$14*E135+(1-'Drug 
costs'!$L$14)*E136),IF(E136*(1-'Drug costs'!$L$14)<E135,E135,(E136*(1-
'Drug costs'!$L$14)))) 
replaced with:  
'Drug costs'!$L$14*E135+(1-'Drug costs'!$L$14)*E136 
ICER (cost per QALY) £20,648 (only affects scenario analyses) 
 
Correction 11 
Issue In the AZA and CCR arms, the Kaplan-Meier curves for OS, PFS and RFS (for use in scenario analyses) are incorrectly 
referenced to the curves for patients with IC as their pre-specified CCR. 
Cells affected ‘KM data’!DD6:DI49 
Original formula Revised formula 
Formula in ‘KM data’!DD6: 
=IF((CHOOSE(PatientGroup,BF6,BL6,BR6,BX6,CD6,CJ6,CP6))=0, NA, 
CHOOSE(PatientGroup,BF6,BL6,BR6,BX6,CD6,CJ6,CP6)) 
replaced with:  
=IF((CHOOSE(PatientGroup, AZ6,BF6,BL6,BR6,BX6,CD6,CJ6,CP6))=0, NA, 
CHOOSE(PatientGroup, AZ6,BF6,BL6,BR6,BX6,CD6,CJ6,CP6)) 
 
(Correct the formulas in the cells below) 
Formula in ‘KM data’!DE6: 
=IF((CHOOSE(PatientGroup,BG6,BM6,BS6,BY6,CE6,CK6,CQ6))=0, NA, 
CHOOSE(PatientGroup,BG6,BM6,BS6,BY6,CE6,CK6,CQ6)) 
replaced with:  
=IF((CHOOSE(PatientGroup, BA6,BG6,BM6,BS6,BY6,CE6,CK6,CQ6))=0, 
NA, CHOOSE(PatientGroup, BA6,BG6,BM6,BS6,BY6,CE6,CK6,CQ6)) 
 
(Correct the formulas in the cells below) 
Formula in ‘KM data’!DF6: 
=IF((CHOOSE(PatientGroup,BH6,BN6,BT6,BZ6,CF6,CL6,CR6))=0, NA, 
CHOOSE(PatientGroup,BH6,BN6,BT6,BZ6,CF6,CL6,CR6)) 




(Correct the formulas in the cells below) 
Formula in ‘KM data’!DG6: 
=IF((CHOOSE(PatientGroup,BI6,BO6,BU6,CA6,CG6,CM6,CS6))=0, NA, 
CHOOSE(PatientGroup,BI6,BO6,BU6,CA6,CG6,CM6,CS6)) 
replaced with:  
=IF((CHOOSE(PatientGroup, BC6,BI6,BO6,BU6,CA6,CG6,CM6,CS6))=0, 
NA, CHOOSE(PatientGroup, BC6,BI6,BO6,BU6,CA6,CG6,CM6,CS6)) 
 
(Correct the formulas in the cells below) 
Formula in ‘KM data’!DH6: 
=IF((CHOOSE(PatientGroup,BJ6,BP6,BV6,CB6,CH6,CN6,CT6))=0, NA, 
CHOOSE(PatientGroup,BJ6,BP6,BV6,CB6,CH6,CN6,CT6)) 
replaced with:  
=IF((CHOOSE(PatientGroup, BD6,BJ6,BP6,BV6,CB6,CH6,CN6,CT6))=0, 
NA, CHOOSE(PatientGroup,  
BD6,BJ6,BP6,BV6,CB6,CH6,CN6,CT6)) 
 
(Correct the formulas in the cells below) 
Formula in ‘KM data’!DI6: 
=IF((CHOOSE(PatientGroup,BK6,BQ6,BW6,CC6,CI6,CO6,CU6))=0, NA, 
CHOOSE(PatientGroup,BK6,BQ6,BW6,CC6,CI6,CO6,CU6)) 
replaced with:  
=IF((CHOOSE(PatientGroup, BE6,BK6,BQ6,BW6,CC6,CI6,CO6,CU6))=0, 
NA, CHOOSE(PatientGroup, BE6,BK6,BQ6,BW6,CC6,CI6,CO6,CU6)) 
 
(Correct the formulas in the cells below) 
ICER (cost per QALY) £20,648 (only affects scenario analyses) 
 
Correction 12 
Issue In the AZA and CCR arms, the costs of drug administration, monitoring tests and transfusions for patients in the Non-
remission (stable disease) state were calculated assuming the proportion of such patients in the cohort is estimated by PFS × 
pSD − RFS × pResponse  (or zero if this is negative) where PFS × pSD is the correct formula, pResponse is the proportion of patients 
with CR/CRi response and pSD = 1 − pResponse. 
Cells affected “Model AZA”! AB23:AD153; “Model CCR”! AB23:AD153 
Original formula Revised formula 
Formula in ‘Model AZA’!AB23: 
='PSA inputs'!$D$52+K23*IF(C23<7,'PSA inputs'!$D$53,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$53))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$54,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$54)) 
replaced with: 
='PSA inputs'!$D$52+K23*IF(C23<7,'PSA inputs'!$D$53,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$53))+L23*IF(C23<7,'PSA 
inputs'!$D$54,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$54)) 
Formula in ‘Model AZA’!AB24: 








(Correct the formulas in the cells below) 
Formula in ‘Model CCR’!AB23: 
='PSA inputs'!$D$71+K23*IF(C23<7,'PSA inputs'!$D$72,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$72))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$73,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$73)) 
replaced with: 
='PSA inputs'!$D$71+K23*IF(C23<7,'PSA inputs'!$D$72,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$72))+L23*IF(C23<7,'PSA 
inputs'!$D$73,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$73)) 
Formula in ‘Model CCR’!AB24: 








(Correct the formulas in the cells below) 
Formula in ‘Model AZA’!AC23: 
='PSA inputs'!$D$57+K23*IF(C23<7,'PSA inputs'!$D$58,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$58))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$59,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$59)) 
replaced with: 
='PSA inputs'!$D$57+K23*IF(C23<7,'PSA inputs'!$D$58,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$58))+L23*IF(C23<7,'PSA 
inputs'!$D$59,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$59)) 
Formula in ‘Model AZA’!AC24: 








(Correct the formulas in the cells below) 
Formula in ‘Model CCR’!AC23: 
='PSA inputs'!$D$76+K23*IF(C23<7,'PSA inputs'!$D$77,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$77))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$78,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$78)) 
 
replaced with: 
='PSA inputs'!$D$76+K23*IF(C23<7,'PSA inputs'!$D$77,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$77))+L23*IF(C23<7,'PSA 
inputs'!$D$78,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$78)) 
 
Formula in ‘Model CCR’!AC24: 








(Correct the formulas in the cells below) 
Formula in ‘Model AZA’!AD23: 
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$63,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$63))+MAX(L23-K23,0)*IF(C23<7,'PSA 
inputs'!$D$64,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$64)) 
replaced with: 
='PSA inputs'!$D$62+K23*IF(C23<7,'PSA inputs'!$D$63,IF(C23>'PSA 
inputs'!$D$121,0,'PSA inputs'!$D$63))+L23*IF(C23<7,'PSA 
inputs'!$D$64,IF(C23>'PSA inputs'!$D$121,0,'PSA inputs'!$D$64)) 
Formula in ‘Model AZA’!AD24: 








(Correct the formulas in the cells below) 
ICER (cost per QALY) −£25,485 (AZA dominant) 
 
